<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer (Dove Med Press)</journal-id><journal-id journal-id-type="iso-abbrev">Breast Cancer (Dove Med Press)</journal-id><journal-id journal-id-type="pmc-domain-id">2249</journal-id><journal-id journal-id-type="pmc-domain">bctt</journal-id><journal-id journal-id-type="publisher-id">bctt</journal-id><journal-title-group><journal-title>Breast Cancer : Targets and Therapy</journal-title></journal-title-group><issn pub-type="epub">1179-1314</issn><publisher><publisher-name>Dove Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12751341</article-id><article-id pub-id-type="pmcid-ver">PMC12751341.1</article-id><article-id pub-id-type="pmcaid">12751341</article-id><article-id pub-id-type="pmcaiid">12751341</article-id><article-id pub-id-type="pmid">41476672</article-id><article-id pub-id-type="doi">10.2147/BCTT.S553421</article-id><article-id pub-id-type="publisher-id">553421</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The Landscape of Potential Targeted Treatments and Chemotherapy Efficacy Biomarkers for TNBC</article-title><alt-title alt-title-type="running-authors">Kang et al</alt-title><alt-title alt-title-type="running-title">Kang et al</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8344-6005</contrib-id><name name-style="western"><surname>Kang</surname><given-names initials="Y">Yujuan</given-names></name><xref rid="aff0001" ref-type="aff">1</xref><xref rid="ft0001" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yanqing</given-names></name><xref rid="aff0001" ref-type="aff">1</xref><xref rid="ft0001" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Liang</surname><given-names initials="Z">Zhi</given-names></name><xref rid="aff0001" ref-type="aff">1</xref><xref rid="ft0001" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Zhang</surname><given-names initials="S">Song</given-names></name><xref rid="aff0001" ref-type="aff">1</xref><xref rid="ft0001" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Qiao</surname><given-names initials="G">Guangdong</given-names></name><xref rid="aff0001" ref-type="aff">1</xref><xref rid="an0001" ref-type="corresp"/></contrib><aff id="aff0001"><label>1</label><institution>Department of Breast Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University</institution>, <addr-line>Yantai</addr-line>, <country>People&#8217;s Republic of China</country></aff></contrib-group><author-notes><corresp id="an0001">Correspondence: Guangdong Qiao, <institution>Department of Breast Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University</institution>, <addr-line>Yantai</addr-line>, <country>People&#8217;s Republic of China</country>, Email qiaoguangdong@ytyhdyy2.wecom.work</corresp><fn id="ft0001"><label>*</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>26</day><month>12</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">479419</issue-id><fpage>1341</fpage><lpage>1367</lpage><history><date date-type="received"><day>13</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>11</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>12</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>31</day><month>12</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-01 09:25:13.190"><day>01</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 Kang et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Kang et al.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#8211; Non Commercial (unported, v4.0) License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bctt-17-1341.pdf"/><abstract><title>Abstract</title><p>Triple negative breast cancer (TNBC) is characterized as an estrogen receptor (ER) negative, progesterone receptor (PR) negative, and human epidermal growth factor receptor (HER-2) negative disease with an enhanced systemic metastatic incidence, chemotherapeutic insensitivity, and drug resistance. The internal characteristics of TNBC are extraordinary complex and are accompanied by numerous gene mutations and constitutively activated signaling networks, which, in turn, augment TNBC malignancy. There is an urgency to uncover new and potent therapeutic targets for TNBC. Herein, we discussed the historical as well as newly discovered subtypes and properties of TNBC. We also presented a systematic outline of the aberrant gene expression and abnormal activated signaling networks in TNBC. Subsequently, we summarized the corresponding targeted therapeutic drugs, and reviewed the current targeted TNBC therapies launched in clinical trials, thereby providing a direction for future TNBC therapy. We also provided a detailed list of coding genes involved in chemo-sensitive and chemo-resistance of TNBC, which can potentially serve as indicators of chemotherapeutic efficacy. Finally, we discussed the novel and future potential treatments of TNBC. This review highlighted the new era of TNBC treatment in the coming years and provided the gene expression profile of TNBC patients who may benefit from chemotherapy.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>TNBC</kwd><kwd>immunotherapy</kwd><kwd>PI3K-AKT-mTOR</kwd><kwd>BRCA</kwd><kwd>EGFR</kwd><kwd>FGFR</kwd><kwd>PD-L1</kwd><kwd>CDK</kwd><kwd>chemo-sensitive</kwd><kwd>chemo-resistance</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>Beijing Vlove Charity Foundation</institution></institution-wrap></funding-source></award-group><award-group><funding-source><institution-wrap><institution>Yantai Yuhuangding Hospital Youth Launch Fund</institution></institution-wrap></funding-source></award-group><award-group><funding-source><institution-wrap><institution>Yantai Yuhuangding Hospital Doctoral Research Launch Fund</institution></institution-wrap></funding-source></award-group><funding-statement>Beijing Vlove Charity Foundation (ky1322); Yantai Yuhuangding Hospital Youth Launch Fund (kj0521) and Yantai Yuhuangding Hospital Doctoral Research Launch Fund (kj0570).</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="4"/><ref-count count="227"/><page-count count="27"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s0001"><title>Introduction</title><p>About 2.1 million women suffer from breast cancer (BC) in a given year, and BC is the largest contributor of cancer-linked deaths among women.<xref rid="cit0001" ref-type="bibr">1</xref> BC is immunohistochemically (IHC) stratified into five sub-cohorts, namely, Luminal A, Luminal B, HER2, TNBC, and Normal-Like BC.<xref rid="cit0002" ref-type="bibr">2</xref> TNBC, marked with no ER, PR, and HER2 contents, make up approximately 15&#8211;20% of all BC patients.<xref rid="cit0003" ref-type="bibr">3</xref> TNBC including six TNBC categories,<xref rid="cit0004" ref-type="bibr">4</xref>,<xref rid="cit0005" ref-type="bibr">5</xref> namely, two Basal-Like (BL1 and BL2), a mesenchymal (M), a mesenchymal stem-like (MSL), an immunomodulatory (IM), and a luminal androgen receptor (LAR).<xref rid="cit0005" ref-type="bibr">5</xref> Due to the poor response of TNBC patients to anti-HER2 monoclonal antibodies (mAb)-based and endocrine interventions, classic anticancer treatments, such as, surgery, radiotherapy, and chemotherapy remain the primary strategies for treating TNBC.<xref rid="cit0006" ref-type="bibr">6</xref> Among TNBC patients, disease progression and recurrence are common within the initial 3&#8211;5 years following diagnosis, and distant metastases frequently occur in the brain and lung.<xref rid="cit0007" ref-type="bibr">7</xref> The primary TNBC intervention is chemotherapy. Anthracyclines and Taxanes are the most effective drugs.<xref rid="cit0008" ref-type="bibr">8</xref> Even though 30% of TNBC patients respond adequately to chemotherapy and have good prognosis, presently, there are no available interventions for chemo-resistant patients.<xref rid="cit0009" ref-type="bibr">9</xref> Among an unselected TNBC population, BRCA mutation incidence is about 20%.<xref rid="cit0010" ref-type="bibr">10</xref> Emerging evidences revealed that platinum agent introduction in metastatic and neoadjuvant settings achieves satisfactory outcomes in patients with BRCA mutations.<xref rid="cit0011" ref-type="bibr">11</xref>,<xref rid="cit0012" ref-type="bibr">12</xref> Furthermore, others have successfully employed poly ADP-ribose polymerase (PARP) inhibitors to cure TNBCs with BRCA mutations.<xref rid="cit0013" ref-type="bibr">13</xref> With growing advancements in medicinal technology, immunotherapeutic agents have emerged as drugs with robust responses and enhancements in patient overall survival (OS).<xref rid="cit0014" ref-type="bibr">14</xref> TNBC exhibits excess tumor infiltrating lymphocytes (TILs),<xref rid="cit0015" ref-type="bibr">15</xref> relative to other subtypes, along with markedly enhanced PD-L1 expression<xref rid="cit0016" ref-type="bibr">16</xref> and OS strongly linked to the severity of immune cell invasion.<xref rid="cit0017" ref-type="bibr">17</xref> Hence, immune checkpoint blockade (ICB) therapies, such as, programmed death-1 (PD-1)- or programmed death-ligand 1 (PD-L1)-specific antibodies were shown to be highly efficacious in suppressing TNBC development.<xref rid="cit0018" ref-type="bibr">18</xref>,<xref rid="cit0019" ref-type="bibr">19</xref></p><p>In addition, dysregulated gene expression and signaling networks are the most prominent feature of TNBC.<xref rid="cit0020" ref-type="bibr">20</xref> Presently, several molecular targeted drugs are recognized as crucial for the treatment of TNBC. Notably, even though some TNBC patients are responsive to chemotherapy, there is still a considerable need for novel targeted therapeutic strategy discovery.<xref rid="cit0021" ref-type="bibr">21</xref> In this review, we summarized the abnormal TNBC gene expression landscape, existing molecular targeted treatments, and chemotherapeutic efficacy biomarkers from the following four aspects: (1) The Molecular Subtypes of TNBC; (2) The Essential Characteristics and Potential Molecular Targeted Therapy of TNBC; (3) Coding Genes Involved in Chemo-Sensitive and Chemo-Resistance of TNBC; (4) Potential Novel Therapeutic Targets for TNBC.</p></sec><sec id="s0002"><title>Results</title><sec id="s0002-s2001"><title>The Molecular Subtypes of TNBC</title><p>TNBC is a diverse disease that displays considerable differences in pathological characteristics, physiological activities, and genetic profiles.<xref rid="cit0005" ref-type="bibr">5</xref>,<xref rid="cit0022" ref-type="bibr">22</xref> The established TNBC subtypes are BL1, BL2, M, MSL, IM, and LAR,<xref rid="cit0005" ref-type="bibr">5</xref> and they are all unique in their features. The BL1 subtype is characterized by enhanced MYC, PI3K catalytic subunit &#945; (PIK3CA), CDK6, AKT2, KRAS, FGFR1, IGF1R, CCNE1, and CDKN2A/B amplification, and augmented prevalence of heterozygous or homozygous deletion of DNA repair-associated genes (BRCA2, PTEN [phosphatase and tensin homolog], MDM2, RB1, and TP53). It is often combated with PARP inhibitors (PARPi) and genotoxic agents.<xref rid="cit0023" ref-type="bibr">23</xref> The BL2 subtype features aberrant activation of EGFR, MET, NGF, Wnt/&#946;-catenin, and IGF-1R pathway activations, and it is treated with mTOR inhibitors and growth factor inhibitors.<xref rid="cit0023" ref-type="bibr">23</xref> The M subtype features constitutive stimulation of the cell migration-associated axis, extracellular matrix-receptor association network, and differentiation axes [Wnt, anaplastic lymphoma kinase, transforming growth factor (TGF)-&#946;],<xref rid="cit0023" ref-type="bibr">23</xref> and it is targeted with mTOR inhibitors and drugs against the epithelial-mesenchymal-transition (EMT).<xref rid="cit0024" ref-type="bibr">24</xref> The MSL subtype exhibited markedly reduced cell proliferation-associated genes, with simultaneous elevations in the stemness-associated genes (ABCA8, PROCR, ENG, ALDHA1, PER1, ABCB1, TERT2IP, BCL2, BMP2, and THY), HOX genes (HOXA5, HOXA10, MEIS1, MEIS2, MEOX1, MEOX2, and MSX1), and mesenchymal stem cell (MSC) markers (BMP2, ENG, ITGAV, KDR, NGFR, NT5E, PDGFR, THY1, and VCAM1), and this is managed using PI3K inhibitors, v-src sarcoma viral oncogene homolog (Src) antagonists, or antiangiogenic drugs. A Src inhibitor (Dasatinib) may also be used to treat M and MSL TNBC.<xref rid="cit0023" ref-type="bibr">23</xref> Of note, the M and MSL categories are linked to an enhanced angiogenesis signature score.<xref rid="cit0025" ref-type="bibr">25</xref> The IM subtype is featured with abundant immune signaling networks, including, Th1/Th2, NK cell, B cell receptor, dendritic cell (DC), T cell receptor, interleukin (IL)-12, and IL-7 networks, and this category is treated with immune checkpoint inhibitor (ICI).<xref rid="cit0023" ref-type="bibr">23</xref> The LAR subtype have enhanced AR signaling, as is evidenced by IHC, which depicts upregulated AR, downstream genes, and auxiliary activators (DHCR24, ALCAM, FASN, FKBP5, APOD, PIP, SPDEF, and CLDN8).<xref rid="cit0026" ref-type="bibr">26</xref>,<xref rid="cit0027" ref-type="bibr">27</xref> LAR tumors also contain PI3KCA (55%), AKT1 (13%) and CDH1 (13%) gene mutations.<xref rid="cit0025" ref-type="bibr">25</xref> LAR responds to anti-AR therapy.<xref rid="cit0005" ref-type="bibr">5</xref></p><p>With advancements in medical technology, there have emerged certain modification to TNBC stratification. Burstein et al proposed a four subtypes classification of TNBC, including, LAR, mesenchymal (MES), basal-like immunosuppressed (BLIS), and basal-like immune activated (BLIA).<xref rid="cit0028" ref-type="bibr">28</xref> The potential corresponding targets were also identified as follows: (i) LAR: AR and MUC1, (ii) MES: growth factor receptors, (iii) BLIS: an immunosuppressing molecule (VTCN1), and (iv) BLIA: STAT-related molecules and cytokines.<xref rid="cit0028" ref-type="bibr">28</xref> Alternatively, Zhao et al identified AR, CD8, FOXC1, and DCLK1 as TNBC bioindicators, and stratified TNBCs into five categories, based on IHC: (a) IHC-based LAR (IHC-LAR; AR-positive [+]), (b) IHC-based immunomodulatory (IHC-IM; AR-negative [&#8722;], CD8+), (c) IHC-based basal-like immune-suppressed (IHC-BLIS; AR&#8722;, CD8&#8722;, FOXC1+), (d) IHC-based mesenchymal (IHC-MES; AR&#8722;, CD8&#8722;, FOXC1&#8722;, DCLK1+), and (e) IHC-based unclassifiable (AR&#8722;, CD8&#8722;, FOXC1&#8722;, DCLK1&#8722;). The IHC-LAR category is marked with a strongly activated HER2 network. The IHC-IM category has CD8<sup>+</sup> T cell invasion into the tumor parenchyma. The IHC-BLIS category has an enhanced VEGF expression. The IHC-MES category is featured by active JAK/STAT3 axis.<xref rid="cit0029" ref-type="bibr">29</xref>
<italic toggle="yes">He</italic> et al stratified TNBC according to immune profiles as follows: High (Immunity_H), Medium (Immunity_M), and Low (Immunity_L). Immunity_H displays a vast immune cell invasion and anti-tumor immunologic activity. Among its immune signatures are excess cellular apoptosis, as well as calcium, MAPK, PI3K&#8211;Akt, and RAS networks. Alternatively, Immunity_L presents with a diminished immune profile and enhanced cellular cycle, Hippo axis, DNA replication, mismatch repair, cell adhesion molecule interaction, spliceosome, adherens junction activity, pyrimidine metabolism, glycosylphosphatidylinositol-anchor biosynthesis, and RNA polymerase networks. There are five transcription factor (TF) genes that are specific to the Immunity_H category, namely, CORO1A, STAT4, BCL11B, ZNF831, and EOMES, and two that are specific to the Immunity_L category, namely, IRF8 and SPI1.<xref rid="cit0030" ref-type="bibr">30</xref> These TNBC classifications facilitate an elevated level of understanding of TNBC (<xref rid="t0001" ref-type="table">Table 1</xref>).
<table-wrap position="float" id="t0001" orientation="portrait"><label>Table 1</label><caption><p>The Subgroups and Properties of TNBC</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">TNBC</th><th align="center" rowspan="1" colspan="1">ER (-)</th><th align="center" rowspan="1" colspan="1">PR (-)</th><th align="center" rowspan="1" colspan="1">HER2 (-)</th><th align="center" rowspan="1" colspan="1">Properties</th><th align="center" rowspan="1" colspan="1">Therapy</th><th align="center" rowspan="1" colspan="1">Ref</th></tr></thead><tbody><tr><td rowspan="6" colspan="1"><italic toggle="yes">Lehmann</italic> et al</td><td colspan="3" rowspan="1">Basal-Like 1 (BL1)</td><td rowspan="1" colspan="1">(a) High expression of MYC, PIK3CA, CDK6, AKT2, KRAS, FGFR1, IGF1R, CCNE1, CDKN2A/B; (b)Augmented prevalence of heterozygous or homozygous deletion of DNA repair-associated genes (BRCA2, PTEN, MDM2, RB1, and TP53)</td><td rowspan="1" colspan="1">PARPi; Genotoxic Agents</td><td rowspan="1" colspan="1">[<xref rid="cit0005" ref-type="bibr">5</xref>, <xref rid="cit0023" ref-type="bibr">23</xref>]</td></tr><tr><td colspan="3" rowspan="1">Basal-Like 2 (BL2)</td><td rowspan="1" colspan="1">(a) Activation of EGFR, MET, NGF, Wnt/&#946;-catenin, IGF-1R pathways</td><td rowspan="1" colspan="1">mTOR Inhibitors; Growth Factor Inhibitors</td><td rowspan="1" colspan="1">[<xref rid="cit0005" ref-type="bibr">5</xref>, <xref rid="cit0023" ref-type="bibr">23</xref>]</td></tr><tr><td colspan="3" rowspan="1">Mesenchymal (M)</td><td rowspan="1" colspan="1"><list list-type="alpha-lower"><list-item><p>Activated cell migration- associated axis, extracellular matrix&#8211;receptor network, and differentiation axes (Wnt, anaplastic lymphoma kinase, TGF-&#946;); (b) Higher signature score for angiogenesis</p></list-item></list></td><td rowspan="1" colspan="1">mTOR Inhibitors; Drugs against EMT; Src Inhibitor</td><td rowspan="1" colspan="1">[<xref rid="cit0005" ref-type="bibr">5</xref>, <xref rid="cit0023" ref-type="bibr">23&#8211;25</xref>]</td></tr><tr><td colspan="3" rowspan="1">Mesenchymal stem-like (MSL)</td><td rowspan="1" colspan="1"><list list-type="alpha-lower"><list-item><p>Reduced cell proliferation-related genes;</p></list-item><list-item><p>Elevation in the stemness-related genes (ABCA8, PROCR, ENG, ALDHA1, PER1, ABCB1, TERT2IP, BCL2, BMP2, and THY);</p></list-item><list-item><p>Elevation in the HOX genes (HOXA5, HOXA10, MEIS1, MEIS2, MEOX1, MEOX2, and MSX1);</p></list-item><list-item><p>Elevation in the MSC-specific markers (BMP2, ENG, ITGAV, KDR, NGFR, NT5E, PDGFR, THY1, and VCAM1);</p></list-item><list-item><p>Higher signature score for angiogenesis;</p></list-item></list></td><td rowspan="1" colspan="1">PI3K Inhibitors; Src Inhibitor; Antiangiogenic drugs</td><td rowspan="1" colspan="1">[<xref rid="cit0005" ref-type="bibr">5</xref>, <xref rid="cit0023" ref-type="bibr">23</xref>, <xref rid="cit0025" ref-type="bibr">25</xref>]</td></tr><tr><td colspan="3" rowspan="1">Immunomodulatory (IM)</td><td rowspan="1" colspan="1"><list list-type="alpha-lower"><list-item><p>Enriched immune related signaling networks, including, Th1/Th2, NK cell, B cell receptor, dendritic cell (DC), T cell receptor, interleukin (IL)-12, and IL-7 networks</p></list-item></list></td><td rowspan="1" colspan="1">ICI</td><td rowspan="1" colspan="1">[<xref rid="cit0005" ref-type="bibr">5</xref>, <xref rid="cit0023" ref-type="bibr">23</xref>]</td></tr><tr><td colspan="3" rowspan="1">Luminal Androgen Receptor (LAR)</td><td rowspan="1" colspan="1"><list list-type="alpha-lower"><list-item><p>Enhanced AR signaling, downstream genes, and auxiliary activators (DHCR24, ALCAM, FASN, FKBP5, APOD, PIP, SPDEF, and CLDN8)</p></list-item></list><break/>(b) Contain PI3KCA (55%), AKT1 (13%) and CDH1 (13%) gene mutations</td><td rowspan="1" colspan="1">AR Antagonist (Bicalutamide)</td><td rowspan="1" colspan="1">[<xref rid="cit0005" ref-type="bibr">5</xref>, <xref rid="cit0025" ref-type="bibr">25&#8211;27</xref>]</td></tr><tr><td rowspan="4" colspan="1"><italic toggle="yes">Burstein</italic> et al</td><td colspan="3" rowspan="1">Luminal androgen receptor (LAR)</td><td colspan="2" rowspan="1">AR and MUC1</td><td rowspan="4" colspan="1">[<xref rid="cit0028" ref-type="bibr">28</xref>]</td></tr><tr><td colspan="3" rowspan="1">Mesenchymal (MES)</td><td colspan="2" rowspan="1">Growth factor receptors</td></tr><tr><td colspan="3" rowspan="1">Basal-like immunosuppressed (BLIS)</td><td colspan="2" rowspan="1">Immunosuppressing molecule (VTCN1)</td></tr><tr><td colspan="3" rowspan="1">Basal-like immune activated (BLIA)</td><td colspan="2" rowspan="1">STAT-related molecules and cytokines</td></tr><tr><td rowspan="5" colspan="1"><italic toggle="yes">Zhao</italic> et al</td><td colspan="3" rowspan="1">IHC-based LAR (IHC-LAR; AR-positive [+])</td><td colspan="2" rowspan="1">Activation of HER2 network</td><td rowspan="5" colspan="1">[<xref rid="cit0029" ref-type="bibr">29</xref>]</td></tr><tr><td colspan="3" rowspan="1">IHC-based immunomodulatory (IHC-IM; AR-negative [&#8722;], CD8+)</td><td colspan="2" rowspan="1">CD8<sup>+</sup> T cell invasion into the tumor parenchyma</td></tr><tr><td colspan="3" rowspan="1">IHC-based basal-like immune-suppressed (IHC-BLIS; AR&#8722;, CD8&#8722;, FOXC1+)</td><td colspan="2" rowspan="1">Enhanced VEGF expression</td></tr><tr><td colspan="3" rowspan="1">IHC-based mesenchymal (IHC-MES; AR&#8722;, CD8&#8722;, FOXC1&#8722;, DCLK1+)</td><td colspan="2" rowspan="1">Active JAK/STAT3 axis</td></tr><tr><td colspan="3" rowspan="1">IHC-based unclassifiable (AR&#8722;, CD8&#8722;,FOXC1&#8722;, DCLK1&#8722;)</td><td colspan="2" rowspan="1">Unknown</td></tr><tr><td rowspan="3" colspan="1"><italic toggle="yes">He</italic> et al</td><td colspan="3" rowspan="1">Immunity High (Immunity_H)</td><td colspan="2" rowspan="1">(a) Excess cellular apoptosis, as well as calcium, MAPK, PI3K&#8211;Akt, and RAS networks; (b) Express five TF genes (CORO1A, STAT4, BCL11B, ZNF831, and EOMES)</td><td rowspan="3" colspan="1">[<xref rid="cit0030" ref-type="bibr">30</xref>]</td></tr><tr><td colspan="3" rowspan="1">Immunity Medium (Immunity_M)</td><td colspan="2" rowspan="1">In the middle</td></tr><tr><td colspan="3" rowspan="1">Immunity Low (Immunity_L)</td><td colspan="2" rowspan="1">(a) Diminished immune profile and enhanced cellular cycle, Hippo axis, DNA replication, mismatch repair, cell adhesion molecule interaction, spliceosome, adherens junction activity, pyrimidine metabolism, glycosylphosphatidylinositol-anchor biosynthesis, and RNA polymerase networks</td></tr></tbody></table></table-wrap></p></sec><sec id="s0002-s2002"><title>The Essential Characteristics and Potential Molecular Targeted Therapy of TNBC</title><p>TNBC prognosis is generally worse than non-TNBC.<xref rid="cit0008" ref-type="bibr">8</xref>,<xref rid="cit0031" ref-type="bibr">31</xref>,<xref rid="cit0032" ref-type="bibr">32</xref> Although chemotherapy is the primary intervention for TNBC, it often produces rather disappointing outcomes. Due to the lack of precision therapeutic targets, TNBC is often aggressive in BC patients.<xref rid="cit0033" ref-type="bibr">33</xref>,<xref rid="cit0034" ref-type="bibr">34</xref> TNBC is a heterogeneous tumor, accompanied by dysregulated gene expression and constitutively activated signaling networks. In this report, we provide a detailed list of gene mutations and aberrantly activated signaling networks in TNBC, as well as corresponding treatment methods for TNBC, based on the following aspects: (a) DNA Damage Response (DDR)-Related BRCA Loss-Function Mutation; (b) PI3K Signaling Network; (c) NOTCH Signaling Network; (d) CDK-Rb Signaling Network; (e) EGFR Activation; (f) Angiogenesis Signaling Network; (g) HER2-Low TNBC; (h) DDR Signaling Network (i) Immunotherapy, and (j) Androgen Receptor (AR) (<xref rid="f0001" ref-type="fig">Figure 1</xref> and <xref rid="t0002" ref-type="table">Table 2</xref>).
<table-wrap position="float" id="t0002" orientation="portrait"><label>Table 2</label><caption><p>The Molecular Targeted Medicines of TNBC</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Drug Type</th><th align="center" rowspan="1" colspan="1">Drugs Name</th><th align="center" rowspan="1" colspan="1">Targeted Gene/Signaling Pathway</th><th align="center" rowspan="1" colspan="1">Ref</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">PARP Inhibitors</td><td rowspan="1" colspan="1">Olaparib; Rucaparib; Niraparib; Talazoparib; Veliparib</td><td rowspan="1" colspan="1">BRCA1/2</td><td rowspan="1" colspan="1">[<xref rid="cit0035" ref-type="bibr">35</xref>]</td></tr><tr><td rowspan="1" colspan="1">PI3K Inhibitors</td><td rowspan="1" colspan="1">Buparlisib; SAR245408; Taselisib; PX-866; Alpelisib; Serabelisib</td><td rowspan="1" colspan="1">PI3K</td><td rowspan="1" colspan="1">[<xref rid="cit0036" ref-type="bibr">36&#8211;41</xref>]</td></tr><tr><td rowspan="1" colspan="1">AKT Inhibitors</td><td rowspan="1" colspan="1">Ipatasertib; Perifosine; MK2206; AZD5363</td><td rowspan="1" colspan="1">AKT</td><td rowspan="1" colspan="1">[<xref rid="cit0042" ref-type="bibr">42&#8211;46</xref>]</td></tr><tr><td rowspan="1" colspan="1">mTOR Inhibitors</td><td rowspan="1" colspan="1">Temsirolimus; Everolimus</td><td rowspan="1" colspan="1">mTOR</td><td rowspan="1" colspan="1">[<xref rid="cit0047" ref-type="bibr">47</xref>]</td></tr><tr><td rowspan="1" colspan="1">Dual PI3K/AKT/mTOR Inhibitors</td><td rowspan="1" colspan="1">Apitolisib; Omipalisib; AZD2014; Voxtalisib; Dactolisib; GDC-0980</td><td rowspan="1" colspan="1">PI3K/AKT/mTOR</td><td rowspan="1" colspan="1">[<xref rid="cit0048" ref-type="bibr">48&#8211;53</xref>]</td></tr><tr><td rowspan="1" colspan="1">Notch Inhibitors</td><td rowspan="1" colspan="1">AL101</td><td rowspan="1" colspan="1">Notch</td><td rowspan="1" colspan="1">[<xref rid="cit0054" ref-type="bibr">54</xref>, <xref rid="cit0055" ref-type="bibr">55</xref>]</td></tr><tr><td rowspan="1" colspan="1">CDK4/6 Inhibitors</td><td rowspan="1" colspan="1">Flavopiridol; Palbociclib; Ribociclib, Abemaciclib; LEE011; LY2835219</td><td rowspan="1" colspan="1">CDK-Rb Pathway</td><td rowspan="1" colspan="1">[<xref rid="cit0056" ref-type="bibr">56&#8211;58</xref>]</td></tr><tr><td rowspan="1" colspan="1">EGFR TKI</td><td rowspan="1" colspan="1">Erlotinib; Gefitinib</td><td rowspan="1" colspan="1">EGFR</td><td rowspan="1" colspan="1">[<xref rid="cit0059" ref-type="bibr">59</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-EGFR mAb</td><td rowspan="1" colspan="1">Afatinib; Lapatinib</td><td rowspan="1" colspan="1">EGFR and ERBB2</td><td rowspan="1" colspan="1">[<xref rid="cit0059" ref-type="bibr">59</xref>]</td></tr><tr><td rowspan="1" colspan="1">VEGFR mAb</td><td rowspan="1" colspan="1">Bevacizumab; Sunitinib; Ramucirumab</td><td rowspan="1" colspan="1">VEGF-A and VEGFR</td><td rowspan="1" colspan="1">[<xref rid="cit0060" ref-type="bibr">60&#8211;62</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-angiogenic</td><td rowspan="1" colspan="1">Semaphorins</td><td rowspan="1" colspan="1">NRP1 and NRP2</td><td rowspan="1" colspan="1">[<xref rid="cit0063" ref-type="bibr">63</xref>]</td></tr><tr><td rowspan="1" colspan="1">VEGF decoy receptor</td><td rowspan="1" colspan="1">Aflibercept</td><td rowspan="1" colspan="1">VEGFR</td><td rowspan="1" colspan="1">[<xref rid="cit0064" ref-type="bibr">64</xref>]</td></tr><tr><td rowspan="1" colspan="1">FGFR Inhibitors</td><td rowspan="1" colspan="1">AZD4547; BGJ398; BLU9931; Debio-1347; Dovitinib; FIIN-2; JNJ-42756493; LY2874455; Ponatinib</td><td rowspan="1" colspan="1">FGFR</td><td rowspan="1" colspan="1">[<xref rid="cit0065" ref-type="bibr">65&#8211;74</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-HER2 ADC</td><td rowspan="1" colspan="1">Trastuzumab Deruxtecan; Trastuzumab Duocarmazine; Disitamab Vedotin; MRG002</td><td rowspan="1" colspan="1">HER2</td><td rowspan="1" colspan="1">[<xref rid="cit0075" ref-type="bibr">75</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-HER2 TKIs</td><td rowspan="1" colspan="1">Neratinib; Poziotinib; Pyrotinib</td><td rowspan="1" colspan="1">HER2</td><td rowspan="1" colspan="1">[<xref rid="cit0076" ref-type="bibr">76</xref>]</td></tr><tr><td rowspan="1" colspan="1">ATR Inhibitors</td><td rowspan="1" colspan="1">VX-970; AZD6738</td><td rowspan="1" colspan="1">ATR-CHK1-WEE1</td><td rowspan="1" colspan="1">[<xref rid="cit0035" ref-type="bibr">35</xref>]</td></tr><tr><td rowspan="1" colspan="1">CHK1 Inhibitors</td><td rowspan="1" colspan="1">AZD7762; V158411; LY2606368; UCN-01</td><td rowspan="1" colspan="1">ATR-CHK1-WEE1</td><td rowspan="1" colspan="1">[<xref rid="cit0077" ref-type="bibr">77&#8211;80</xref>]</td></tr><tr><td rowspan="1" colspan="1">WEE Inhibitors</td><td rowspan="1" colspan="1">AZD1775</td><td rowspan="1" colspan="1">ATR-CHK1-WEE1</td><td rowspan="1" colspan="1">[<xref rid="cit0081" ref-type="bibr">81</xref>]</td></tr><tr><td rowspan="1" colspan="1">CTLA-4 Inhibitors</td><td rowspan="1" colspan="1">Ipilimumab; Tremelimumab</td><td rowspan="1" colspan="1">CTLA-4</td><td rowspan="1" colspan="1">[<xref rid="cit0082" ref-type="bibr">82</xref>]</td></tr><tr><td rowspan="1" colspan="1">PD-1 Inhibitors</td><td rowspan="1" colspan="1">Pembrolizumab; Pidilizumab; Nivolumab</td><td rowspan="1" colspan="1">PD-1</td><td rowspan="1" colspan="1">[<xref rid="cit0083" ref-type="bibr">83</xref>]</td></tr><tr><td rowspan="1" colspan="1">PD-L1 Inhibitors</td><td rowspan="1" colspan="1">Atezolizumab</td><td rowspan="1" colspan="1">PD-L1</td><td rowspan="1" colspan="1">[<xref rid="cit0083" ref-type="bibr">83</xref>]</td></tr><tr><td rowspan="1" colspan="1">AR Inhibitors</td><td rowspan="1" colspan="1">Bicalutamide; Enzalutamide; Seviteronel</td><td rowspan="1" colspan="1">AR</td><td rowspan="1" colspan="1">[<xref rid="cit0084" ref-type="bibr">84</xref>]</td></tr><tr><td rowspan="1" colspan="1">Ferroptosis related drugs</td><td rowspan="1" colspan="1">1-methyl-3-isobutylxanthine; Rosiglitazone</td><td rowspan="1" colspan="1">Ferroptosis Pathway</td><td rowspan="1" colspan="1">[<xref rid="cit0085" ref-type="bibr">85</xref>]</td></tr><tr><td rowspan="1" colspan="1">Targeted ADC bioindicators</td><td rowspan="1" colspan="1">Sacituzumab Govitecan (IMMU-132); Ladiratuzumab vedotin (SGN-LIV1A); Glembatumumab Vedotin (CDX-011); AVID100; U3-1402; CAB-ROR2-ADC; SAR566658</td><td rowspan="1" colspan="1">Trop-2; LIV1; EGFR; gpNMB; EGFR; HER3; ROR2; DS6</td><td rowspan="1" colspan="1">[<xref rid="cit0086" ref-type="bibr">86&#8211;89</xref>]</td></tr><tr><td rowspan="1" colspan="1">Ceritinib</td><td rowspan="1" colspan="1">Ceritinib</td><td rowspan="1" colspan="1">RTK-ACK1/FAK-AR</td><td rowspan="1" colspan="1">[<xref rid="cit0090" ref-type="bibr">90</xref>, <xref rid="cit0091" ref-type="bibr">91</xref>]</td></tr><tr><td rowspan="1" colspan="1">Src Inhibitor</td><td rowspan="1" colspan="1">Dasatinib</td><td rowspan="1" colspan="1">Src</td><td rowspan="1" colspan="1">[<xref rid="cit0092" ref-type="bibr">92&#8211;96</xref>]</td></tr><tr><td rowspan="1" colspan="1">CDK12/CDK13 Inhibitor</td><td rowspan="1" colspan="1">SR-4835</td><td rowspan="1" colspan="1">CDK12/CDK13</td><td rowspan="1" colspan="1">[<xref rid="cit0097" ref-type="bibr">97</xref>]</td></tr></tbody></table></table-wrap>
<fig position="float" id="f0001" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><p>The abnormal gene and cell signal transduction profiles, as well as corresponding targeted TNBC therapy. (<bold>a</bold>) DNA Damage Response (DDR)-Related BRCA Loss-Function Mutation; (<bold>b</bold>) PI3K Signaling Network; (<bold>c</bold>) NOTCH Signaling Network; (<bold>d</bold>) CDK-Rb Signaling Network; (<bold>e</bold>) EGFR Activation; (<bold>f</bold>) Angiogenesis Signaling Network; (<bold>g</bold>) HER2-Low TNBC; (<bold>h</bold>) DDR Signaling Network (<bold>i</bold>) Immunotherapy, and (<bold>j</bold>) Androgen Receptor (AR).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="BCTT-17-1341-g0001.jpg"/></fig></p><sec id="s0002-s2002-s3001"><title>DDR-Related BRCA Loss-Function Mutation</title><p>Among the cancer features are DNA damage and impaired repair.<xref rid="cit0098" ref-type="bibr">98</xref> Prior reports demonstrated loss-of-function mutations in two essential BC susceptibility genes (BRCA1 and BRCA2) that modulate DDR, in 5% of BC patients.<xref rid="cit0099" ref-type="bibr">99&#8211;101</xref> BRCA1 and BRCA2 proteins modulate DNA replication for stabilization and homologous recombination (HR).<xref rid="cit0102" ref-type="bibr">102</xref> Based on one report, 70% of the inherited BRCA1 mutation-harboring BC patients and 16~23% of BRCA2 mutation-harboring BC patients are TNBC.<xref rid="cit0103" ref-type="bibr">103</xref> TNBC PARP enzymes are essential to the base excision repair mechanism, and PARP1 and PARP2 modulate DDR process.<xref rid="cit0104" ref-type="bibr">104</xref> BRCA1/2-mutated tumors tend to possess extra sensitivity toward PARP1 inhibition induced synthetic lethality. Thus, PARP1 inhibitors are promising for BRCA1/2 mutated patients.<xref rid="cit0105" ref-type="bibr">105</xref> The PARPi Olaparib is highly potent as a monotherapy in BC patients.<xref rid="cit0106" ref-type="bibr">106</xref> Presently, there are five BC-combating PARPi are under clinical validation: Olaparib, Rucaparib, Niraparib, Talazoparib, and Veliparib.<xref rid="cit0035" ref-type="bibr">35</xref> Additionally, emerging preclinical and clinical investigations demonstrated strong efficacy of platinum-based chemotherapy among TNBC patients.<xref rid="cit0107" ref-type="bibr">107</xref> Moreover, relevant clinical investigations were launched to accurately access the therapeutic effect of PARPi in TNBC and BC (<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/" ext-link-type="uri">https://clinicaltrials.gov/</ext-link></underline>) (<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/553421/553421%20Revised%20Supplemental%20Table%201.docx" ext-link-type="uri">Supplemental Table 1</ext-link></underline>).</p></sec><sec id="s0002-s2002-s3002"><title>PI3K Signaling Network</title><p>Dysregulated phosphoinositide 3-kinase (PI3K)/AKT/mTOR is a hallmark of cancerous development.<xref rid="cit0105" ref-type="bibr">105</xref> This axis is essential for the receptor tyrosine kinase (RTK) signaling and tumor growth in BC.<xref rid="cit0108" ref-type="bibr">108</xref> In fact, PI3K pathway mutations form a special subgroup among TNBC patients.<xref rid="cit0020" ref-type="bibr">20</xref> In TNBC, the aberrant PI3K/AKT/mTOR axis activation is regulated by upstream regulator, activating PIK3CA mutations, PTEN loss of function or expression mutation, and proline-rich inositol poly-phosphatase (negative PI3K modulator) downregulation.<xref rid="cit0109" ref-type="bibr">109</xref>,<xref rid="cit0110" ref-type="bibr">110</xref> Herein, we summarized the underlying mechanisms and PI3K signaling-targeted drugs associated with TNBC.</p><sec id="s0002-s2002-s3002-s4001"><title>PI3K Inhibitors</title><p>In a previous report, it was revealed that pan-PI3K inhibitor (Buparlisib), combined with Buparlisib and Olaparib, diminishes BRCA1/2 content and encourages HR deficiency in BRCA1 WT TNBC patients.<xref rid="cit0036" ref-type="bibr">36</xref> In addition, the pan-PI3K inhibitors (SAR245408, Taselisib, and PX-866) are undergoing studied for HER2<sup>+</sup> and HR<sup>+</sup> BC.<xref rid="cit0037" ref-type="bibr">37&#8211;39</xref> Alpelisib is an isoform-specific PI3K inhibitor under examination in clinical trials.<xref rid="cit0040" ref-type="bibr">40</xref> Moreover, there is ongoing development of Serabelisib, a robust and targeted PIK3CA inhibitor for management of solid tumors.<xref rid="cit0041" ref-type="bibr">41</xref> The relevant clinical trials are listed in <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/553421/553421%20Revised%20Supplemental%20Table%201.docx" ext-link-type="uri">Supplemental Table 1</ext-link></underline>.</p></sec><sec id="s0002-s2002-s3002-s4002"><title>AKT Inhibitors</title><p>Ipatasertib inhibits AKT which is downstream of PI3K.<xref rid="cit0042" ref-type="bibr">42</xref> Early AKT inhibitors, namely, Perifosine and MK2206, exhibited no clinical significance in Phase II trials,<xref rid="cit0043" ref-type="bibr">43</xref> however, novel AKT inhibitors appear to be highly promising in Phase I trials.<xref rid="cit0044" ref-type="bibr">44</xref>,<xref rid="cit0045" ref-type="bibr">45</xref> Other AKT inhibitors (AZD5363) are under clinical development either as a mono- or chemo-combined therapy or as targeted agents for TNBC therapy.<xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>
<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/553421/553421%20Revised%20Supplemental%20Table%201.docx" ext-link-type="uri">Supplemental Table 1</ext-link></underline> summarizes the related clinical trials.</p></sec><sec id="s0002-s2002-s3002-s4003"><title>mTOR Inhibitors</title><p>A phase I investigation explored the synergistic effect of the chemotherapeutic doxorubicin, antiangiogenic bevacizumab, and mTOR inhibitors (Temsirolimus, Everolimus) in TNBC patients.<xref rid="cit0047" ref-type="bibr">47</xref> Clinical trials related with them are provided <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/553421/553421%20Revised%20Supplemental%20Table%201.docx" ext-link-type="uri">Supplemental Table 1</ext-link></underline>.</p></sec><sec id="s0002-s2002-s3002-s4004"><title>Dual PI3K/AKT/mTOR Inhibitors</title><p>Apitolisib is a PI3K inhibitor that also targets mTORC.<xref rid="cit0048" ref-type="bibr">48</xref> Omipalisib is reported to have strong pan-PI3K and mTORC suppression abilities in a HER2<sup>+</sup> model.<xref rid="cit0049" ref-type="bibr">49</xref> Preclinical information confirmed the mTORC1/2 inhibitor AZD2014-based inhibition of p-AKT, relative to everolimus in TNBC patient-based xerograph models.<xref rid="cit0050" ref-type="bibr">50</xref> Voxtalisib is another PI3K and mTOR inhibitor that is presently under investigation in clinical trials as a potential HR<sup>+</sup> tumor treatment.<xref rid="cit0051" ref-type="bibr">51</xref> Dual PI3K/AKT/mTOR inhibitors are often administered alongside other drugs. Dactolisib is a potential PI3K and mTOR inhibitor that will supplement MEK162 (a MEK inhibitor) therapy in treated TNBC.<xref rid="cit0052" ref-type="bibr">52</xref>
<italic toggle="yes">De</italic> et al also reported that the synergistic effect of GDC-0980 (pan-PI3K and mTOR inhibitor) and ABT888 (a PARPi) significantly suppressed tumor development in a PTEN-null TNBC model.<xref rid="cit0053" ref-type="bibr">53</xref> Clinical trials are summarized in <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/553421/553421%20Revised%20Supplemental%20Table%201.docx" ext-link-type="uri">Supplemental Table 1</ext-link></underline>.</p></sec></sec><sec id="s0002-s2002-s3003"><title>NOTCH Signaling Network</title><p>The NOTCH axis is a robust bioindicator of TNBC. Notch gain of function mutations occured in 10% of TNBC patients. The NOTCH signaling pathway utilizes four distinct receptor types (Notch-1 through Notch-4) which interact with five specific ligand molecules (Delta-like 1, 3, and 4 along with Jagged proteins 1 and 2).<xref rid="cit0054" ref-type="bibr">54</xref> AL101 is currently being developed as a pan-Notch inhibitor of the NOTCH network.<xref rid="cit0055" ref-type="bibr">55</xref> Relevant clinical trials are summarized in <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/553421/553421%20Revised%20Supplemental%20Table%201.docx" ext-link-type="uri">Supplemental Table 1</ext-link></underline>.</p></sec><sec id="s0002-s2002-s3004"><title>CDK-Rb Signaling Network</title><p>The cyclin-dependent kinases 4 and 6 (CDK4/6)&#8211;RB1 axis modulates the G1 phase restriction point of the cell cycle, and cancers often impair this signal transduction to initiate constitutively active cell proliferation.<xref rid="cit0111" ref-type="bibr">111</xref>,<xref rid="cit0112" ref-type="bibr">112</xref> Mutations and aberrations impacting the Rb axis are another hallmark of TNBC etiology.<xref rid="cit0004" ref-type="bibr">4</xref>,<xref rid="cit0113" ref-type="bibr">113</xref> Pharmaceutics-based CDK4/6 inhibition (CDK4/6i) generally abrogates RB phosphorylation, thereby affecting the G1/S checkpoint.<xref rid="cit0114" ref-type="bibr">114</xref> More recently, it was revealed that RB-harboring TNBC are highly responsive to CDK4/6 inhibition, thereby providing ample evidence of the strong potential of CDK4/6i as a successful TNBC therapy.<xref rid="cit0021" ref-type="bibr">21</xref>,<xref rid="cit0115" ref-type="bibr">115&#8211;117</xref> Flavopiridol became the first broad-spectrum CDK inhibitor examined in clinical trials.<xref rid="cit0056" ref-type="bibr">56</xref> Palbociclib, a specific CDK4/6 inhibitor, has been approved by the FDA for the treatment of ER-positive advanced BC<xref rid="cit0057" ref-type="bibr">57</xref>,<xref rid="cit0058" ref-type="bibr">58</xref> and is expected to provide new treatment strategies for TNBC patients, especially the LAR subtype of TNBC.<xref rid="cit0021" ref-type="bibr">21</xref> At present, there are three FDA-approved CDK4/6i: Palbociclib, Ribociclib, and Abemaciclib for BC patients. Two other CDK4/6i (LEE011 and LY2835219) are under examination in dose-screening Phase I investigations. Relevant clinical trials are presented in <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/553421/553421%20Revised%20Supplemental%20Table%201.docx" ext-link-type="uri">Supplemental Table 1</ext-link></underline>.</p></sec><sec id="s0002-s2002-s3005"><title>EGFR Activation</title><p>Unlike non-TNBC,<xref rid="cit0118" ref-type="bibr">118</xref>,<xref rid="cit0119" ref-type="bibr">119</xref> TNBCs exhibited close to 78% EGFR overexpression,<xref rid="cit0118" ref-type="bibr">118</xref>,<xref rid="cit0120" ref-type="bibr">120&#8211;123</xref> indicating the possibility of using EGFR as a target for TNBC therapy. Among the reasons for EGFR overexpression in TNBC is EGFR gene amplification, which is highly variable and present in close to 24% TNBC patients,<xref rid="cit0124" ref-type="bibr">124&#8211;126</xref> and EGFR gene mutation.<xref rid="cit0124" ref-type="bibr">124</xref>,<xref rid="cit0126" ref-type="bibr">126</xref> Given these evidences, EGFR tyrosine kinase inhibitors (TKI) and anti-EGFR mAb have been examined alone and alongside chemotherapy in the early<xref rid="cit0127" ref-type="bibr">127</xref>,<xref rid="cit0128" ref-type="bibr">128</xref> and metastatic stage of disease.<xref rid="cit0129" ref-type="bibr">129</xref>,<xref rid="cit0130" ref-type="bibr">130</xref> TKIs like Erlotinib and Gefitinib target EGFR; anti-EGFR mAb, which include Afatinib and Lapatinib target EGFR and ERBB2<xref rid="cit0059" ref-type="bibr">59</xref> in TNBC therapy. The available clinical information involving Erlotinib, Afatinib, and Lapatinib usage are presented in <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/553421/553421%20Revised%20Supplemental%20Table%201.docx" ext-link-type="uri">Supplemental Table 1</ext-link></underline>.</p></sec><sec id="s0002-s2002-s3006"><title>Angiogenesis Signaling Network</title><p>Angiogenesis critically modulates tumor growth.<xref rid="cit0131" ref-type="bibr">131</xref> Vascular endothelial growth factor (VEGF) is the primary angiogenic modulator, and it is synthesized during BC.<xref rid="cit0131" ref-type="bibr">131</xref> Angiogenic homeostasis is maintained via an intricate balance of pro- angiogenic agents (VEGF, FGF and PDGF, HIFs) and anti-angiogenic agents (thrombospondin, angiostatin and endostatin).<xref rid="cit0132" ref-type="bibr">132</xref> VEGF are expressed in 30&#8211;60% of TNBC,<xref rid="cit0133" ref-type="bibr">133</xref> thereby raising the possibility of an anti-VEGF based therapy for TNBC. Herein, we summarized relevant and potential therapies targeting angiogenesis in TNBC.</p><sec id="s0002-s2002-s3006-s4001"><title>VEGFR</title><p>TNBC patients exhibit markedly elevated intra-tumoral VEGF rates, relative to non-TNBC patients.<xref rid="cit0134" ref-type="bibr">134</xref> VEGF family includes five ligands (VEGFA, VEGFB, VEGFC, VEGFD, and placental growth factor), five receptors (VEGFR1, VEGFR2, VEGFR3, NRP1 and NRP2).<xref rid="cit0132" ref-type="bibr">132</xref> Since angiogenesis is critical for tumor cell proliferation, Bevacizumab, a VEGF-A-binding mAb, has gained much attention as a potential TNBC therapeutic target.<xref rid="cit0060" ref-type="bibr">60</xref> Under a neoadjuvant situation, bevacizumab is reported to strongly enhance pathological complete response (pCR).<xref rid="cit0135" ref-type="bibr">135</xref> In addition, the VEGF axis-targeting interaction efficacy can potentially be modified using other ligands, such as, Semaphorins, that associate with both NRP1 and NRP2, suggesting that Semaphorins a potential may be new anti-angiogenic therapeutic target.<xref rid="cit0063" ref-type="bibr">63</xref> Small molecule TKIs have been developed to prohibit angiogenesis through binding receptors.<xref rid="cit0136" ref-type="bibr">136</xref> Sunitinib represents one such agent, binding multiple moieties including VEGFR1, VEGFR2, PDGFR and KIT.<xref rid="cit0061" ref-type="bibr">61</xref> IMC-1121 (Ramucirumab) is a fully humanized mAb of VEGFR, and it is reported to demonstrate strong efficacy against BC.<xref rid="cit0062" ref-type="bibr">62</xref> VEGF-Trap (Aflibercept) is a decoy VEGFR that potentially sequesters VEGF to disrupt its association with its true receptor.<xref rid="cit0064" ref-type="bibr">64</xref> Ongoing clinical investigations evaluating the effectiveness of the aforementioned drugs are summarized in <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/553421/553421%20Revised%20Supplemental%20Table%201.docx" ext-link-type="uri">Supplemental Table 1</ext-link></underline>.</p></sec><sec id="s0002-s2002-s3006-s4002"><title>Fibroblast Growth Factor Receptors (FGFR)</title><p>FGFRs belong to the trans-membranal receptor family that are crucial for angiogenic regulation.<xref rid="cit0055" ref-type="bibr">55</xref> Tumor-based fibroblasts are ubiquitous present in BC, whereby they generate a myriad of growth factors, namely, basic fibroblast growth factor (bFGF).<xref rid="cit0137" ref-type="bibr">137</xref> The bFGF-FGFR axis activation is a hallmark of carcinogenesis.<xref rid="cit0138" ref-type="bibr">138</xref> FGFR1, FGFR2, FGFR3, and FGFR4 make up the FGFR family of RTKs.<xref rid="cit0139" ref-type="bibr">139&#8211;141</xref> FGFR1 over-expression is typically found in 18% of TNBC patients, with the FGFR1 gene amplification accounting for 33% of cases,<xref rid="cit0142" ref-type="bibr">142</xref> and FGFR2 amplification in &lt;5% of cases.<xref rid="cit0143" ref-type="bibr">143</xref> Clinical trials have reported favorable outcomes for both multi-targeted TKIs<xref rid="cit0144" ref-type="bibr">144</xref> and FGFR-specific TKIs.<xref rid="cit0145" ref-type="bibr">145</xref> Unlike TKIs, anti-FGFR isoform antibodies<xref rid="cit0146" ref-type="bibr">146</xref> and FGF ligand inhibitors were also shown to have strong anti-TNBC efficacies.<xref rid="cit0147" ref-type="bibr">147</xref> AZD4547,<xref rid="cit0065" ref-type="bibr">65</xref>,<xref rid="cit0066" ref-type="bibr">66</xref> BGJ398 (Infigratinib),<xref rid="cit0067" ref-type="bibr">67</xref> BLU9931,<xref rid="cit0068" ref-type="bibr">68</xref> Debio-1347,<xref rid="cit0069" ref-type="bibr">69</xref> Dovitinib (TKI258),<xref rid="cit0070" ref-type="bibr">70</xref> FIIN-2,<xref rid="cit0071" ref-type="bibr">71</xref> JNJ-42756493,<xref rid="cit0072" ref-type="bibr">72</xref> LY2874455<xref rid="cit0073" ref-type="bibr">73</xref> and Ponatinib<xref rid="cit0074" ref-type="bibr">74</xref> are small but robust molecular compounds that suppress FGFRs at reduced concentrations. Relevant clinical trials were hoped to develop in the future.</p></sec></sec><sec id="s0002-s2002-s3007"><title>HER2-Low TNBC</title><p>A new stratification was proposed for BC with reduced HER2 content and undetectable gene amplification (IHC) 1+ or IHC 2+ with negative in situ hybridization (ISH). This is termed as HER2-low.<xref rid="cit0055" ref-type="bibr">55</xref> Anti-HER2 agent technology has also been transformed from the classical binary stratification to the &#8220;HER2-low&#8221; BC classification.<xref rid="cit0075" ref-type="bibr">75</xref> Antibody-drug conjugates (ADCs) are a relatively new anticancer therapy that facilitates the specific deployment of a robust cytotoxic &#8220;payload&#8221; to cancer cells via targeted association between antibody and cancer cell surface molecule.<xref rid="cit0148" ref-type="bibr">148</xref> At present, multiple ADCs are being examined for drug efficacy and safety.<xref rid="cit0149" ref-type="bibr">149</xref> Till now, four anti-HER2 ADCs were reported to produce strong anti-cancer activity among HER2-low BC patients: Trastuzumab Deruxtecan (DXd), Trastuzumab Duocarmazine, Disitamab Vedotin, and MRG002.<xref rid="cit0075" ref-type="bibr">75</xref> The anti-HER2 ADC Dxd (DS-8201a) demonstrated satisfactory outcome in a Phase 1 investigation involving advanced HER2-low solid tumors, which including BC (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02564900">NCT02564900</ext-link>). Trastuzumab Duocarmazine (SYD985) comprises an anti-HER2 antibody attached to a DNA-alkylating duocarmycin payload via a cleavable linker.<xref rid="cit0075" ref-type="bibr">75</xref> Disitamab Vedotin (RC48-ADC) is an ADC made up of a new anti-HER2 humanized antibody, hertuzumab, which is attached to a microtubular inhibitor monomethyl auristatin E (MMAE) payload via a cleavable linker.<xref rid="cit0075" ref-type="bibr">75</xref> MRG002 is a newly designed HER2-targeted ADC made up of modified trastuzumab linked with a cleavable linker to a MMAE payload.<xref rid="cit0075" ref-type="bibr">75</xref> Several anti-HER2 vaccines are currently being examined among HER2-low BC population, among them, some displayed good outcome among TNBC patients.<xref rid="cit0149" ref-type="bibr">149</xref>,<xref rid="cit0150" ref-type="bibr">150</xref> Anti-HER2 TKIs, Neratinib,<xref rid="cit0076" ref-type="bibr">76</xref> and other anti-HER2 TKIs, namely, Poziotinib and Pyrotinib, are also under investigation as potential anti-cancer agents. Relevant clinical trials are provided in <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/553421/553421%20Revised%20Supplemental%20Table%201.docx" ext-link-type="uri">Supplemental Table 1</ext-link></underline>.</p></sec><sec id="s0002-s2002-s3008"><title>DDR Signaling Network</title><p>TNBC patients exhibited a high frequency of distinctive DDR alterations.<xref rid="cit0004" ref-type="bibr">4</xref>,<xref rid="cit0151" ref-type="bibr">151&#8211;153</xref> The DDR axis, which modulates damaged DNA repair and genomic stability maintenance, is, in turn, regulated by DNA damage sensors, cell cycle checkpoints, diverse DNA repair signals and cellular apoptosis.<xref rid="cit0154" ref-type="bibr">154</xref>,<xref rid="cit0155" ref-type="bibr">155</xref> The ATR-CHK1-WEE1 axis is most targeted among all the DDR networks. VX-970 (VE-822 or Berzosertib) is a robust and specific ATR inhibitor, and the first ATR inhibitor to be examined in clinical trials. In another clinical trial, AZD6738 (Ceralasertib), a targeted ATR inhibitor, was employed as a second ATR inhibitor.<xref rid="cit0035" ref-type="bibr">35</xref> The CHK1 inhibitor AZD7762 is an ATP-competitive dual CHK1/2 inhibitor, which exerts its primary antitumor property via CHK1 suppression.<xref rid="cit0077" ref-type="bibr">77</xref> TNBC sensitivity to AZD7762 is substantially augmented by RB deficiency in vitro and <italic toggle="yes">in xenografts</italic> likely due to the non-existent RB enhanced DNA replication stress.<xref rid="cit0078" ref-type="bibr">78</xref> V158411, another ATP-competitive CHK1/2 inhibitor, demonstrated marked cytotoxicity in TNBC versus HR<sup>+</sup> BC. LY2606368 (Prexasertib) is a second-generation CHK1/2 dual inhibitor that selectively targets CHK1. LY2606368 monotherapy was proven to be safe and efficacious among high-grade ovarian carcinoma patients, who have numerous commonalities with TNBC patients.<xref rid="cit0079" ref-type="bibr">79</xref> UCN-01 was the first proposed CHK1 inhibitor, and its synergistic effect with gemcitabine inhibits TNBC as UCN-01 drives the gemcitabine-induced S-phase cell arrest the through G2/M checkpoints, thereby augmenting DNA damage, and accelerating cellular death.<xref rid="cit0080" ref-type="bibr">80</xref> Despite the recent emergence of several small-molecule WEE1 inhibitors, AZD1775 (Adavosertib) is the most studied, and only molecule to enter clinical trials till date.<xref rid="cit0081" ref-type="bibr">81</xref> Relevant clinical trials are provided in <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/553421/553421%20Revised%20Supplemental%20Table%201.docx" ext-link-type="uri">Supplemental Table 1</ext-link></underline>.</p></sec><sec id="s0002-s2002-s3009"><title>Immunotherapy</title><p>TNBC have strongly upregulated PD-1/PD-L1 levels. Consequently, scientists examined the efficacies of these checkpoint inhibitors in mono- and combined therapies, with modest outcome.<xref rid="cit0156" ref-type="bibr">156</xref> CTLA-4, PD-1, and PD-L1 inhibitors are the extensively examined immune checkpoint blockers (ICB). CTLA-4/CD152, found on CD8<sup>+</sup> and CD4<sup>+</sup> T cells,<xref rid="cit0157" ref-type="bibr">157</xref> critically activates or inhibits T cell-induced immune response. Among the current CTLA-4 inhibitors are Ipilimumab and Tremelimumab.<xref rid="cit0082" ref-type="bibr">82</xref> PD-1/CD279 functions as a single-chain glycoprotein<xref rid="cit0158" ref-type="bibr">158</xref> predominantly expressed on the membranes of various immune cells including T lymphocytes, B lymphocytes, NK cells, monocytic cells, DCs and tumor tissues.<xref rid="cit0159" ref-type="bibr">159</xref> PD-1 is a major activated T cell immune checkpoint receptor, and it strongly modulates immune suppression. The current PD-1 inhibitors are Pembrolizumab, Pidilizumab, and Nivolumab. Among them, nivolumab is a fully humanized IgG4 mAb<xref rid="cit0083" ref-type="bibr">83</xref> with remarkable clinical outcome. PD-L1 inhibits and inactivates T-cell via its association with the PD-1 and B7-1 receptors on stimulated T cells.<xref rid="cit0160" ref-type="bibr">160</xref> Atezolizumab, a humanized anti-PD-L1 IgG-1 mAb,<xref rid="cit0083" ref-type="bibr">83</xref> also enhances median OS and ORR among lung cancer patients.<xref rid="cit0161" ref-type="bibr">161</xref> Relevant clinical trials are summarized in <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/553421/553421%20Revised%20Supplemental%20Table%201.docx" ext-link-type="uri">Supplemental Table 1</ext-link></underline>.</p></sec><sec id="s0002-s2002-s3010"><title>Androgen Receptor (AR)</title><p>Approximately, 25&#8211;75% TNBC patients have enhanced AR expression level, among whom, the strongest expression is seen among patients with the LAR subtype.<xref rid="cit0162" ref-type="bibr">162</xref> Using both in vitro and in vivo investigations, AR<sup>+</sup> TNBCs were shown to respond well to AR antagonist therapy.<xref rid="cit0163" ref-type="bibr">163</xref>,<xref rid="cit0164" ref-type="bibr">164</xref> Currently, three anti-AR drugs, Bicalutamide, Enzalutamide, and Seviteronel, are under clinical investigation.<xref rid="cit0084" ref-type="bibr">84</xref> All available anti-androgen therapy-based clinical information are provided in <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/553421/553421%20Revised%20Supplemental%20Table%201.docx" ext-link-type="uri">Supplemental Table 1</ext-link></underline>.</p></sec></sec><sec id="s0002-s2003"><title>Coding Genes Involved in Chemo-Sensitive and Chemo-Resistance of TNBC</title><p>Unlike non-TNBC, TNBC are generally larger, of enhanced grade, and node positive. Hence, for TNBC, chemotherapy is the best treatment option.<xref rid="cit0007" ref-type="bibr">7</xref> Among the recommended interventions are taxanes and anthracyclines, however, platinum-based regimens could be employed in neo-adjuvant settings.<xref rid="cit0165" ref-type="bibr">165</xref> Taxanes are the primary constituents of neoadjuvant chemotherapy. Mechanically, they suppress microtubule depolymerization to repress cancer cell proliferation.<xref rid="cit0166" ref-type="bibr">166</xref> TNBC patients are typically more responsive to neoadjuvant therapy than ER<sup>+</sup> BC. They also have considerably worse OS, relative to non-TNBC tumor patients despite having better pCR rates; thus, this is known as the &#8220;triple negative paradox&#8221;.<xref rid="cit0167" ref-type="bibr">167</xref> Given that chemotherapy is the main form of TNBC treatment, chemoresistance is the primary contributor of TNBC recurrence and metastasis. Currently, there is a lack of clinically employed bioindicators for sensitive or resistant tumor classification. Moreover, there are no treatment approaches geared toward the chemo-refractory cases.<xref rid="cit0168" ref-type="bibr">168</xref> In this report, we first discussed the TNBC-associated chemotherapy-sensitivity and chemotherapy-resistance coding genes. The chemo-sensitive genes are strongly diminished in chemo-resistant TNBCs. It is speculated that future TNBC treatment may utilize overexpression of the chemo-sensitive genes (<xref rid="f0002" ref-type="fig">Figure 2</xref> and <xref rid="t0003" ref-type="table">Table 3</xref>). Alternatively, the chemo-resistant genes are ubiquitously expressed in chemo-resistant TNBC. Thus, future research may entail suppression of the aforementioned genes in TNBC (<xref rid="f0003" ref-type="fig">Figure 3</xref> and <xref rid="t0004" ref-type="table">Table 4</xref>). Due to the strongly altered states of these genes, they are served as strong candidates for estimating the chemotherapeutic response of TNBC patients, which, in turn, can assist in enhancing patient care and prognosis. However, whether these genes can become indicators of drug resistance in patients still has a long way to go.
<table-wrap position="float" id="t0003" orientation="portrait"><label>Table 3</label><caption><p>Chemotherapy-Sensitive Genes of TNBC</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Genes</th><th align="center" rowspan="1" colspan="1">Target Gene</th><th align="center" rowspan="1" colspan="1">Medication</th><th align="center" rowspan="1" colspan="1">Refs.</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">CLDN1</td><td rowspan="1" colspan="1">Unknown pathway</td><td rowspan="1" colspan="1">PTX</td><td rowspan="1" colspan="1">[<xref rid="cit0169" ref-type="bibr">169</xref>]</td></tr><tr><td rowspan="1" colspan="1">DAB2IP</td><td rowspan="1" colspan="1">RAC1-mediated &#946;-catenin nuclear accumulation</td><td rowspan="1" colspan="1">Docetaxel</td><td rowspan="1" colspan="1">[<xref rid="cit0170" ref-type="bibr">170</xref>]</td></tr><tr><td rowspan="1" colspan="1">TXNIP</td><td rowspan="1" colspan="1">ROS-based DNA damage</td><td rowspan="1" colspan="1">DOX</td><td rowspan="1" colspan="1">[<xref rid="cit0171" ref-type="bibr">171&#8211;173</xref>]</td></tr><tr><td rowspan="1" colspan="1">C/EBP-&#946; LIP</td><td rowspan="1" colspan="1">Pgp</td><td rowspan="1" colspan="1">Anthracycline</td><td rowspan="1" colspan="1">[<xref rid="cit0174" ref-type="bibr">174</xref>, <xref rid="cit0175" ref-type="bibr">175</xref>]</td></tr><tr><td rowspan="1" colspan="1">CREB3L1</td><td rowspan="1" colspan="1">Unknown pathway</td><td rowspan="1" colspan="1">Doxorubicin</td><td rowspan="1" colspan="1">[<xref rid="cit0176" ref-type="bibr">176</xref>]</td></tr><tr><td rowspan="1" colspan="1">ATL-I</td><td rowspan="1" colspan="1">CTGF</td><td rowspan="1" colspan="1">PTX</td><td rowspan="1" colspan="1">[<xref rid="cit0177" ref-type="bibr">177</xref>, <xref rid="cit0178" ref-type="bibr">178</xref>]</td></tr><tr><td rowspan="1" colspan="1">SLFN12</td><td rowspan="1" colspan="1">CHK1 and CHK2</td><td rowspan="1" colspan="1">PTX</td><td rowspan="1" colspan="1">[<xref rid="cit0179" ref-type="bibr">179</xref>, <xref rid="cit0180" ref-type="bibr">180</xref>]</td></tr><tr><td rowspan="1" colspan="1">PAR-4</td><td rowspan="1" colspan="1">Caspase-8</td><td rowspan="1" colspan="1">Doxorubicin</td><td rowspan="1" colspan="1">[<xref rid="cit0181" ref-type="bibr">181</xref>]</td></tr><tr><td rowspan="1" colspan="1">ETS-1</td><td rowspan="1" colspan="1">IKK&#945;/NF-&#954;B pathway</td><td rowspan="1" colspan="1">Cisplatin</td><td rowspan="1" colspan="1">[<xref rid="cit0182" ref-type="bibr">182</xref>]</td></tr></tbody></table></table-wrap>
<table-wrap position="float" id="t0004" orientation="portrait"><label>Table 4</label><caption><p>Chemotherapy-Resistant Genes of TNBC</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Genes</th><th align="center" rowspan="1" colspan="1">Target Gene/Signaling Pathway</th><th align="center" rowspan="1" colspan="1">Medicine</th><th align="center" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">SERCA2</td><td rowspan="1" colspan="1">LC3B</td><td rowspan="1" colspan="1">PTX</td><td rowspan="1" colspan="1">[<xref rid="cit0183" ref-type="bibr">183</xref>]</td></tr><tr><td rowspan="1" colspan="1">HORMAD1</td><td rowspan="1" colspan="1">Apoptosis and Autophagy</td><td rowspan="1" colspan="1">Docetaxel</td><td rowspan="1" colspan="1">[<xref rid="cit0184" ref-type="bibr">184&#8211;187</xref>]</td></tr><tr><td rowspan="1" colspan="1">TNFSF13</td><td rowspan="1" colspan="1">AKT-mTOR</td><td rowspan="1" colspan="1">PTX</td><td rowspan="1" colspan="1">[<xref rid="cit0188" ref-type="bibr">188</xref>]</td></tr><tr><td rowspan="1" colspan="1">PPP1R14B</td><td rowspan="1" colspan="1">STMN1</td><td rowspan="1" colspan="1">Paclitaxel</td><td rowspan="1" colspan="1">[<xref rid="cit0189" ref-type="bibr">189</xref>]</td></tr><tr><td rowspan="1" colspan="1">CENPF</td><td rowspan="1" colspan="1">Chk1</td><td rowspan="1" colspan="1">Adriamycin</td><td rowspan="1" colspan="1">[<xref rid="cit0190" ref-type="bibr">190&#8211;192</xref>]</td></tr><tr><td rowspan="1" colspan="1">Notch1</td><td rowspan="1" colspan="1">MVP/AKT</td><td rowspan="1" colspan="1">Cisplatin</td><td rowspan="1" colspan="1">[<xref rid="cit0193" ref-type="bibr">193</xref>]</td></tr><tr><td rowspan="1" colspan="1">HJURP</td><td rowspan="1" colspan="1">HJURP/YAP1/NDRG1 axis</td><td rowspan="1" colspan="1">Doxorubicin</td><td rowspan="1" colspan="1">[<xref rid="cit0194" ref-type="bibr">194</xref>]</td></tr><tr><td rowspan="1" colspan="1">BAIAP2L1</td><td rowspan="1" colspan="1">RPL3/AKT</td><td rowspan="1" colspan="1">Docetaxel</td><td rowspan="1" colspan="1">[<xref rid="cit0195" ref-type="bibr">195</xref>]</td></tr><tr><td rowspan="1" colspan="1">RASAL2</td><td rowspan="1" colspan="1">MEK/EGFR</td><td rowspan="1" colspan="1">Cisplatin</td><td rowspan="1" colspan="1">[<xref rid="cit0168" ref-type="bibr">168</xref>]</td></tr><tr><td rowspan="1" colspan="1">SYTL4</td><td rowspan="1" colspan="1">C2A domain</td><td rowspan="1" colspan="1">PTX</td><td rowspan="1" colspan="1">[<xref rid="cit0196" ref-type="bibr">196</xref>]</td></tr><tr><td rowspan="1" colspan="1">MENA</td><td rowspan="1" colspan="1">MAPK signaling</td><td rowspan="1" colspan="1">PTX</td><td rowspan="1" colspan="1">[<xref rid="cit0197" ref-type="bibr">197</xref>]</td></tr><tr><td rowspan="1" colspan="1">Aurora-A</td><td rowspan="1" colspan="1">FOXM1</td><td rowspan="1" colspan="1">PTX</td><td rowspan="1" colspan="1">[<xref rid="cit0198" ref-type="bibr">198</xref>]</td></tr><tr><td rowspan="1" colspan="1">GRP78</td><td rowspan="1" colspan="1">p-AKT/mTOR pathway</td><td rowspan="1" colspan="1">Pirarubicin</td><td rowspan="1" colspan="1">[<xref rid="cit0199" ref-type="bibr">199</xref>, <xref rid="cit0200" ref-type="bibr">200</xref>]</td></tr><tr><td rowspan="1" colspan="1">CXCL8</td><td rowspan="1" colspan="1">Apoptosis signaling</td><td rowspan="1" colspan="1">PTX</td><td rowspan="1" colspan="1">[<xref rid="cit0201" ref-type="bibr">201</xref>, <xref rid="cit0202" ref-type="bibr">202</xref>]</td></tr><tr><td rowspan="1" colspan="1">BCKDK</td><td rowspan="1" colspan="1">BCAA flux</td><td rowspan="1" colspan="1">DOX</td><td rowspan="1" colspan="1">[<xref rid="cit0203" ref-type="bibr">203</xref>]</td></tr><tr><td rowspan="1" colspan="1">PRKCQ</td><td rowspan="1" colspan="1">Bim</td><td rowspan="1" colspan="1">PTX; doxorubicin</td><td rowspan="1" colspan="1">[<xref rid="cit0204" ref-type="bibr">204</xref>]</td></tr><tr><td rowspan="1" colspan="1">PSMB5</td><td rowspan="1" colspan="1">Apoptosis</td><td rowspan="1" colspan="1">PTX</td><td rowspan="1" colspan="1">[<xref rid="cit0205" ref-type="bibr">205</xref>]</td></tr><tr><td rowspan="1" colspan="1">LIN9</td><td rowspan="1" colspan="1">CCSAP</td><td rowspan="1" colspan="1">PTX</td><td rowspan="1" colspan="1">[<xref rid="cit0206" ref-type="bibr">206</xref>]</td></tr><tr><td rowspan="1" colspan="1">PGK1</td><td rowspan="1" colspan="1">XAF1</td><td rowspan="1" colspan="1">PTX</td><td rowspan="1" colspan="1">[<xref rid="cit0207" ref-type="bibr">207</xref>]</td></tr><tr><td rowspan="1" colspan="1">SERPINE1</td><td rowspan="1" colspan="1">VEGFA</td><td rowspan="1" colspan="1">PTX</td><td rowspan="1" colspan="1">[<xref rid="cit0208" ref-type="bibr">208</xref>]</td></tr><tr><td rowspan="1" colspan="1">ATAD3A</td><td rowspan="1" colspan="1">PINK1</td><td rowspan="1" colspan="1">PTX</td><td rowspan="1" colspan="1">[<xref rid="cit0209" ref-type="bibr">209</xref>]</td></tr><tr><td rowspan="1" colspan="1">TRA2A</td><td rowspan="1" colspan="1">Splicing factors</td><td rowspan="1" colspan="1">PTX</td><td rowspan="1" colspan="1">[<xref rid="cit0210" ref-type="bibr">210</xref>]</td></tr><tr><td rowspan="1" colspan="1">HMGA1</td><td rowspan="1" colspan="1">HMGA1/p27/stathmin</td><td rowspan="1" colspan="1">Paclitaxel</td><td rowspan="1" colspan="1">[<xref rid="cit0211" ref-type="bibr">211</xref>, <xref rid="cit0212" ref-type="bibr">212</xref>]</td></tr><tr><td rowspan="1" colspan="1">IMP3</td><td rowspan="1" colspan="1">ABCG2</td><td rowspan="1" colspan="1">Doxorubicin</td><td rowspan="1" colspan="1">[<xref rid="cit0213" ref-type="bibr">213</xref>]</td></tr><tr><td rowspan="1" colspan="1">RAD6</td><td rowspan="1" colspan="1">Microtubule dynamics</td><td rowspan="1" colspan="1">PTX</td><td rowspan="1" colspan="1">[<xref rid="cit0214" ref-type="bibr">214</xref>]</td></tr><tr><td rowspan="1" colspan="1">G6PD</td><td rowspan="1" colspan="1">Unknown signaling</td><td rowspan="1" colspan="1">DOX</td><td rowspan="1" colspan="1">[<xref rid="cit0215" ref-type="bibr">215</xref>]</td></tr><tr><td rowspan="1" colspan="1">NEK2B</td><td rowspan="1" colspan="1">&#946;-catenin</td><td rowspan="1" colspan="1">PTX</td><td rowspan="1" colspan="1">[<xref rid="cit0216" ref-type="bibr">216</xref>, <xref rid="cit0217" ref-type="bibr">217</xref>]</td></tr><tr><td rowspan="1" colspan="1">CERK</td><td rowspan="1" colspan="1">Unknown signaling</td><td rowspan="1" colspan="1">Paclitaxel; Cisplatin</td><td rowspan="1" colspan="1">[<xref rid="cit0218" ref-type="bibr">218</xref>]</td></tr><tr><td rowspan="1" colspan="1">RUNX1</td><td rowspan="1" colspan="1">Unknown signaling</td><td rowspan="1" colspan="1">Paclitaxel</td><td rowspan="1" colspan="1">[<xref rid="cit0219" ref-type="bibr">219</xref>]</td></tr><tr><td rowspan="1" colspan="1">DSTYK</td><td rowspan="1" colspan="1">Unknown signaling</td><td rowspan="1" colspan="1">DOX</td><td rowspan="1" colspan="1">[<xref rid="cit0220" ref-type="bibr">220</xref>]</td></tr></tbody></table></table-wrap>
<fig position="float" id="f0002" fig-type="figure" orientation="portrait"><label>Figure 2</label><caption><p>Genes promoting chemotherapeutic sensitivity in TNBC.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="BCTT-17-1341-g0002.jpg"/></fig>
<fig position="float" id="f0003" fig-type="figure" orientation="portrait"><label>Figure 3</label><caption><p>Genes promoting chemotherapeutic resistance in TNBC.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="BCTT-17-1341-g0003.jpg"/></fig></p><sec id="s0002-s2003-s3001"><title>Chemotherapy-Sensitivity Genes of TNBC</title><sec id="s0002-s2003-s3001-s4001"><title>CLDN1</title><p>Approximately 77% TNBC display little to no claudin-1 (CLDN1) expression, and this deficiency is strongly associated with worse outcome. One study reported that CLDN1 enhances TNBC cell line sensitivity to chemotherapeutic agents (paclitaxel, abbreviated as PTX) for BC therapy. These evidences confirm CLDN1 as a chemotherapeutic response indicator for TNBC patients.<xref rid="cit0169" ref-type="bibr">169</xref></p></sec><sec id="s0002-s2003-s3001-s4002"><title>DAB2IP</title><p>DAB2IP abrogates TNBC chemoresistance (Docetaxel) by suppressing the RAC1-triggered nuclear &#946;-catenin transfer. Decitabine treatment re-expresses DAB2IP by preventing DNA methylation, thereby enhancing its potential in the management of TNBC.<xref rid="cit0170" ref-type="bibr">170</xref></p></sec><sec id="s0002-s2003-s3001-s4003"><title>Thioredoxin-Interacting Protein (TXNIP)</title><p>TXNIP originates from the &#945;-arrestin family of proteins,<xref rid="cit0171" ref-type="bibr">171</xref> which tightly modulate various physiological activities via interaction with other proteins.<xref rid="cit0172" ref-type="bibr">172</xref> TXNIP accelerates cellular apoptosis, and inhibits chemo-resistant TNBC cellular growth both in vitro and in vivo by enhancing ROS-based DNA damage. The small molecular c-Myc inhibitor 10058-F4 enhances TXNIP content and augments intracellular ROS production to downregulate DOX-stimulated chemoresistance in TNBC. Combination with DOX further enhances the chemotherapeutic cytotoxic properties of 10058-F4.<xref rid="cit0173" ref-type="bibr">173</xref></p></sec><sec id="s0002-s2003-s3001-s4004"><title>C/EBP-&#946; LIP</title><p>Doxorubicin effectiveness depends on the number of drug efflux transporters like P-glycoprotein (Pgp) present within tumor cells.<xref rid="cit0174" ref-type="bibr">174</xref> One report revealed that blocking C/EBP-&#946; LIP degradation strongly enhances nitric oxide content, while reducing Pgp expression and activity, which, in turn, restores ER stress-dependent apoptosis and Doxorubicin-induced immunogenic cell apoptosis. This, in turn, rescues the anthracycline therapeutic activity in Pgp-positive TNBC.<xref rid="cit0175" ref-type="bibr">175</xref></p></sec><sec id="s0002-s2003-s3001-s4005"><title>cAMP Response Element Binding Protein 3-Like 1 (CREB3L1)</title><p>Researchers reported high CREB3L1 levels in chemotherapeutic sensitive cancers than chemotherapeutic resistant cancers. Similarly, high CREB3L1-harboring TNBC responds better to doxorubicin-based chemotherapy than low CREB3L1-harboring TNBC.<xref rid="cit0176" ref-type="bibr">176</xref></p></sec><sec id="s0002-s2003-s3001-s4006"><title>Atractylenolide-I (ATL-I)</title><p>ATL-I exerts strong anti-tumor influences against BC.<xref rid="cit0177" ref-type="bibr">177</xref> In particular, ATL-I reduces the CTGF transcript levels in TNBC, which reduces TNBC cell migration, diminishes the fibroblast to cancer-associated fibroblasts (CAFs) transformation, and enhances TNBC cell sensitivity to PTX.<xref rid="cit0178" ref-type="bibr">178</xref></p></sec><sec id="s0002-s2003-s3001-s4007"><title>SLFN12</title><p>SLFN12 is a newly discovered protein, with strong association with TNBC patient prognosis.<xref rid="cit0179" ref-type="bibr">179</xref> SLFN12 was shown to enhance TNBC cell sensitivity to radiation and cytotoxic drugs via reduction of CHK1 and CHK2 phosphorylation, which may be responsible for the OS differences between high and low SLFN12 tumor patients.<xref rid="cit0180" ref-type="bibr">180</xref></p></sec><sec id="s0002-s2003-s3001-s4008"><title>Prostate Apoptosis Response-4 (PAR-4)</title><p>PAR-4 deficiency in TNBC facilitates resistance to DNA damage-driven apoptosis, while simultaneously preventing caspase-8 activation. PAR-4 is downstream of caspase-8, and it functions by cleavage-triggered nuclear transfer of the C-terminal. Herein, researchers demonstrated that the nuclear transfer of the C-terminal PAR-4 fragment strongly depletes cIAP1, then activates caspase-8.<xref rid="cit0181" ref-type="bibr">181</xref></p></sec><sec id="s0002-s2003-s3001-s4009"><title>ETS1</title><p>Strong evidence suggests that the ETS1 dysregulation is behind the cisplatin resistance of TNBC. This indicates that ETS1 overexpression can potentially enhance cisplatin chemosensitivity by augmenting ABC transporters via the IKK&#945;/NF-&#954;B axis.<xref rid="cit0182" ref-type="bibr">182</xref></p></sec></sec><sec id="s0002-s2003-s3002"><title>Chemotherapy-Resistance Genes of TNBC</title><sec id="s0002-s2003-s3002-s4001"><title>Autophagy-Related Genes</title><sec id="s0002-s2003-s3002-s4001-s5001"><title>SERCA2</title><p>SERCA2 is intricately linked to TNBC progression, and it enhances TNBC cell chemoresistance. SERCA2 was shown to interact with LC3B via the LIR motif in order to augment WIPI2-independent autophagosome production, which promotes autophagy.<xref rid="cit0183" ref-type="bibr">183</xref></p></sec><sec id="s0002-s2003-s3002-s4001-s5002"><title>HORMA Domain&#8209;containing Protein 1 (HORMAD1)</title><p>HORMAD1 is a CTA with normal testicular expression, whereby it is engaged in essential physiological activities.<xref rid="cit0184" ref-type="bibr">184</xref> In TNBC, however, it is expressed in substantially elevated levels.<xref rid="cit0185" ref-type="bibr">185</xref>,<xref rid="cit0186" ref-type="bibr">186</xref> HORMAD1 modulates autophagy, and autophagic partially augments docetaxel-induced cellular apoptosis.<xref rid="cit0187" ref-type="bibr">187</xref></p></sec><sec id="s0002-s2003-s3002-s4001-s5003"><title>TNFSF13</title><p>TNFSF13 accelerates autophagy and desensitizes TNBC cells to chemotherapy by inhibiting the AKT-mTOR axis. Hence, the TNFSF13-autophagy network is an excellent target for reversing TNBC chemoresistance.<xref rid="cit0188" ref-type="bibr">188</xref></p></sec></sec><sec id="s0002-s2003-s3002-s4002"><title>Cell Cycle-Related Genes</title><sec id="s0002-s2003-s3002-s4002-s5001"><title>Protein Phosphatase 1 Regulatory Subunit 14B (PPP1R14B)</title><p>PPP1R14B belongs to the protein phosphatase 1 family of modulatory subunits, and it is strongly elevated in TNBC tissues. PPP1R14B augments STMN1-based &#945;-tubulin acetylation, microtubular stability, and cell-cycle progression, which, in turn, facilitates TNBC cell resistance to PTX.<xref rid="cit0189" ref-type="bibr">189</xref></p></sec><sec id="s0002-s2003-s3002-s4002-s5002"><title>CENPF</title><p>CENPF expression is strongly elevated in TNBC, and it is linked to worse outcome in patients undergoing chemotherapy.<xref rid="cit0190" ref-type="bibr">190</xref>,<xref rid="cit0191" ref-type="bibr">191</xref> In vitro CENPF deficiency strongly enhances adriamycin (ADR)&#8209;driven cytotoxicity in MDA&#8209;MB&#8209;231 and ADR&#8209;resistant cells (MDA&#8209;MB&#8209;231/ADR). CENPF also modulates the Chk1&#8209;based G2/M phase arrest, and associates with Rb to sequester E2F1 in TNBC. Given the critical E2F1 role in DNA damage response and repair, discovery of a new signal transduction whereby CENPF modulates the Rb&#8209;E2F1 network will enable a novel approach to overcoming chemoresistance in TNBC.<xref rid="cit0192" ref-type="bibr">192</xref></p></sec></sec><sec id="s0002-s2003-s3002-s4003"><title>Proliferation-Related Genes</title><sec id="s0002-s2003-s3002-s4003-s5001"><title>Notch1</title><p>Notch1 and major vault protein (MVP) are robust regulators of TNBC cell chemoresistance. It does so by modulating MVP expression to stimulate the AKT and EMT axes. Notch1 deficiency increases TNBC cell sensitivity to cisplatin-based chemotherapy.<xref rid="cit0193" ref-type="bibr">193</xref></p></sec><sec id="s0002-s2003-s3002-s4003-s5002"><title>HJURP</title><p>HJURP modulates Yes-Associated Protein (YAP1) protein ubiquitination to control its downstream transcriptional activity. In addition, YAP1 associated with the NDRG1 gene promoter to enhance gene transcription. Subsequently, the HJURP/YAP1/NDRG1 network modulates cell proliferation and doxorubicin resistance in TNBC. Together, these evidences indicate that the HJURP/YAP1/NDRG1 network modulation is essential in TNBC progression and therapeutic response.<xref rid="cit0194" ref-type="bibr">194</xref></p></sec><sec id="s0002-s2003-s3002-s4003-s5003"><title>BAI-Associated Protein 2-Like 1 (BAIAP2L1)</title><p>Excess BAIAP2L1 expression markedly induces BC proliferation potentially via AKT activation. Conversely, exposure to AKT inhibitor LY294002 diminishes BAIAP2L1 expression in BC cells. BAIAP2L1 interacts with the AA202-288 of ribosomal protein L3 (RPL3) within its SRC homology 3 (SH3) domain. In contrast, its deficiency abolishes AKT signaling to enhance PIK3CA degradation. Additionally, BAIAP2L1 overexpression enhances docetaxel resistance.<xref rid="cit0195" ref-type="bibr">195</xref></p></sec><sec id="s0002-s2003-s3002-s4003-s5004"><title>RASAL2</title><p>Emerging evidences revealed that excess RASAL2 forms a chemotherapy-unresponsive TNBC subset. RASAL2 GAP function is critical for kinase inhibitor sensitivity, and RASAL2-high TNBCs maintain basal RAS activity via inhibition of negative feedback modulators SPRY1/2, along with EGFR elevation. As a result, RASAL2 expression reduces feedback compensation following MEK1/2 and EGFR co-suppression thereby inducing synergistic apoptosis in vitro and in vivo. Among TNBC patients, elevated RASAL2 contents indicate clinical chemotherapeutic response (Cisplatin).<xref rid="cit0168" ref-type="bibr">168</xref></p></sec><sec id="s0002-s2003-s3002-s4003-s5005"><title>Synaptotagmin-Like 4 (SYTL4)</title><p>SYTL4 is a relatively new chemo-resistant gene in TNBC. SYTL4 downregulation stabilizes the microtubular network by decelerating microtubular growth rate. Additionally, SYTL4 expresses alongside microtubules and interacts with the middle region of microtubules via a linker and C2A domain. SYTL4 also induces PTX resistance in TNBC in vitro and in vivo.<xref rid="cit0196" ref-type="bibr">196</xref></p></sec><sec id="s0002-s2003-s3002-s4003-s5006"><title>MENA</title><p>The MENA isoform disrupts the balance between dynamic and stable microtubules in PTX-exposed cells. Following PTX exposure, MENA activates MAPK. Conversely, following MEK inhibitor co-treatment, reduced ERK phosphorylation restores PTX sensitivity by enhancing microtubule stabilization in MENA isoform-harboring cells.<xref rid="cit0197" ref-type="bibr">197</xref></p></sec><sec id="s0002-s2003-s3002-s4003-s5007"><title>Aurora Kinase A (Aurora&#8208;A)</title><p>Aurora&#8208;A modulates FOXM1 in TNBC. Aurora&#8208;A&#8208;induced FOXM1 stabilization represents its kinase&#8208;independent induction of augmented TNBC cell proliferative capacity. Even though Aurora&#8208;A kinase inhibition is a potentially potent TNBC treatment regimen, the report indicated that the antibiotic drug thiostrepton usage, which downregulates Aurora&#8208;A and FOXM1 contents, can work together with PTX to revert PTX chemoresistance in TNBC.<xref rid="cit0198" ref-type="bibr">198</xref></p></sec><sec id="s0002-s2003-s3002-s4003-s5008"><title>GRP78</title><p>GRP78 is intricately linked to apoptosis, and GRP78 deficiency enhances BC apoptosis.<xref rid="cit0199" ref-type="bibr">199</xref> GRP78 silencing strongly reduces MDR1 levels by negatively modulating the Akt/mTOR network in MDA-MB-231R cells.<xref rid="cit0200" ref-type="bibr">200</xref> Furthermore, it reverts pirarubicin resistance of TNBC using miR-495-3p mimics and the p-AKT/mTOR axis.<xref rid="cit0200" ref-type="bibr">200</xref></p></sec></sec><sec id="s0002-s2003-s3002-s4004"><title>Apoptosis-Related Genes</title><sec id="s0002-s2003-s3002-s4004-s5001"><title>Cxcl8</title><p>CXCL8, otherwise called IL-8, originates from the proangiogenic chemokine family, and it is strongly linked to CXCR1/2.<xref rid="cit0201" ref-type="bibr">201</xref> CXCL8 is ubiquitously present in PTX-resistant TNBC cells. In contrast, CXCL8 deficiency enhances TNBC cell sensitivity to PTX via regulation of the cell apoptosis network.<xref rid="cit0202" ref-type="bibr">202</xref></p></sec><sec id="s0002-s2003-s3002-s4004-s5002"><title>Branched-Chain Ketoacid Dehydrogenase Kinase (BCKDK)</title><p>Based on transcriptome analysis, BCKDK silencing dysregulates mitochondrial metabolic axes and upregulates the apoptotic axis. BCKDK suppression and simultaneous DOX exposure exacerbate apoptosis, caspase activity, and inhibition of TNBC proliferation. Collectively, BCKDK inactivity in TNBC alters BCAA flux, diminishes protein translation, thereby accelerating cell apoptosis, ATP insufficiency, and susceptibility toward genotoxic stress.<xref rid="cit0203" ref-type="bibr">203</xref></p></sec><sec id="s0002-s2003-s3002-s4004-s5003"><title>PRKCQ</title><p>Excess PRKCQ content strongly suppresses PTX- or doxorubicin-induced cell apoptosis. Conversely, PRKCQ deficiency enhances chemotherapy-induced TNBC cell apoptosis. PRKCQ modulates chemotherapy responsiveness by regulating Bim (a pro-apoptotic Bcl2 family member) content. Bim suppression abrogates the simultaneous PRKCQ deficiency- and chemotherapy treatment-induced cell apoptosis.<xref rid="cit0204" ref-type="bibr">204</xref></p></sec><sec id="s0002-s2003-s3002-s4004-s5004"><title>Proteasome Subunit Beta 5 (PSMB5)</title><p>Excess PSMB5 expression is strongly associated with worse TNBC patent outcome. In contrast, PSMB5 deficiency enhances TBNC cell apoptosis and augments chemotherapeutic sensitivity to PTX.<xref rid="cit0205" ref-type="bibr">205</xref></p></sec><sec id="s0002-s2003-s3002-s4004-s5005"><title>LIN9</title><p>PTX-resistant TNBC cells have strongly elevated LIN9 content, relative to corresponding parental cells. LIN9 knockdown or PTX-resistant TNBC cell exposure to a bromo- and extra-terminal domain inhibitor (BETi) JQ1 substantially diminished LIN9 levels while enhancing PTX-resistant TNBC cell sensitivity to PTX. LIN9 suppression in resistant cell lines visibly reduces tumor cell survivability, increases multinucleated cell production, and enhances tumor cell apoptosis via direct regulation of CCSAP.<xref rid="cit0206" ref-type="bibr">206</xref></p></sec><sec id="s0002-s2003-s3002-s4004-s5006"><title>PGK1</title><p>PGK1 silencing markedly increased TNBC cell line sensitivity to PTX therapy by enhancing drug-induced apoptosis. Moreover, PGK1-knockdown cells display excess XAF1, as well as apoptotic proteins cleaved caspase-3 and Bax expressions.<xref rid="cit0207" ref-type="bibr">207</xref></p></sec><sec id="s0002-s2003-s3002-s4004-s5007"><title>SERPINE1</title><p>Enhanced SERPINE1 expression confers BC resistance to PTX treatment via elevation of VEGFA, and inhibition of cell apoptosis.<xref rid="cit0208" ref-type="bibr">208</xref></p></sec></sec><sec id="s0002-s2003-s3002-s4005"><title>Mitophagy-Related Genes</title><sec id="s0002-s2003-s3002-s4005-s5001"><title>ATAD3A</title><p>PINK1 transports PD-L1 to the mitochondria for mitophagy-mediated destruction. PTX also increases ATAD3A content to impair PD-L1 proteostasis via modulation of PINK1-reliant mitophagy. In the clinics, tumor patients who have elevated ATAD3A levels prior to ICI and PTX co-treatment experienced substantially reduced PFS relative to those with ATAD3A-low tumors.<xref rid="cit0209" ref-type="bibr">209</xref></p></sec></sec><sec id="s0002-s2003-s3002-s4006"><title>Cancer-Related Splicing Genes</title><sec id="s0002-s2003-s3002-s4006-s5001"><title>Transformer2A (TRA2A)</title><p>TRA2A promotes TNBC cell proliferation, survival, migration, and invasion. Additionally, TRA2A induces PTX resistance of TNBC cells via specific regulation of cancer-associated splicing, independent of other splicing factors.<xref rid="cit0210" ref-type="bibr">210</xref></p></sec></sec><sec id="s0002-s2003-s3002-s4007"><title>Microtubule-Destabilizing-Related Splicing Genes</title><sec id="s0002-s2003-s3002-s4007-s5001"><title>High Mobility Group A1 (HMGA1)</title><p>HMGA1 is typically ubiquitously expressed during embryogenesis, and it declines to little or no expression in adults. However, it is strongly expressed in multiple tumors.<xref rid="cit0211" ref-type="bibr">211</xref> The HMGA1/p27/stathmin network regulates TNBC cell motility. Therefore, HMGA1 silencing in TNBC cells strongly diminishes in stathmin content and action on microtubules. This, in turn, impairs cell motility in a p27-reliant fashion. Additionally, in a xenograft mouse model, HMGA1-depleted TNBC cells are more responsive to PTX treatment.<xref rid="cit0212" ref-type="bibr">212</xref></p></sec></sec><sec id="s0002-s2003-s3002-s4008"><title>ATP-Binding Cassette Transporter-Related Genes</title><sec id="s0002-s2003-s3002-s4008-s5001"><title>IMP3</title><p>BC resistance protein (BCRP), otherwise called ABCG2, belongs to the ATP-binding cassette transporter family. The IMP3 protein is reported to enhance chemoresistance (Doxorubicin) of BC cells via modulating ABCG2 levels.<xref rid="cit0213" ref-type="bibr">213</xref></p></sec></sec><sec id="s0002-s2003-s3002-s4009"><title>Unknown Signaling-Related Genes</title><sec id="s0002-s2003-s3002-s4009-s5001"><title>RAD6</title><p>SMI#9 (a RAD6 inhibitor) and PTX share the same mechanism of microtubular modulation. Therefore, the synergistic effect of both PTX and RAD6 inhibitor has potential advantages on enhancing TNBC sensitivities to PTX while eliminating toxicity. The aforementioned investigations were the first to uncover a role for RAD6 in modulating microtubule dynamics.<xref rid="cit0214" ref-type="bibr">214</xref></p></sec><sec id="s0002-s2003-s3002-s4009-s5002"><title>Glucose-6-Phosphate Dehydrogenase (G6PD)</title><p>Metastatic TNBC cells exhibit markedly elevated G6PD levels once DOX resistance form following lung metastasis. Moreover, G6PD suppression abrogates DOX resistance in the same mTNBC cells, while enhancing parental TNBC cell responsiveness to DOX.<xref rid="cit0215" ref-type="bibr">215</xref></p></sec><sec id="s0002-s2003-s3002-s4009-s5003"><title>NEK2B</title><p>Elevated Nek2B expression is intricately linked to worse disease-free survival (DFS) and OS in TNBC.<xref rid="cit0216" ref-type="bibr">216</xref> Nek2B interacts with &#946;-catenin to negatively regulate TNBC patient prognosis. Their synergistic action enhances TNBC chemo-resistance to PTX.<xref rid="cit0217" ref-type="bibr">217</xref></p></sec><sec id="s0002-s2003-s3002-s4009-s5004"><title>Ceramide Kinase (CERK)</title><p>Upregulated CERK activates numerous oncogenic networks to promote chemo-resistance in TNBC cells. Additionally, excess CERK expression heavily influences chemo-sensitivity (PTX and cisplatin), and therefore serve as a potential bioindicator of chemo-resistance risk classification in newly diagnosed TNBC patients.<xref rid="cit0218" ref-type="bibr">218</xref></p></sec><sec id="s0002-s2003-s3002-s4009-s5005"><title>RUNX1</title><p>Suppression of RUNX1 transcriptional activity strongly enhances chemotherapy sensitivity in (AR<sup>+</sup>) TNBC cell lines both in culture and forced suspension. Pharmacologic RUNX1 suppression also augments the effects of the aforementioned combinational treatments (PTX).<xref rid="cit0219" ref-type="bibr">219</xref></p></sec><sec id="s0002-s2003-s3002-s4009-s5006"><title>DSTYK</title><p>One investigation knocked out DSTYK using the CRISPR/Cas9 method, and revealed considerable chemo-resistant cell death following drug intervention. In addition, DSTYK knockout enhances the chemotherapeutic drug-driven tumor cell apoptosis in an orthotopic mouse model. Collectively, these results indicate that DSTYK is essential for DOX chemoresistance.<xref rid="cit0220" ref-type="bibr">220</xref></p></sec></sec></sec></sec><sec id="s0002-s2004"><title>Potential Novel Therapeutic Targets for TNBC</title><p>Considering the aforementioned TNBC-based evidences, a detailed and extensive list of chemotherapy, as well as existing and ongoing targeted molecular therapy including the following: (1) chemotherapy; (2) DRR axis inhibitors (targeting BRCA, ATR-CHK1-WEE1); (3) proliferation-associated network inhibitors (targeting PI3K-AKT-mTOR; NOTCH; RB; EGFR); (4) ICBs (targeting PD-L1/PD-1); (5) AR inhibitor. With emerging investigations, more researchers have proposed additional approaches to treating TNBC. Here, we have summarized the most current potential TNBC therapies, namely, ferroptosis-associated network; potential targeted ADC markers; Ceritinib; Src Inhibitor; CDK12/CDK13 inhibitor. All TNBC-related therapies and medications are presented in <xref rid="f0004" ref-type="fig">Figure 4</xref> and <xref rid="t0002" ref-type="table">Table 2</xref>.
<fig position="float" id="f0004" fig-type="figure" orientation="portrait"><label>Figure 4</label><caption><p>An illustration of all available therapeutic means of TNBC including the DNA damage pathway, immunotherapy, chemotherapy, proliferation pathway, androgen receptor, potential therapeutic pathway.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="BCTT-17-1341-g0004.jpg"/></fig></p><sec id="s0002-s2004-s3001"><title>Ferroptosis-Associated Network</title><p>Twelve genes linked to ferroptosis were analyzed for prognostic evaluation in TNBC cases, with seven genetic markers (ASNS, LAMP2, CAV1, DPP4, HELLS, TF, ZFP69B) emerging as viable therapeutic candidates. Additionally, two pharmaceutical compounds (1-methyl-3-isobutylxanthine and rosiglitazone) demonstrated potential efficacy in TNBC treatment scenarios.<xref rid="cit0085" ref-type="bibr">85</xref></p></sec><sec id="s0002-s2004-s3002"><title>Potential Targeted ADC Bioindicators</title><p>ADC enhances high cytotoxic drug concentration delivery to ADC-containing cells.<xref rid="cit0086" ref-type="bibr">86</xref> Sacituzumab govitecan (IMMU-132) is an SN-38 conjugate Trop-2-targeting antibody. Trop-2 is present in approximately 90% of all TNBCs.<xref rid="cit0087" ref-type="bibr">87</xref> Ladiratuzumab Vedotin (SGN-LIV1A), with monomethyl-auristatin-E (MMAE) as the payload, achieves a 25% ORR and median PFS of 11 months among TNBC patients. Excess glycoprotein-NMB (gpNMB) expression, indicated by &#8805;25% of tumor epithelial cell staining, occurs in about 40% of TNBCs, and in this subgroup, glembatumumab vedotin (CDX-011, an ADC that interacts with gpNMB to deploy MMAE) achieves 40% ORR versus 0% with the author&#180;s therapy of choice.<xref rid="cit0088" ref-type="bibr">88</xref> Some new ADC medicines have also been created and engaged in clinical trials. AVID100 is an anti-EGFR ADC that targets EGFR and is conjugated with DM1.<xref rid="cit0089" ref-type="bibr">89</xref> U3-1402 is an anti-HER3 ADC that is conjugated with a topoisomerase I inhibitor exatecan derivative via a peptidyllinker.<xref rid="cit0221" ref-type="bibr">221</xref> CAB-ROR2-ADC is an ADC composed of a conditionally active biologic antibody directing receptor tyrosine kinase-like orphan receptor 2 (ROR2) conjugated to an undisclosed payload.<xref rid="cit0089" ref-type="bibr">89</xref> Anti-CA6-DM4 immunoconjugate (SAR566658) is a humanized DS6 antibody directed against CA6 conjugated to DM4.<xref rid="cit0089" ref-type="bibr">89</xref> New targeted for ADC drug development is the most potential direction for TNBC therapy.</p></sec><sec id="s0002-s2004-s3003"><title>Ceritinib</title><p>Ceritinib, an FDA-approved anti-lung cancer medication,<xref rid="cit0090" ref-type="bibr">90</xref> significantly inhibits LAR TNBC development. Additionally, Activated CDC42 Kinase 1 (ACK1) is a strong ceritinib target in LAR TNBC cells, whereby ceritinib inactivates the RTK-ACK1/FAK-AR network in LAR TNBC cells. Lastly, this investigation established a new treatment approach for AR<sup>+</sup> TNBC tumors involving a combinational therapy for AR<sup>&#8722;</sup> or AR low TNBCs.<xref rid="cit0091" ref-type="bibr">91</xref></p></sec><sec id="s0002-s2004-s3004"><title>Src Inhibitor</title><p>Src is a specific tyrosine kinase that has gained recognition as a possible target for multi-cancer treatment.<xref rid="cit0092" ref-type="bibr">92</xref>,<xref rid="cit0093" ref-type="bibr">93</xref> Prior investigations by <italic toggle="yes">Finn</italic> et al<xref rid="cit0094" ref-type="bibr">94</xref> reported that TNBC cell lines are especially responsive to dasatinib, whereas, <italic toggle="yes">Huang</italic> et al demonstrated that a BC subgroup harboring the dasatinib-responsive signature includes patients with TNBC.<xref rid="cit0095" ref-type="bibr">95</xref> It was also revealed that dasatinib suppresses different TNBC cellular growth in culture. However, Src content or phosphorylation failed to indicate dasatinib responsiveness in vitro.<xref rid="cit0096" ref-type="bibr">96</xref></p></sec><sec id="s0002-s2004-s3005"><title>CDK12/CDK13 Inhibitor</title><p>CDKs are serine/threonine kinase activities are heavily reliant on their association with the cyclin modulatory subunit.<xref rid="cit0222" ref-type="bibr">222</xref> The CDK enzyme family modulates the cell cycle and transcription processes.<xref rid="cit0223" ref-type="bibr">223</xref>
<italic toggle="yes">Quereda</italic> et al established a targeted dual CDK12/CDK13 inhibitor (SR-4835) that diminishes core DNA damage response gene expressions by upregulating intronic polyadenylation site cleavage, which results in impaired DNA damage repair, thereby increasing cellular responsiveness to DNA-damaging agents and PARP inhibitors.<xref rid="cit0097" ref-type="bibr">97</xref></p></sec></sec></sec><sec id="s0003"><title>Conclusion and Future Perspective</title><p>TNBC is a disease marked by enhanced heterogeneity and poor prognosis. Unlike HR-positive BC, TNBC is correlated with a younger patient age, increased visceral metastases risk, enhanced early recurrence risk, and extremely poor outcome.<xref rid="cit0009" ref-type="bibr">9</xref>,<xref rid="cit0224" ref-type="bibr">224</xref>,<xref rid="cit0225" ref-type="bibr">225</xref> Therapy for TNBC patients, who lack ER and PR expressions as well as HER2 amplification, is quite challenging due to the heterogenic characteristic of this disease, as well as the lack of well-established molecular targets.<xref rid="cit0167" ref-type="bibr">167</xref>,<xref rid="cit0226" ref-type="bibr">226</xref>,<xref rid="cit0227" ref-type="bibr">227</xref> Gene expression profiling-related molecular TNBC subtyping is critical for elucidating the underlying mechanisms of this disease, which, in turn, will benefit personalized treatment.<xref rid="cit0029" ref-type="bibr">29</xref> Hence, an extensive exploration of all subtypes and properties is crucial. Additionally, newly discovered subtype stratification enables clinicians to better manage TNBC. As a result, given the poor outcome of TNBC patients, it is essential to gain an extensive comprehension of the disease, particularly, in relation to the following aspects: (a) DDR-associated BRCA Loss-Function Mutation; (b) PI3K axis; (c) NOTCH network; (d) CDK-Rb axis; (e) EGFR Activation; (f) Angiogenesis network; (g) HER2-Low; (h) DDR signal transduction; (i) Immunotherapy and (j) AR signaling. Based on the aforementioned genes and aberrant signal networks, scientists have developed potential targeted therapies, as is presented in <xref rid="t0002" ref-type="table">Table 2</xref>. The relevant clinical trials are summarized in <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/553421/553421%20Revised%20Supplemental%20Table%201.docx" ext-link-type="uri">Supplemental Table 1</ext-link></underline>. It is our hope and speculation that the mentioned medications will be incredibly advantageous to TNBC therapy in near future. Notably, with the emergence of the HER2-low concept, drugs targeting HER2-low are being proposed and placed in clinical trials. Furthermore, given that chemotherapy is the standard intervention for TNBC, herein, we summarized the coding genes associated with TNBC chemoresistance, which may eventually be targets of future TNBC therapy. Additionally, we also listed the known chemo-sensitive and chemo-resistance genes associated with TNBC. Moreover, the CLDN1, DAB2IP, TXNIP, C/EBP-&#946; LIP, CREB3L1, ATL-1, SLFN12, PAR-4, and ETS-1 genes may can be used to predict patient sensitivity to chemotherapy or neoadjuvant-chemotherapy in the clinic. Similarly, the HJURP, CXCL8, SERCA2, PPP1R14B, HORMAD1, DSTYK, Notch1, and CENPF genes serve as indicators of patient resistance to chemotherapy in the clinic. We speculate that the aforementioned chemo-sensitive and chemo-resistant genes will be examined further in coming years for the development of better anti-TNBC therapy. We also discussed the emergence of new treatments for TNBC, namely, the ferroptosis-associated network, ADC, Ceritinib, Src inhibitor, and CDK12/CDK13 inhibitor. Considering that the aforementioned drugs continue to show benefit against TNBC, they may enter clinical trials relatively soon, and be administered to TNBC patients in the clinic.</p><p>In summary, this review presents an extensive overview of the gene mutation profile of TNBC, as well as the corresponding targeted immune- and chemotherapies. This will provide a direction and beacon for the development of highly efficacious future TNBC therapy.</p></sec></body><back><sec id="s0004"><title>Abbreviations</title><p>ACK1, Activated CDC42 Kinase 1; ADCs, Antibody-drug conjugates; ADR, Adriamycin; Aurora&#8208;A, Aurora kinase A; AR, Androgen Receptor; ATL-I, Atractylenolide-I; BAIAP2L1, BAI-associated protein 2- like 1; BC, Breast Cancer; BCKDK, Branched-chain ketoacid dehydrogenase kinase; BCRP, Breast cancer Resistance Protein; BETi, bromo- and extra-terminal domain inhibitor; bFGF, Basic Fibroblast Growth Factor; BLIA, Basal-like Immune activated; BLIS, Basal-like Immunosuppressed; CAFs, Cancer-Associated Fibroblasts; CDK 4/6, Cyclin-Dependent Kinases 4 and 6; CDK4/6i, CDK4/6 inhibitor; CERK, Ceramide Kinase; CLDN1, Claudin-1; CREB3L1, cAMP response element binding protein 3-like 1; DC, Dendritic Cell; DDR, DNA Damage Response; DFS, Disease-Free Survival; ER, Estrogen Receptor; EMT, Epithelial&#8211;Mesenchymal Transition; FGFR, Fibroblast Growth Factor Receptors; G6PD, Glucose-6-phosphate Dehydrogenase; gpNMB, Glycoprotein-NMB; HER-2, Human Epidermal Growth Factor Receptor; HMGA1, High Mobility Group A1; HORMAD1, HORMA domain&#8209;containing protein 1; HR, Homologous Recombination; ICB, Immune Checkpoint Blockade; ICI, Immune checkpoint inhibitor; IHC, Immunohistochemical; IHC-BLIS, IHC-based basal-like immune-suppressed; IHC-LAR, IHC-based luminal androgen receptor; IHC-IM, IHC-based immunomodulatory; IHC-MES, IHC-based mesenchymal; IL-8, Interleukin-8; IM, Immunomodulatory; ISH, In Situ Hybridization; LAR, Luminal Androgen Receptor; mAb, Monoclonal Antibodies; MES, Mesenchymal; MSC, Mesenchymal Stem Cell; MSL, Mesenchymal stem-like; MMAE, Monomethyl-Auristatin-E; MVP, Major Vault Protein; OS, Overall Survival; PAR-4, Prostate apoptosis response-4; PARP, Poly ADP-ribose Polymerase; PARPi, Poly ADP-ribose Polymerase Inhibitor; pCR, Pathological Complete Response; PD-1, programmed death-1; PD-L1, programmed death-ligand 1; PIK3CA, PI3K catalytic subunit &#945;; Pgp, P-glycoprotein; PI3K, Phosphoinositide 3-kinase; PPP1R14B, Protein phosphatase 1 regulatory subunit; PR, Progesterone Receptor; PSMB5, Proteasome Subunit Beta 5; PTEN, Phosphatase And Tensin Homolog; PTX, Paclitaxel; ROR2, Receptor Tyrosine Kinase-Like Orphan Receptor 2; RPL3, ribosomal protein L3; RTK, Receptor Tyrosine Kinase; SH3, SRC homology 3; Src, v-src Sarcoma Viral Oncogene Homolog; SYTL4, Synaptotagmin-like 4; TF, Transcription Factor; TGF, transforming growth factor; TNBC, Triple Negative Breast Cancer; TILs, Tumor Infiltrating Lymphocytes; TKI, Tyrosine kinase inhibitors; TRA2A, Transformer2A; TXNIP, Thioredoxin-interacting protein; VEGF, Vascular endothelial growth factor; YAP1, Yes-Associated Protein.</p></sec><sec sec-type="data-availability" id="s0005"><title>Data Sharing Statement</title><p>No datasets were generated or analyzed during the current study.</p></sec><sec id="s0006"><title>Human and Animal Rights and Informed Consent</title><p>This article does not contain any studies with human or animal subjects performed by any of the authors.</p></sec><sec id="s0007"><title>Author Contributions</title><p>All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.</p></sec><sec sec-type="COI-statement" id="s0008"><title>Disclosure</title><p>The authors declare no competing interests.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Junnuthula</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Kolimi</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Nyavanandi</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sampathi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Vora</surname><given-names>LK</given-names></string-name>, <string-name name-style="western"><surname>Dyawanapelly</surname><given-names>S</given-names></string-name>. <article-title>Polymeric Micelles for Breast Cancer Therapy: recent Updates, Clinical Translation and Regulatory Considerations</article-title>. <source><italic toggle="yes">Pharmaceutics</italic></source>. <year>2022</year>;<volume>14</volume>(<issue>9</issue>):<fpage>1860</fpage>. doi:<pub-id pub-id-type="doi">10.3390/pharmaceutics14091860</pub-id><pub-id pub-id-type="pmid">36145608</pub-id><pub-id pub-id-type="pmcid">PMC9501124</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Feng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Spezia</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>S</given-names></string-name>, et al. <article-title>Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis</article-title>. <source><italic toggle="yes">Genes Dis</italic></source>. <year>2018</year>;<volume>5</volume>(<issue>2</issue>):<fpage>77</fpage>&#8211;<lpage>106</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.gendis.2018.05.001</pub-id><pub-id pub-id-type="pmid">30258937</pub-id><pub-id pub-id-type="pmcid">PMC6147049</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Cheang</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Voduc</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bajdik</surname><given-names>C</given-names></string-name>, et al. <article-title>Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype</article-title>. <source><italic toggle="yes">Clin Cancer Res</italic></source>. <year>2008</year>;<volume>14</volume>(<issue>5</issue>):<fpage>1368</fpage>&#8211;<lpage>1376</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-1658</pub-id><pub-id pub-id-type="pmid">18316557</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><collab>Cancer Genome Atlas Network</collab>. <article-title>Comprehensive molecular portraits of human breast tumours</article-title>. <source><italic toggle="yes">Nature</italic></source>. <year>2012</year>;<volume>490</volume>(<issue>7418</issue>):<fpage>61</fpage>&#8211;<lpage>70</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature11412</pub-id><pub-id pub-id-type="pmid">23000897</pub-id><pub-id pub-id-type="pmcid">PMC3465532</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lehmann</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Bauer</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, et al. <article-title>Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies</article-title>. <source><italic toggle="yes">J Clin Invest</italic></source>. <year>2011</year>;<volume>121</volume>(<issue>7</issue>):<fpage>2750</fpage>&#8211;<lpage>2767</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI45014</pub-id><pub-id pub-id-type="pmid">21633166</pub-id><pub-id pub-id-type="pmcid">PMC3127435</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zeichner</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Terawaki</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Gogineni</surname><given-names>K</given-names></string-name>. <article-title>A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer</article-title>. <source><italic toggle="yes">Breast Cancer</italic></source>. <year>2016</year>;<volume>10</volume>:<fpage>25</fpage>&#8211;<lpage>36</lpage>. doi:<pub-id pub-id-type="doi">10.4137/BCBCR.S32783</pub-id><pub-id pub-id-type="pmid">27042088</pub-id><pub-id pub-id-type="pmcid">PMC4807882</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Dent RTrudeau</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pritchard</surname><given-names>KI</given-names></string-name>, <string-name name-style="western"><surname>Hanna</surname><given-names>WM</given-names></string-name>, et al. <article-title>Triple-negative breast cancer: clinical features and patterns of recurrence</article-title>. <source><italic toggle="yes">Clin Cancer Res</italic></source>. <year>2007</year>;<volume>13</volume>(<issue>15</issue>):<fpage>4429</fpage>&#8211;<lpage>4434</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-3045</pub-id><pub-id pub-id-type="pmid">17671126</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Foulkes</surname><given-names>WD</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>IE</given-names></string-name>, <string-name name-style="western"><surname>Reis-Filho</surname><given-names>JS</given-names></string-name>. <article-title>Triple-negative breast cancer</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2010</year>;<volume>363</volume>(<issue>20</issue>):<fpage>1938</fpage>&#8211;<lpage>1948</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMra1001389</pub-id><pub-id pub-id-type="pmid">21067385</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Liedtke</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Mazouni</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hess</surname><given-names>KR</given-names></string-name>, et al. <article-title>Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer</article-title>. <source><italic toggle="yes">J Clin Oncol</italic></source>. <year>2008</year>;<volume>26</volume>(<issue>8</issue>):<fpage>1275</fpage>&#8211;<lpage>1281</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2007.14.4147</pub-id><pub-id pub-id-type="pmid">18250347</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gonzalez-Angulo</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Timms</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, et al. <article-title>Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer</article-title>. <source><italic toggle="yes">Clin Cancer Res</italic></source>. <year>2011</year>;<volume>17</volume>(<issue>5</issue>):<fpage>1082</fpage>&#8211;<lpage>1089</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-2560</pub-id><pub-id pub-id-type="pmid">21233401</pub-id><pub-id pub-id-type="pmcid">PMC3048924</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sikov</surname><given-names>WM</given-names></string-name>, <string-name name-style="western"><surname>Berry</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Perou</surname><given-names>CM</given-names></string-name>, et al. <article-title>Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)</article-title>. <source><italic toggle="yes">J Clin Oncol</italic></source>. <year>2015</year>;<volume>33</volume>(<issue>1</issue>):<fpage>13</fpage>&#8211;<lpage>21</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2014.57.0572</pub-id><pub-id pub-id-type="pmid">25092775</pub-id><pub-id pub-id-type="pmcid">PMC4268249</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Von Minckwitz</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Schneeweiss</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Loibl</surname><given-names>S</given-names></string-name>, et al. <article-title>Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised Phase 2 trial</article-title>. <source><italic toggle="yes">Lancet Oncol</italic></source>. <year>2014</year>;<volume>15</volume>(<issue>7</issue>):<fpage>747</fpage>&#8211;<lpage>756</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1470-2045(14)70160-3</pub-id><pub-id pub-id-type="pmid">24794243</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Rose</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Burgess</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;byrne</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Richard</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Bolderson</surname><given-names>E</given-names></string-name>. <article-title>PARP Inhibitors: clinical Relevance, Mechanisms of Action and Tumor Resistance</article-title>. <source><italic toggle="yes">Front Cell Dev Biol</italic></source>. <year>2020</year>;<volume>8</volume>:<fpage>564601</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fcell.2020.564601</pub-id><pub-id pub-id-type="pmid">33015058</pub-id><pub-id pub-id-type="pmcid">PMC7509090</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sharma</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Allison</surname><given-names>JP</given-names></string-name>. <article-title>Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential</article-title>. <source><italic toggle="yes">Cell</italic></source>. <year>2015</year>;<volume>161</volume>(<issue>2</issue>):<fpage>205</fpage>&#8211;<lpage>214</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2015.03.030</pub-id><pub-id pub-id-type="pmid">25860605</pub-id><pub-id pub-id-type="pmcid">PMC5905674</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Stanton</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Adams</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Disis</surname><given-names>ML</given-names></string-name>. <article-title>Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: a Systematic Review</article-title>. <source><italic toggle="yes">JAMA Oncol</italic></source>. <year>2016</year>;<volume>2</volume>(<issue>10</issue>):<fpage>1354</fpage>&#8211;<lpage>1360</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaoncol.2016.1061</pub-id><pub-id pub-id-type="pmid">27355489</pub-id></mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wimberly</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Schalper</surname><given-names>K</given-names></string-name>, et al. <article-title>PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer</article-title>. <source><italic toggle="yes">Cancer Immunol Res</italic></source>. <year>2015</year>;<volume>3</volume>(<issue>4</issue>):<fpage>326</fpage>&#8211;<lpage>332</lpage>. doi:<pub-id pub-id-type="doi">10.1158/2326-6066.CIR-14-0133</pub-id><pub-id pub-id-type="pmid">25527356</pub-id><pub-id pub-id-type="pmcid">PMC4390454</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Iglesia</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Vincent</surname><given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Parker</surname><given-names>JS</given-names></string-name>, et al. <article-title>Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer</article-title>. <source><italic toggle="yes">Clin Cancer Res</italic></source>. <year>2014</year>;<volume>20</volume>(<issue>14</issue>):<fpage>3818</fpage>&#8211;<lpage>3829</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-3368</pub-id><pub-id pub-id-type="pmid">24916698</pub-id><pub-id pub-id-type="pmcid">PMC4102637</pub-id></mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>. <article-title>T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances</article-title>. <source><italic toggle="yes">J Cancer Res Clin Oncol</italic></source>. <year>2019</year>;<volume>145</volume>(<issue>4</issue>):<fpage>941</fpage>&#8211;<lpage>956</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00432-019-02867-6</pub-id><pub-id pub-id-type="pmid">30798356</pub-id><pub-id pub-id-type="pmcid">PMC11810215</pub-id></mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Marra</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Viale</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Curigliano</surname><given-names>G</given-names></string-name>. <article-title>Recent advances in triple negative breast cancer: the immunotherapy era</article-title>. <source><italic toggle="yes">BMC Med</italic></source>. <year>2019</year>;<volume>17</volume>(<issue>1</issue>):<fpage>90</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12916-019-1326-5</pub-id><pub-id pub-id-type="pmid">31068190</pub-id><pub-id pub-id-type="pmcid">PMC6507064</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Pascual</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Turner</surname><given-names>NC</given-names></string-name>. <article-title>Targeting the PI3-kinase pathway in triple-negative breast cancer</article-title>. <source><italic toggle="yes">Ann Oncol</italic></source>. <year>2019</year>;<volume>30</volume>(<issue>7</issue>):<fpage>1051</fpage>&#8211;<lpage>1060</lpage>. doi:<pub-id pub-id-type="doi">10.1093/annonc/mdz133</pub-id><pub-id pub-id-type="pmid">31050709</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Asghar</surname><given-names>US</given-names></string-name>, <string-name name-style="western"><surname>Barr</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Cutts</surname><given-names>R</given-names></string-name>, et al. <article-title>Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer</article-title>. <source><italic toggle="yes">Clin Cancer Res</italic></source>. <year>2017</year>;<volume>23</volume>(<issue>18</issue>):<fpage>5561</fpage>&#8211;<lpage>5572</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-0369</pub-id><pub-id pub-id-type="pmid">28606920</pub-id><pub-id pub-id-type="pmcid">PMC6175044</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Metzger-Filho</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Tutt</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>De Azambuja</surname><given-names>E</given-names></string-name>, et al. <article-title>Dissecting the heterogeneity of triple-negative breast cancer</article-title>. <source><italic toggle="yes">J Clin Oncol</italic></source>. <year>2012</year>;<volume>30</volume>(<issue>15</issue>):<fpage>1879</fpage>&#8211;<lpage>1887</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2011.38.2010</pub-id><pub-id pub-id-type="pmid">22454417</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lehmann</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Pietenpol</surname><given-names>JA</given-names></string-name>. <article-title>Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes</article-title>. <source><italic toggle="yes">J Pathol</italic></source>. <year>2014</year>;<volume>232</volume>(<issue>2</issue>):<fpage>142</fpage>&#8211;<lpage>150</lpage>. doi:<pub-id pub-id-type="doi">10.1002/path.4280</pub-id><pub-id pub-id-type="pmid">24114677</pub-id><pub-id pub-id-type="pmcid">PMC4090031</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gibson</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Qian</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ku</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Lai</surname><given-names>LL</given-names></string-name>. <article-title>Metaplastic breast cancer: clinical features and outcomes</article-title>. <source><italic toggle="yes">Am Surg</italic></source>. <year>2005</year>;<volume>71</volume>(<issue>9</issue>):<fpage>725</fpage>&#8211;<lpage>730</lpage>. doi:<pub-id pub-id-type="doi">10.1177/000313480507100906</pub-id><pub-id pub-id-type="pmid">16468506</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bareche</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Venet</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ignatiadis</surname><given-names>M</given-names></string-name>, et al. <article-title>Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis</article-title>. <source><italic toggle="yes">Ann Oncol</italic></source>. <year>2018</year>;<volume>29</volume>(<issue>4</issue>):<fpage>895</fpage>&#8211;<lpage>902</lpage>. doi:<pub-id pub-id-type="doi">10.1093/annonc/mdy024</pub-id><pub-id pub-id-type="pmid">29365031</pub-id><pub-id pub-id-type="pmcid">PMC5913636</pub-id></mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hayes</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Emmons</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Giordano</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Kleer</surname><given-names>CG</given-names></string-name>. <article-title>Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast</article-title>. <source><italic toggle="yes">Clin Cancer Res</italic></source>. <year>2008</year>;<volume>14</volume>(<issue>13</issue>):<fpage>4038</fpage>&#8211;<lpage>4044</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-4379</pub-id><pub-id pub-id-type="pmid">18593979</pub-id><pub-id pub-id-type="pmcid">PMC3060761</pub-id></mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yin</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Duan</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Bian</surname><given-names>XW</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>SC</given-names></string-name>. <article-title>Triple-negative breast cancer molecular subtyping and treatment progress</article-title>. <source><italic toggle="yes">Breast Cancer Res</italic></source>. <year>2020</year>;<volume>22</volume>(<issue>1</issue>):<fpage>61</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13058-020-01296-5</pub-id><pub-id pub-id-type="pmid">32517735</pub-id><pub-id pub-id-type="pmcid">PMC7285581</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Burstein</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Tsimelzon</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Poage</surname><given-names>GM</given-names></string-name>, et al. <article-title>Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer</article-title>. <source><italic toggle="yes">Clin Cancer Res</italic></source>. <year>2015</year>;<volume>21</volume>(<issue>7</issue>):<fpage>1688</fpage>&#8211;<lpage>1698</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-0432</pub-id><pub-id pub-id-type="pmid">25208879</pub-id><pub-id pub-id-type="pmcid">PMC4362882</pub-id></mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zhao</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>Y</given-names></string-name>, et al. <article-title>Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: molecular Basis and Clinical Relevance</article-title>. <source><italic toggle="yes">Oncologist</italic></source>. <year>2020</year>;<volume>25</volume>(<issue>10</issue>):<fpage>e1481</fpage>&#8211;<lpage>e1491</lpage>. doi:<pub-id pub-id-type="doi">10.1634/theoncologist.2019-0982</pub-id><pub-id pub-id-type="pmid">32406563</pub-id><pub-id pub-id-type="pmcid">PMC7543239</pub-id></mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>He</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>. <article-title>Classification of triple-negative breast cancers based on Immunogenomic profiling</article-title>. <source><italic toggle="yes">J Exp Clin Cancer Res</italic></source>. <year>2018</year>;<volume>37</volume>(<issue>1</issue>):<fpage>327</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13046-018-1002-1</pub-id><pub-id pub-id-type="pmid">30594216</pub-id><pub-id pub-id-type="pmcid">PMC6310928</pub-id></mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bonotto</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gerratana</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Poletto</surname><given-names>E</given-names></string-name>, et al. <article-title>Measures of outcome in metastatic breast cancer: insights from a real-world scenario</article-title>. <source><italic toggle="yes">Oncologist</italic></source>. <year>2014</year>;<volume>19</volume>(<issue>6</issue>):<fpage>608</fpage>&#8211;<lpage>615</lpage>. doi:<pub-id pub-id-type="doi">10.1634/theoncologist.2014-0002</pub-id><pub-id pub-id-type="pmid">24794159</pub-id><pub-id pub-id-type="pmcid">PMC4041678</pub-id></mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Dent</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hanna</surname><given-names>WM</given-names></string-name>, <string-name name-style="western"><surname>Trudeau</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rawlinson</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Narod</surname><given-names>SA</given-names></string-name>. <article-title>Pattern of metastatic spread in triple-negative breast cancer</article-title>. <source><italic toggle="yes">Breast Cancer Res Treat</italic></source>. <year>2009</year>;<volume>115</volume>(<issue>2</issue>):<fpage>423</fpage>&#8211;<lpage>428</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10549-008-0086-2</pub-id><pub-id pub-id-type="pmid">18543098</pub-id></mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bianchini</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>De Angelis</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Licata</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gianni</surname><given-names>L</given-names></string-name>. <article-title>Treatment landscape of triple-negative breast cancer - expanded options, evolving needs</article-title>. <source><italic toggle="yes">Nat Rev Clin Oncol</italic></source>. <year>2022</year>;<volume>19</volume>(<issue>2</issue>):<fpage>91</fpage>&#8211;<lpage>113</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41571-021-00565-2</pub-id><pub-id pub-id-type="pmid">34754128</pub-id></mixed-citation></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Marra</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Trapani</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Viale</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Criscitiello</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Curigliano</surname><given-names>G</given-names></string-name>. <article-title>Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies</article-title>. <source><italic toggle="yes">NPJ Breast Cancer</italic></source>. <year>2020</year>;<volume>6</volume>(<issue>1</issue>):<fpage>54</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41523-020-00197-2</pub-id><pub-id pub-id-type="pmid">33088912</pub-id><pub-id pub-id-type="pmcid">PMC7568552</pub-id></mixed-citation></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Jin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tao</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>X</given-names></string-name>. <article-title>DNA damage response inhibitors: an avenue for TNBC treatment</article-title>. <source><italic toggle="yes">Biochim Biophys Acta Rev Cancer</italic></source>. <year>2021</year>;<volume>1875</volume>(<issue>2</issue>):<fpage>188521</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbcan.2021.188521</pub-id><pub-id pub-id-type="pmid">33556453</pub-id></mixed-citation></ref><ref id="cit0036"><label>36.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ibrahim</surname><given-names>YH</given-names></string-name>, <string-name name-style="western"><surname>Garcia-Garcia</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Serra</surname><given-names>V</given-names></string-name>, et al. <article-title>PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition</article-title>. <source><italic toggle="yes">Cancer Discov</italic></source>. <year>2012</year>;<volume>2</volume>(<issue>11</issue>):<fpage>1036</fpage>&#8211;<lpage>1047</lpage>. doi:<pub-id pub-id-type="doi">10.1158/2159-8290.CD-11-0348</pub-id><pub-id pub-id-type="pmid">22915752</pub-id><pub-id pub-id-type="pmcid">PMC5125254</pub-id></mixed-citation></ref><ref id="cit0037"><label>37.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Tolaney</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Burris</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Gartner</surname><given-names>E</given-names></string-name>, et al. <article-title>Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer</article-title>. <source><italic toggle="yes">Breast Cancer Res Treat</italic></source>. <year>2015</year>;<volume>149</volume>(<issue>1</issue>):<fpage>151</fpage>&#8211;<lpage>161</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10549-014-3248-4</pub-id><pub-id pub-id-type="pmid">25537644</pub-id></mixed-citation></ref><ref id="cit0038"><label>38.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Peek</surname><given-names>GW</given-names></string-name>, <string-name name-style="western"><surname>Tollefsbol</surname><given-names>TO</given-names></string-name>. <article-title>Combinatorial PX-866 and Raloxifene Decrease Rb Phosphorylation, Cyclin E2 Transcription, and Proliferation of MCF-7 Breast Cancer Cells</article-title>. <source><italic toggle="yes">J Cell Biochem</italic></source>. <year>2016</year>;<volume>117</volume>(<issue>7</issue>):<fpage>1688</fpage>&#8211;<lpage>1696</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jcb.25462</pub-id><pub-id pub-id-type="pmid">26660119</pub-id><pub-id pub-id-type="pmcid">PMC5135016</pub-id></mixed-citation></ref><ref id="cit0039"><label>39.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hoeflich</surname><given-names>KP</given-names></string-name>, <string-name name-style="western"><surname>Guan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Edgar</surname><given-names>KA</given-names></string-name>, et al. <article-title>The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase</article-title>. <source><italic toggle="yes">Genes Cancer</italic></source>. <year>2016</year>;<volume>7</volume>(<issue>3&#8211;4</issue>):<fpage>73</fpage>&#8211;<lpage>85</lpage>. doi:<pub-id pub-id-type="doi">10.18632/genesandcancer.100</pub-id><pub-id pub-id-type="pmid">27382432</pub-id><pub-id pub-id-type="pmcid">PMC4918946</pub-id></mixed-citation></ref><ref id="cit0040"><label>40.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Fritsch</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chatenay-Rivauday</surname><given-names>C</given-names></string-name>, et al. <article-title>Characterization of the novel and specific PI3Kalpha inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials</article-title>. <source><italic toggle="yes">Mol Cancer Ther</italic></source>. <year>2014</year>;<volume>13</volume>(<issue>5</issue>):<fpage>1117</fpage>&#8211;<lpage>1129</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-13-0865</pub-id><pub-id pub-id-type="pmid">24608574</pub-id></mixed-citation></ref><ref id="cit0041"><label>41.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Juric</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>De Bono</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Lorusso</surname><given-names>PM</given-names></string-name>, et al. <article-title>A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kalpha Isoform Inhibitor, in Patients with Advanced Solid Malignancies</article-title>. <source><italic toggle="yes">Clin Cancer Res</italic></source>. <year>2017</year>;<volume>23</volume>(<issue>17</issue>):<fpage>5015</fpage>&#8211;<lpage>5023</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-2888</pub-id><pub-id pub-id-type="pmid">28490463</pub-id><pub-id pub-id-type="pmcid">PMC6858996</pub-id></mixed-citation></ref><ref id="cit0042"><label>42.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sampath</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Nannini</surname><given-names>MA</given-names></string-name>, et al. <article-title>Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models</article-title>. <source><italic toggle="yes">Clin Cancer Res</italic></source>. <year>2013</year>;<volume>19</volume>(<issue>7</issue>):<fpage>1760</fpage>&#8211;<lpage>1772</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-3072</pub-id><pub-id pub-id-type="pmid">23287563</pub-id></mixed-citation></ref><ref id="cit0043"><label>43.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Leighl</surname><given-names>NB</given-names></string-name>, <string-name name-style="western"><surname>Dent</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Clemons</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hedley</surname><given-names>D</given-names></string-name>. <article-title>A Phase 2 study of perifosine in advanced or metastatic breast cancer</article-title>. <source><italic toggle="yes">Breast Cancer Res Treat</italic></source>. <year>2008</year>;<volume>108</volume>:<fpage>87</fpage>&#8211;<lpage>92</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10549-007-9584-x</pub-id><pub-id pub-id-type="pmid">17458693</pub-id></mixed-citation></ref><ref id="cit0044"><label>44.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Banerji</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Dean</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Perez-Fidalgo</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Batist</surname><given-names>G</given-names></string-name>. <article-title>A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363</article-title>. <source><italic toggle="yes">Clin Cancer Res</italic></source>. <year>2018</year>;<volume>24</volume>:<fpage>2050</fpage>&#8211;<lpage>2059</lpage>.<pub-id pub-id-type="pmid">29066505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-17-2260</pub-id></mixed-citation></ref><ref id="cit0045"><label>45.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Saura</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Roda</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Rosello</surname><given-names>S</given-names></string-name>, et al. <article-title>Correction: a First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors</article-title>. <source><italic toggle="yes">Cancer Discov</italic></source>. <year>2018</year>;<volume>8</volume>:<fpage>1490</fpage>.<pub-id pub-id-type="pmid">30385525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-18-1114</pub-id></mixed-citation></ref><ref id="cit0046"><label>46.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wisinski</surname><given-names>KB</given-names></string-name>, <string-name name-style="western"><surname>Tevaarwerk</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Burkard</surname><given-names>ME</given-names></string-name>, et al. <article-title>Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer</article-title>. <source><italic toggle="yes">Clin Cancer Res</italic></source>. <year>2016</year>;<volume>22</volume>(<issue>11</issue>):<fpage>2659</fpage>&#8211;<lpage>2667</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-2365</pub-id><pub-id pub-id-type="pmid">27026198</pub-id><pub-id pub-id-type="pmcid">PMC4891227</pub-id></mixed-citation></ref><ref id="cit0047"><label>47.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Basho</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Gilcrease</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Murthy</surname><given-names>RK</given-names></string-name>, et al. <article-title>Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab</article-title>. <source><italic toggle="yes">JAMA Oncol</italic></source>. <year>2017</year>;<volume>3</volume>(<issue>4</issue>):<fpage>509</fpage>&#8211;<lpage>515</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaoncol.2016.5281</pub-id><pub-id pub-id-type="pmid">27893038</pub-id></mixed-citation></ref><ref id="cit0048"><label>48.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sutherlin</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Bao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Berry</surname><given-names>M</given-names></string-name>, et al. <article-title>Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer</article-title>. <source><italic toggle="yes">J Med Chem</italic></source>. <year>2011</year>;<volume>54</volume>(<issue>21</issue>):<fpage>7579</fpage>&#8211;<lpage>7587</lpage>. doi:<pub-id pub-id-type="doi">10.1021/jm2009327</pub-id><pub-id pub-id-type="pmid">21981714</pub-id></mixed-citation></ref><ref id="cit0049"><label>49.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Knight</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Adams</surname><given-names>ND</given-names></string-name>, <string-name name-style="western"><surname>Burgess</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Dhanak</surname><given-names>D</given-names></string-name>. <article-title>Discovery of GSK2126458</article-title>. <source><italic toggle="yes">ACS Med Chem Lett</italic></source>. <year>2010</year>;<volume>1</volume>:<fpage>39</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">24900173</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ml900028r</pub-id><pub-id pub-id-type="pmcid">PMC4007793</pub-id></mixed-citation></ref><ref id="cit0050"><label>50.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hatem</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>El Botty</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chateau-Joubert</surname><given-names>S</given-names></string-name>, et al. <article-title>Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers</article-title>. <source><italic toggle="yes">Oncotarget</italic></source>. <year>2016</year>;<volume>7</volume>(<issue>30</issue>):<fpage>48206</fpage>&#8211;<lpage>48219</lpage>. doi:<pub-id pub-id-type="doi">10.18632/oncotarget.10195</pub-id><pub-id pub-id-type="pmid">27374081</pub-id><pub-id pub-id-type="pmcid">PMC5217012</pub-id></mixed-citation></ref><ref id="cit0051"><label>51.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Garcia-Echeverria</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sellers</surname><given-names>WR</given-names></string-name>. <article-title>Drug discovery approaches targeting the PI3K/Akt pathway in cancer</article-title>. <source><italic toggle="yes">Oncogene</italic></source>. <year>2008</year>;<volume>27</volume>(<issue>41</issue>):<fpage>5511</fpage>&#8211;<lpage>5526</lpage>. doi:<pub-id pub-id-type="doi">10.1038/onc.2008.246</pub-id><pub-id pub-id-type="pmid">18794885</pub-id></mixed-citation></ref><ref id="cit0052"><label>52.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Maira</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Stauffer</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Brueggen</surname><given-names>J</given-names></string-name>, et al. <article-title>Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity</article-title>. <source><italic toggle="yes">Mol Cancer Ther</italic></source>. <year>2008</year>;<volume>7</volume>(<issue>7</issue>):<fpage>1851</fpage>&#8211;<lpage>1863</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-08-0017</pub-id><pub-id pub-id-type="pmid">18606717</pub-id></mixed-citation></ref><ref id="cit0053"><label>53.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>De</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Carlson</surname><given-names>JH</given-names></string-name>, et al. <article-title>Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness</article-title>. <source><italic toggle="yes">Neoplasia</italic></source>. <year>2014</year>;<volume>16</volume>(<issue>1</issue>):<fpage>43</fpage>&#8211;<lpage>72</lpage>. doi:<pub-id pub-id-type="doi">10.1593/neo.131694</pub-id><pub-id pub-id-type="pmid">24563619</pub-id><pub-id pub-id-type="pmcid">PMC3924548</pub-id></mixed-citation></ref><ref id="cit0054"><label>54.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Speiser</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Ersahin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Osipo</surname><given-names>C</given-names></string-name>. <article-title>The functional role of Notch signaling in triple-negative breast cancer</article-title>. <source><italic toggle="yes">Vitam Horm</italic></source>. <year>2013</year>;<volume>93</volume>:<fpage>277</fpage>&#8211;<lpage>306</lpage>.<pub-id pub-id-type="pmid">23810012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/B978-0-12-416673-8.00013-7</pub-id></mixed-citation></ref><ref id="cit0055"><label>55.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sukumar</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gast</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Quiroga</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lustberg</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>N</given-names></string-name>. <article-title>Triple-negative breast cancer: promising prognostic biomarkers currently in development</article-title>. <source><italic toggle="yes">Expert Rev Anticancer Ther</italic></source>. <year>2021</year>;<volume>21</volume>(<issue>2</issue>):<fpage>135</fpage>&#8211;<lpage>148</lpage>. doi:<pub-id pub-id-type="doi">10.1080/14737140.2021.1840984</pub-id><pub-id pub-id-type="pmid">33198517</pub-id><pub-id pub-id-type="pmcid">PMC8174647</pub-id></mixed-citation></ref><ref id="cit0056"><label>56.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>. <article-title>Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer</article-title>. <source><italic toggle="yes">Cancer Manag Res</italic></source>. <year>2021</year>;<volume>13</volume>:<fpage>5223</fpage>&#8211;<lpage>5237</lpage>. doi:<pub-id pub-id-type="doi">10.2147/CMAR.S310649</pub-id><pub-id pub-id-type="pmid">34234565</pub-id><pub-id pub-id-type="pmcid">PMC8257068</pub-id></mixed-citation></ref><ref id="cit0057"><label>57.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Finn</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Crown</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Lang</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Boer</surname><given-names>K</given-names></string-name>. <article-title>The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study</article-title>. <source><italic toggle="yes">Lancet Oncol</italic></source>. <year>2015</year>;<volume>16</volume>(<issue>1</issue>):<fpage>25</fpage>&#8211;<lpage>35</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1470-2045(14)71159-3</pub-id><pub-id pub-id-type="pmid">25524798</pub-id></mixed-citation></ref><ref id="cit0058"><label>58.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Raphael</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Helou</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pritchard</surname><given-names>KI</given-names></string-name>, <string-name name-style="western"><surname>Naimark</surname><given-names>DM</given-names></string-name>. <article-title>Palbociclib in hormone receptor positive advanced breast cancer: a cost-utility analysis</article-title>. <source><italic toggle="yes">Eur J Cancer</italic></source>. <year>2017</year>;<volume>85</volume>:<fpage>146</fpage>&#8211;<lpage>154</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejca.2017.08.018</pub-id><pub-id pub-id-type="pmid">28930692</pub-id></mixed-citation></ref><ref id="cit0059"><label>59.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Katoh</surname><given-names>M</given-names></string-name>. <article-title>FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review</article-title>. <source><italic toggle="yes">Int J Mol Med</italic></source>. <year>2016</year>;<volume>38</volume>(<issue>1</issue>):<fpage>3</fpage>&#8211;<lpage>15</lpage>. doi:<pub-id pub-id-type="doi">10.3892/ijmm.2016.2620</pub-id><pub-id pub-id-type="pmid">27245147</pub-id><pub-id pub-id-type="pmcid">PMC4899036</pub-id></mixed-citation></ref><ref id="cit0060"><label>60.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Garcia</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hurwitz</surname><given-names>HI</given-names></string-name>, <string-name name-style="western"><surname>Sandler</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Miles</surname><given-names>D</given-names></string-name>. <article-title>Bevacizumab (Avastin(R)) in cancer treatment: a review of 15 years of clinical experience and future outlook</article-title>. <source><italic toggle="yes">Cancer Treat Rev</italic></source>. <year>2020</year>;<volume>86</volume>:<fpage>102017</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ctrv.2020.102017</pub-id><pub-id pub-id-type="pmid">32335505</pub-id></mixed-citation></ref><ref id="cit0061"><label>61.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mendel</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>Laird</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Xin</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Louie</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Schreck</surname><given-names>RE</given-names></string-name>. <article-title>In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship</article-title>. <source><italic toggle="yes">Clin Cancer Res</italic></source>. <year>2003</year>;<volume>9</volume>(<issue>1</issue>):<fpage>327</fpage>&#8211;<lpage>337</lpage>.<pub-id pub-id-type="pmid">12538485</pub-id></mixed-citation></ref><ref id="cit0062"><label>62.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>O&#8217;sullivan Coyne</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Burotto</surname><given-names>M</given-names></string-name>. <article-title>Clinical experience with ramucirumab: outcomes in breast cancer</article-title>. <source><italic toggle="yes">Expert Opin Biol Ther</italic></source>. <year>2014</year>;<volume>14</volume>(<issue>9</issue>):<fpage>1351</fpage>&#8211;<lpage>1360</lpage>. doi:<pub-id pub-id-type="doi">10.1517/14712598.2014.939069</pub-id><pub-id pub-id-type="pmid">25018016</pub-id></mixed-citation></ref><ref id="cit0063"><label>63.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bender</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Mac Gabhann</surname><given-names>F</given-names></string-name>. <article-title>Expression of VEGF and semaphorin genes define subgroups of triple negative breast cancer</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2013</year>;<volume>8</volume>:<fpage>e61788</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0061788</pub-id><pub-id pub-id-type="pmid">23667446</pub-id><pub-id pub-id-type="pmcid">PMC3648524</pub-id></mixed-citation></ref><ref id="cit0064"><label>64.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Grothey</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ellis</surname><given-names>LM</given-names></string-name>. <article-title>Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies</article-title>. <source><italic toggle="yes">Cancer J</italic></source>. <year>2008</year>;<volume>14</volume>(<issue>3</issue>):<fpage>170</fpage>&#8211;<lpage>177</lpage>. doi:<pub-id pub-id-type="doi">10.1097/PPO.0b013e318178d9de</pub-id><pub-id pub-id-type="pmid">18536556</pub-id></mixed-citation></ref><ref id="cit0065"><label>65.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gavine</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Mooney</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kilgour</surname><given-names>E</given-names></string-name>, et al. <article-title>AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family</article-title>. <source><italic toggle="yes">Cancer Res</italic></source>. <year>2012</year>;<volume>72</volume>(<issue>8</issue>):<fpage>2045</fpage>&#8211;<lpage>2056</lpage>. doi:<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-3034</pub-id><pub-id pub-id-type="pmid">22369928</pub-id></mixed-citation></ref><ref id="cit0066"><label>66.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kwak</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hur</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Sim</surname><given-names>T</given-names></string-name>. <article-title>Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells</article-title>. <source><italic toggle="yes">Mol Cancer Ther</italic></source>. <year>2015</year>;<volume>14</volume>(<issue>10</issue>):<fpage>2292</fpage>&#8211;<lpage>2302</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-15-0032</pub-id><pub-id pub-id-type="pmid">26294741</pub-id></mixed-citation></ref><ref id="cit0067"><label>67.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Guagnano</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Kauffmann</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wohrle</surname><given-names>S</given-names></string-name>, et al. <article-title>FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor</article-title>. <source><italic toggle="yes">Cancer Discov</italic></source>. <year>2012</year>;<volume>2</volume>(<issue>12</issue>):<fpage>1118</fpage>&#8211;<lpage>1133</lpage>. doi:<pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0210</pub-id><pub-id pub-id-type="pmid">23002168</pub-id></mixed-citation></ref><ref id="cit0068"><label>68.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hagel</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Miduturu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sheets</surname><given-names>M</given-names></string-name>, et al. <article-title>First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway</article-title>. <source><italic toggle="yes">Cancer Discov</italic></source>. <year>2015</year>;<volume>5</volume>(<issue>4</issue>):<fpage>424</fpage>&#8211;<lpage>437</lpage>. doi:<pub-id pub-id-type="doi">10.1158/2159-8290.CD-14-1029</pub-id><pub-id pub-id-type="pmid">25776529</pub-id></mixed-citation></ref><ref id="cit0069"><label>69.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Nakanishi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Akiyama</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Tsukaguchi</surname><given-names>T</given-names></string-name>, et al. <article-title>The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor</article-title>. <source><italic toggle="yes">Mol Cancer Ther</italic></source>. <year>2014</year>;<volume>13</volume>(<issue>11</issue>):<fpage>2547</fpage>&#8211;<lpage>2558</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-14-0248</pub-id><pub-id pub-id-type="pmid">25169980</pub-id></mixed-citation></ref><ref id="cit0070"><label>70.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lee</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Lopes De Menezes</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Vora</surname><given-names>J</given-names></string-name>, et al. <article-title>In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models</article-title>. <source><italic toggle="yes">Clin Cancer Res</italic></source>. <year>2005</year>;<volume>11</volume>(<issue>10</issue>):<fpage>3633</fpage>&#8211;<lpage>3641</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-2129</pub-id><pub-id pub-id-type="pmid">15897558</pub-id></mixed-citation></ref><ref id="cit0071"><label>71.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Tan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Z</given-names></string-name>, et al. <article-title>Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors</article-title>. <source><italic toggle="yes">Proc Natl Acad Sci U S A</italic></source>. <year>2014</year>;<volume>111</volume>(<issue>45</issue>):<fpage>E4869</fpage>&#8211;<lpage>77</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1403438111</pub-id><pub-id pub-id-type="pmid">25349422</pub-id><pub-id pub-id-type="pmcid">PMC4234547</pub-id></mixed-citation></ref><ref id="cit0072"><label>72.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Tabernero</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bahleda</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Dienstmann</surname><given-names>R</given-names></string-name>, et al. <article-title>Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors</article-title>. <source><italic toggle="yes">J Clin Oncol</italic></source>. <year>2015</year>;<volume>33</volume>(<issue>30</issue>):<fpage>3401</fpage>&#8211;<lpage>3408</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2014.60.7341</pub-id><pub-id pub-id-type="pmid">26324363</pub-id></mixed-citation></ref><ref id="cit0073"><label>73.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zhao</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>WY</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>D</given-names></string-name>, et al. <article-title>A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models</article-title>. <source><italic toggle="yes">Mol Cancer Ther</italic></source>. <year>2011</year>;<volume>10</volume>(<issue>11</issue>):<fpage>2200</fpage>&#8211;<lpage>2210</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-11-0306</pub-id><pub-id pub-id-type="pmid">21900693</pub-id></mixed-citation></ref><ref id="cit0074"><label>74.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>O&#8217;hare</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Shakespeare</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>X</given-names></string-name>, et al. <article-title>AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</article-title>. <source><italic toggle="yes">Cancer Cell</italic></source>. <year>2009</year>;<volume>16</volume>(<issue>5</issue>):<fpage>401</fpage>&#8211;<lpage>412</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ccr.2009.09.028</pub-id><pub-id pub-id-type="pmid">19878872</pub-id><pub-id pub-id-type="pmcid">PMC2804470</pub-id></mixed-citation></ref><ref id="cit0075"><label>75.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Nicolo</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Boscolo Bielo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Curigliano</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Tarantino</surname><given-names>P</given-names></string-name>. <article-title>The HER2-low revolution in breast oncology: steps forward and emerging challenges</article-title>. <source><italic toggle="yes">Ther Adv Med Oncol</italic></source>. <year>2023</year>;<volume>15</volume>:<fpage>17588359231152842</fpage>. doi:<pub-id pub-id-type="doi">10.1177/17588359231152842</pub-id><pub-id pub-id-type="pmid">36844387</pub-id><pub-id pub-id-type="pmcid">PMC9943960</pub-id></mixed-citation></ref><ref id="cit0076"><label>76.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hyman</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Piha-Paul</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Won</surname><given-names>H</given-names></string-name>, et al. <article-title>Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers</article-title>. <source><italic toggle="yes">Nature</italic></source>. <year>2019</year>;<volume>566</volume>(<issue>7745</issue>):<fpage>E11</fpage>&#8211;<lpage>E12</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-019-0974-0</pub-id><pub-id pub-id-type="pmid">30755741</pub-id></mixed-citation></ref><ref id="cit0077"><label>77.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Qiu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Oleinick</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>. <article-title>ATR/CHK1 inhibitors and cancer therapy</article-title>. <source><italic toggle="yes">Radiother Oncol</italic></source>. <year>2018</year>;<volume>126</volume>(<issue>3</issue>):<fpage>450</fpage>&#8211;<lpage>464</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.radonc.2017.09.043</pub-id><pub-id pub-id-type="pmid">29054375</pub-id><pub-id pub-id-type="pmcid">PMC5856582</pub-id></mixed-citation></ref><ref id="cit0078"><label>78.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Witkiewicz</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Chung</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Brough</surname><given-names>R</given-names></string-name>, et al. <article-title>Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer</article-title>. <source><italic toggle="yes">Cell Rep</italic></source>. <year>2018</year>;<volume>22</volume>(<issue>5</issue>):<fpage>1185</fpage>&#8211;<lpage>1199</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.celrep.2018.01.022</pub-id><pub-id pub-id-type="pmid">29386107</pub-id><pub-id pub-id-type="pmcid">PMC5967622</pub-id></mixed-citation></ref><ref id="cit0079"><label>79.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lee</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Nair</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zimmer</surname><given-names>A</given-names></string-name>, et al. <article-title>Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study</article-title>. <source><italic toggle="yes">Lancet Oncol</italic></source>. <year>2018</year>;<volume>19</volume>(<issue>2</issue>):<fpage>207</fpage>&#8211;<lpage>215</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1470-2045(18)30009-3</pub-id><pub-id pub-id-type="pmid">29361470</pub-id><pub-id pub-id-type="pmcid">PMC7366122</pub-id></mixed-citation></ref><ref id="cit0080"><label>80.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bennett</surname><given-names>CN</given-names></string-name>, <string-name name-style="western"><surname>Tomlinson</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Michalowski</surname><given-names>AM</given-names></string-name>, et al. <article-title>Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer</article-title>. <source><italic toggle="yes">Breast Cancer Res</italic></source>. <year>2012</year>;<volume>14</volume>(<issue>4</issue>):<fpage>R109</fpage>. doi:<pub-id pub-id-type="doi">10.1186/bcr3230</pub-id><pub-id pub-id-type="pmid">22812567</pub-id><pub-id pub-id-type="pmcid">PMC3680937</pub-id></mixed-citation></ref><ref id="cit0081"><label>81.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Guertin</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, et al. <article-title>Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy</article-title>. <source><italic toggle="yes">Mol Cancer Ther</italic></source>. <year>2013</year>;<volume>12</volume>(<issue>8</issue>):<fpage>1442</fpage>&#8211;<lpage>1452</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-13-0025</pub-id><pub-id pub-id-type="pmid">23699655</pub-id></mixed-citation></ref><ref id="cit0082"><label>82.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Jia</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Truica</surname><given-names>CI</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, et al. <article-title>Immunotherapy for triple-negative breast cancer: existing challenges and exciting prospects</article-title>. <source><italic toggle="yes">Drug Resist Updat</italic></source>. <year>2017</year>;<volume>32</volume>:<fpage>1</fpage>&#8211;<lpage>15</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drup.2017.07.002</pub-id><pub-id pub-id-type="pmid">29145974</pub-id></mixed-citation></ref><ref id="cit0083"><label>83.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Walter</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Weinschenk</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Stenzl</surname><given-names>A</given-names></string-name>, et al. <article-title>Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival</article-title>. <source><italic toggle="yes">Nat Med</italic></source>. <year>2012</year>;<volume>18</volume>(<issue>8</issue>):<fpage>1254</fpage>&#8211;<lpage>1261</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nm.2883</pub-id><pub-id pub-id-type="pmid">22842478</pub-id></mixed-citation></ref><ref id="cit0084"><label>84.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Arce-Salinas</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Riesco-Martinez</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Hanna</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Bedard</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Warner</surname><given-names>E</given-names></string-name>. <article-title>Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: case Report and Review of the Literature</article-title>. <source><italic toggle="yes">J Clin Oncol</italic></source>. <year>2016</year>;<volume>34</volume>:<fpage>e21</fpage>&#8211;<lpage>4</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2013.49.8899</pub-id><pub-id pub-id-type="pmid">24888812</pub-id></mixed-citation></ref><ref id="cit0085"><label>85.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Xu</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, et al. <article-title>Ferroptosis and triple-negative breast cancer: potential therapeutic targets</article-title>. <source><italic toggle="yes">Front Oncol</italic></source>. <year>2022</year>;<volume>12</volume>:<fpage>1017041</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fonc.2022.1017041</pub-id><pub-id pub-id-type="pmid">36568247</pub-id><pub-id pub-id-type="pmcid">PMC9780505</pub-id></mixed-citation></ref><ref id="cit0086"><label>86.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Garrido-Castro</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>NU</given-names></string-name>, <string-name name-style="western"><surname>Polyak</surname><given-names>K</given-names></string-name>. <article-title>Insights into Molecular Classifications of Triple-Negative Breast Cancer: improving Patient Selection for Treatment</article-title>. <source><italic toggle="yes">Cancer Discov</italic></source>. <year>2019</year>;<volume>9</volume>(<issue>2</issue>):<fpage>176</fpage>&#8211;<lpage>198</lpage>. doi:<pub-id pub-id-type="doi">10.1158/2159-8290.CD-18-1177</pub-id><pub-id pub-id-type="pmid">30679171</pub-id><pub-id pub-id-type="pmcid">PMC6387871</pub-id></mixed-citation></ref><ref id="cit0087"><label>87.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bardia</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mayer</surname><given-names>IA</given-names></string-name>, <string-name name-style="western"><surname>Diamond</surname><given-names>JR</given-names></string-name>, et al. <article-title>Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer</article-title>. <source><italic toggle="yes">J Clin Oncol</italic></source>. <year>2017</year>;<volume>35</volume>(<issue>19</issue>):<fpage>2141</fpage>&#8211;<lpage>2148</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2016.70.8297</pub-id><pub-id pub-id-type="pmid">28291390</pub-id><pub-id pub-id-type="pmcid">PMC5559902</pub-id></mixed-citation></ref><ref id="cit0088"><label>88.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yardley</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Weaver</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Melisko</surname><given-names>ME</given-names></string-name>, et al. <article-title>EMERGE: a Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer</article-title>. <source><italic toggle="yes">J Clin Oncol</italic></source>. <year>2015</year>;<volume>33</volume>(<issue>14</issue>):<fpage>1609</fpage>&#8211;<lpage>1619</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2014.56.2959</pub-id><pub-id pub-id-type="pmid">25847941</pub-id></mixed-citation></ref><ref id="cit0089"><label>89.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Nagayama</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Vidula</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bardia</surname><given-names>A</given-names></string-name>. <article-title>Novel Therapies for Metastatic Triple-Negative Breast Cancer: spotlight on Immunotherapy and Antibody-Drug Conjugates</article-title>. <source><italic toggle="yes">Oncology</italic></source>. <year>2021</year>;<volume>35</volume>(<issue>3505</issue>):<fpage>249</fpage>&#8211;<lpage>254</lpage>. doi:<pub-id pub-id-type="doi">10.46883/ONC.2021.3505.0249</pub-id><pub-id pub-id-type="pmid">33983696</pub-id></mixed-citation></ref><ref id="cit0090"><label>90.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gristina</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>La Mantia</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Iacono</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Galvano</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Russo</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bazan</surname><given-names>V</given-names></string-name>. <article-title>The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer</article-title>. <source><italic toggle="yes">Pharmaceuticals</italic></source>. <year>2020</year>;<volume>13</volume>(<issue>12</issue>):<fpage>474</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ph13120474</pub-id><pub-id pub-id-type="pmid">33352844</pub-id><pub-id pub-id-type="pmcid">PMC7766858</pub-id></mixed-citation></ref><ref id="cit0091"><label>91.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Dong</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yousefi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Iv</surname><given-names>S</given-names></string-name>, et al. <article-title>Ceritinib is a novel triple negative breast cancer therapeutic agent</article-title>. <source><italic toggle="yes">Mol Cancer</italic></source>. <year>2022</year>;<volume>21</volume>(<issue>1</issue>):<fpage>138</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12943-022-01601-0</pub-id><pub-id pub-id-type="pmid">35768871</pub-id><pub-id pub-id-type="pmcid">PMC9241294</pub-id></mixed-citation></ref><ref id="cit0092"><label>92.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kim</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Haura</surname><given-names>EB</given-names></string-name>. <article-title>Src kinases as therapeutic targets for cancer</article-title>. <source><italic toggle="yes">Nat Rev Clin Oncol</italic></source>. <year>2009</year>;<volume>6</volume>(<issue>10</issue>):<fpage>587</fpage>&#8211;<lpage>595</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrclinonc.2009.129</pub-id><pub-id pub-id-type="pmid">19787002</pub-id></mixed-citation></ref><ref id="cit0093"><label>93.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wheeler</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Iida</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dunn</surname><given-names>EF</given-names></string-name>. <article-title>The role of Src in solid tumors</article-title>. <source><italic toggle="yes">Oncologist</italic></source>. <year>2009</year>;<volume>14</volume>(<issue>7</issue>):<fpage>667</fpage>&#8211;<lpage>678</lpage>. doi:<pub-id pub-id-type="doi">10.1634/theoncologist.2009-0009</pub-id><pub-id pub-id-type="pmid">19581523</pub-id><pub-id pub-id-type="pmcid">PMC3303596</pub-id></mixed-citation></ref><ref id="cit0094"><label>94.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Finn</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Dering</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ginther</surname><given-names>C</given-names></string-name>, et al. <article-title>Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/&#8220;triple-negative&#8221; breast cancer cell lines growing in vitro</article-title>. <source><italic toggle="yes">Breast Cancer Res Treat</italic></source>. <year>2007</year>;<volume>105</volume>(<issue>3</issue>):<fpage>319</fpage>&#8211;<lpage>326</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10549-006-9463-x</pub-id><pub-id pub-id-type="pmid">17268817</pub-id></mixed-citation></ref><ref id="cit0095"><label>95.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Huang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Reeves</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>X</given-names></string-name>, et al. <article-title>Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection</article-title>. <source><italic toggle="yes">Cancer Res</italic></source>. <year>2007</year>;<volume>67</volume>(<issue>5</issue>):<fpage>2226</fpage>&#8211;<lpage>2238</lpage>. doi:<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3633</pub-id><pub-id pub-id-type="pmid">17332353</pub-id></mixed-citation></ref><ref id="cit0096"><label>96.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Tryfonopoulos</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Walsh</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Collins</surname><given-names>DM</given-names></string-name>, et al. <article-title>Src: a potential target for the treatment of triple-negative breast cancer</article-title>. <source><italic toggle="yes">Ann Oncol</italic></source>. <year>2011</year>;<volume>22</volume>(<issue>10</issue>):<fpage>2234</fpage>&#8211;<lpage>2240</lpage>. doi:<pub-id pub-id-type="doi">10.1093/annonc/mdq757</pub-id><pub-id pub-id-type="pmid">21357651</pub-id></mixed-citation></ref><ref id="cit0097"><label>97.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Quereda</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Bayle</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Vena</surname><given-names>F</given-names></string-name>, et al. <article-title>Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer</article-title>. <source><italic toggle="yes">Cancer Cell</italic></source>. <year>2019</year>;<volume>36</volume>(<issue>5</issue>):<fpage>545</fpage>&#8211;<lpage>558e7</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ccell.2019.09.004</pub-id><pub-id pub-id-type="pmid">31668947</pub-id></mixed-citation></ref><ref id="cit0098"><label>98.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Cortesi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Rugo</surname><given-names>HS</given-names></string-name>, <string-name name-style="western"><surname>Jackisch</surname><given-names>C</given-names></string-name>. <article-title>An Overview of PARP Inhibitors for the Treatment of Breast Cancer</article-title>. <source><italic toggle="yes">Target Oncol</italic></source>. <year>2021</year>;<volume>16</volume>(<issue>3</issue>):<fpage>255</fpage>&#8211;<lpage>282</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11523-021-00796-4</pub-id><pub-id pub-id-type="pmid">33710534</pub-id><pub-id pub-id-type="pmcid">PMC8105250</pub-id></mixed-citation></ref><ref id="cit0099"><label>99.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Rizzolo</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Silvestri</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Falchetti</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ottini</surname><given-names>L</given-names></string-name>. <article-title>Inherited and acquired alterations in development of breast cancer</article-title>. <source><italic toggle="yes">Appl Clin Genet</italic></source>. <year>2011</year>;<volume>4</volume>:<fpage>145</fpage>&#8211;<lpage>158</lpage>. doi:<pub-id pub-id-type="doi">10.2147/TACG.S13226</pub-id><pub-id pub-id-type="pmid">23776375</pub-id><pub-id pub-id-type="pmcid">PMC3681186</pub-id></mixed-citation></ref><ref id="cit0100"><label>100.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Godet</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Gilkes</surname><given-names>DM</given-names></string-name>. <article-title>BRCA1 and BRCA2 mutations and treatment strategies for breast cancer</article-title>. <source><italic toggle="yes">Integr Cancer Sci Ther</italic></source>. <year>2017</year>;<volume>4</volume>(<issue>1</issue>). doi:<pub-id pub-id-type="doi">10.15761/ICST.1000228</pub-id><pub-id pub-id-type="pmcid">PMC5505673</pub-id><pub-id pub-id-type="pmid">28706734</pub-id></mixed-citation></ref><ref id="cit0101"><label>101.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Winter</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Nilsson</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Olsson</surname><given-names>E</given-names></string-name>, et al. <article-title>Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic</article-title>. <source><italic toggle="yes">Ann Oncol</italic></source>. <year>2016</year>;<volume>27</volume>(<issue>8</issue>):<fpage>1532</fpage>&#8211;<lpage>1538</lpage>. doi:<pub-id pub-id-type="doi">10.1093/annonc/mdw209</pub-id><pub-id pub-id-type="pmid">27194814</pub-id><pub-id pub-id-type="pmcid">PMC4959927</pub-id></mixed-citation></ref><ref id="cit0102"><label>102.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lord</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Ashworth</surname><given-names>A</given-names></string-name>. <article-title>The DNA damage response and cancer therapy</article-title>. <source><italic toggle="yes">Nature</italic></source>. <year>2012</year>;<volume>481</volume>(<issue>7381</issue>):<fpage>287</fpage>&#8211;<lpage>294</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature10760</pub-id><pub-id pub-id-type="pmid">22258607</pub-id></mixed-citation></ref><ref id="cit0103"><label>103.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Perou</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Sorlie</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Eisen</surname><given-names>MB</given-names></string-name>, et al. <article-title>Molecular portraits of human breast tumours</article-title>. <source><italic toggle="yes">Nature</italic></source>. <year>2000</year>;<volume>406</volume>(<issue>6797</issue>):<fpage>747</fpage>&#8211;<lpage>752</lpage>. doi:<pub-id pub-id-type="doi">10.1038/35021093</pub-id><pub-id pub-id-type="pmid">10963602</pub-id></mixed-citation></ref><ref id="cit0104"><label>104.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Walsh</surname><given-names>CS</given-names></string-name>. <article-title>Two decades beyond BRCA1/2: homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy</article-title>. <source><italic toggle="yes">Gynecol Oncol</italic></source>. <year>2015</year>;<volume>137</volume>(<issue>2</issue>):<fpage>343</fpage>&#8211;<lpage>350</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ygyno.2015.02.017</pub-id><pub-id pub-id-type="pmid">25725131</pub-id></mixed-citation></ref><ref id="cit0105"><label>105.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bai</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ni</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Beretov</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Graham</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>. <article-title>Triple-negative breast cancer therapeutic resistance: where is the Achilles&#8217; heel?</article-title><source><italic toggle="yes">Cancer Lett</italic></source>. <year>2021</year>;<volume>497</volume>:<fpage>100</fpage>&#8211;<lpage>111</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.canlet.2020.10.016</pub-id><pub-id pub-id-type="pmid">33069769</pub-id></mixed-citation></ref><ref id="cit0106"><label>106.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Tutt</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Robson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Garber</surname><given-names>JE</given-names></string-name>, et al. <article-title>Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial</article-title>. <source><italic toggle="yes">Lancet</italic></source>. <year>2010</year>;<volume>376</volume>(<issue>9737</issue>):<fpage>235</fpage>&#8211;<lpage>244</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(10)60892-6</pub-id><pub-id pub-id-type="pmid">20609467</pub-id></mixed-citation></ref><ref id="cit0107"><label>107.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Jin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Ji</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Guan</surname><given-names>X</given-names></string-name>. <article-title>Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy</article-title>. <source><italic toggle="yes">Cancer Biol Ther</italic></source>. <year>2017</year>;<volume>18</volume>(<issue>6</issue>):<fpage>369</fpage>&#8211;<lpage>378</lpage>. doi:<pub-id pub-id-type="doi">10.1080/15384047.2017.1323582</pub-id><pub-id pub-id-type="pmid">28494179</pub-id><pub-id pub-id-type="pmcid">PMC5536940</pub-id></mixed-citation></ref><ref id="cit0108"><label>108.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Cantley</surname><given-names>LC</given-names></string-name>. <article-title>The phosphoinositide 3-kinase pathway</article-title>. <source><italic toggle="yes">Science</italic></source>. <year>2002</year>;<volume>296</volume>(<issue>5573</issue>):<fpage>1655</fpage>&#8211;<lpage>1657</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.296.5573.1655</pub-id><pub-id pub-id-type="pmid">12040186</pub-id></mixed-citation></ref><ref id="cit0109"><label>109.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Cossu-Rocca</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Orru</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Muroni</surname><given-names>MR</given-names></string-name>, et al. <article-title>Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2015</year>;<volume>10</volume>(<issue>11</issue>):<fpage>e0141763</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0141763</pub-id><pub-id pub-id-type="pmid">26540293</pub-id><pub-id pub-id-type="pmcid">PMC4634768</pub-id></mixed-citation></ref><ref id="cit0110"><label>110.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ooms</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Binge</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Davies</surname><given-names>EM</given-names></string-name>, et al. <article-title>The Inositol Polyphosphate 5-Phosphatase PIPP Regulates AKT1-Dependent Breast Cancer Growth and Metastasis</article-title>. <source><italic toggle="yes">Cancer Cell</italic></source>. <year>2015</year>;<volume>28</volume>(<issue>2</issue>):<fpage>155</fpage>&#8211;<lpage>169</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ccell.2015.07.003</pub-id><pub-id pub-id-type="pmid">26267533</pub-id></mixed-citation></ref><ref id="cit0111"><label>111.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hanahan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Weinberg</surname><given-names>RA</given-names></string-name>. <article-title>Hallmarks of cancer: the next generation</article-title>. <source><italic toggle="yes">Cell</italic></source>. <year>2011</year>;<volume>144</volume>(<issue>5</issue>):<fpage>646</fpage>&#8211;<lpage>674</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></mixed-citation></ref><ref id="cit0112"><label>112.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Asghar</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Witkiewicz</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Turner</surname><given-names>NC</given-names></string-name>, <string-name name-style="western"><surname>Knudsen</surname><given-names>ES</given-names></string-name>. <article-title>The history and future of targeting cyclin-dependent kinases in cancer therapy</article-title>. <source><italic toggle="yes">Nat Rev Drug Discov</italic></source>. <year>2015</year>;<volume>14</volume>(<issue>2</issue>):<fpage>130</fpage>&#8211;<lpage>146</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrd4504</pub-id><pub-id pub-id-type="pmid">25633797</pub-id><pub-id pub-id-type="pmcid">PMC4480421</pub-id></mixed-citation></ref><ref id="cit0113"><label>113.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Curtis</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Shah</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Chin</surname><given-names>SF</given-names></string-name>, et al. <article-title>The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups</article-title>. <source><italic toggle="yes">Nature</italic></source>. <year>2012</year>;<volume>486</volume>(<issue>7403</issue>):<fpage>346</fpage>&#8211;<lpage>352</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature10983</pub-id><pub-id pub-id-type="pmid">22522925</pub-id><pub-id pub-id-type="pmcid">PMC3440846</pub-id></mixed-citation></ref><ref id="cit0114"><label>114.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Finn</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Dering</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Conklin</surname><given-names>D</given-names></string-name>, et al. <article-title>PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro</article-title>. <source><italic toggle="yes">Breast Cancer Res</italic></source>. <year>2009</year>;<volume>11</volume>(<issue>5</issue>):<fpage>R77</fpage>. doi:<pub-id pub-id-type="doi">10.1186/bcr2419</pub-id><pub-id pub-id-type="pmid">19874578</pub-id><pub-id pub-id-type="pmcid">PMC2790859</pub-id></mixed-citation></ref><ref id="cit0115"><label>115.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Liu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>M</given-names></string-name>, et al. <article-title>CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1</article-title>. <source><italic toggle="yes">Nat Commun</italic></source>. <year>2017</year>;<volume>8</volume>(<issue>1</issue>):<fpage>13923</fpage>. doi:<pub-id pub-id-type="doi">10.1038/ncomms13923</pub-id><pub-id pub-id-type="pmid">28067227</pub-id><pub-id pub-id-type="pmcid">PMC5228031</pub-id></mixed-citation></ref><ref id="cit0116"><label>116.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yamamoto</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kanaya</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Somlo</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>S</given-names></string-name>. <article-title>Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer</article-title>. <source><italic toggle="yes">Breast Cancer Res Treat</italic></source>. <year>2019</year>;<volume>174</volume>(<issue>3</issue>):<fpage>615</fpage>&#8211;<lpage>625</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10549-018-05104-9</pub-id><pub-id pub-id-type="pmid">30607633</pub-id><pub-id pub-id-type="pmcid">PMC6452902</pub-id></mixed-citation></ref><ref id="cit0117"><label>117.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yuan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yost</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Xing</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Mortimer</surname><given-names>J</given-names></string-name>. <article-title>Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer</article-title>. <source><italic toggle="yes">Sci Rep</italic></source>. <year>2019</year>;<volume>9</volume>(<issue>1</issue>):<fpage>7509</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-019-43429-7</pub-id><pub-id pub-id-type="pmid">31101835</pub-id><pub-id pub-id-type="pmcid">PMC6525251</pub-id></mixed-citation></ref><ref id="cit0118"><label>118.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Rakha</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>El-Sayed</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Green</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Robertson</surname><given-names>JF</given-names></string-name>, <string-name name-style="western"><surname>Ellis</surname><given-names>IO</given-names></string-name>. <article-title>Prognostic markers in triple-negative breast cancer</article-title>. <source><italic toggle="yes">Cancer</italic></source>. <year>2007</year>;<volume>109</volume>(<issue>1</issue>):<fpage>25</fpage>&#8211;<lpage>32</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cncr.22381</pub-id><pub-id pub-id-type="pmid">17146782</pub-id></mixed-citation></ref><ref id="cit0119"><label>119.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Tan</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Marchio</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Savage</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Dowsett</surname><given-names>M</given-names></string-name>. <article-title>Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients</article-title>. <source><italic toggle="yes">Breast Cancer Res Treat</italic></source>. <year>2008</year>;<volume>111</volume>(<issue>1</issue>):<fpage>27</fpage>&#8211;<lpage>44</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10549-007-9756-8</pub-id><pub-id pub-id-type="pmid">17922188</pub-id></mixed-citation></ref><ref id="cit0120"><label>120.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Choi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jung</surname><given-names>WH</given-names></string-name>, <string-name name-style="western"><surname>Koo</surname><given-names>JS</given-names></string-name>. <article-title>Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers</article-title>. <source><italic toggle="yes">Histol Histopathol</italic></source>. <year>2012</year>;<volume>27</volume>(<issue>11</issue>):<fpage>1481</fpage>&#8211;<lpage>1493</lpage>. doi:<pub-id pub-id-type="doi">10.14670/HH-27.1481</pub-id><pub-id pub-id-type="pmid">23018247</pub-id></mixed-citation></ref><ref id="cit0121"><label>121.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gumuskaya</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Alper</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hucumenoglu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Altundag</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Uner</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Guler</surname><given-names>G</given-names></string-name>. <article-title>EGFR expression and gene copy number in triple-negative breast carcinoma</article-title>. <source><italic toggle="yes">Cancer Genet Cytogenet</italic></source>. <year>2010</year>;<volume>203</volume>(<issue>2</issue>):<fpage>222</fpage>&#8211;<lpage>229</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cancergencyto.2010.07.118</pub-id><pub-id pub-id-type="pmid">21156237</pub-id></mixed-citation></ref><ref id="cit0122"><label>122.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Martin</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Botta</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Zanellato</surname><given-names>E</given-names></string-name>, et al. <article-title>Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features</article-title>. <source><italic toggle="yes">Histol Histopathol</italic></source>. <year>2012</year>;<volume>27</volume>(<issue>6</issue>):<fpage>785</fpage>&#8211;<lpage>792</lpage>. doi:<pub-id pub-id-type="doi">10.14670/HH-27.785</pub-id><pub-id pub-id-type="pmid">22473698</pub-id></mixed-citation></ref><ref id="cit0123"><label>123.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Reis-Filho</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Pinheiro</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lambros</surname><given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Milanezi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Carvalho</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Savage</surname><given-names>K</given-names></string-name>. <article-title>EGFR amplification and lack of activating mutations in metaplastic breast carcinomas</article-title>. <source><italic toggle="yes">J Pathol</italic></source>. <year>2006</year>;<volume>209</volume>(<issue>4</issue>):<fpage>445</fpage>&#8211;<lpage>453</lpage>. doi:<pub-id pub-id-type="doi">10.1002/path.2004</pub-id><pub-id pub-id-type="pmid">16739104</pub-id></mixed-citation></ref><ref id="cit0124"><label>124.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Grob</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Heilenkotter</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Geist</surname><given-names>S</given-names></string-name>, et al. <article-title>Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer</article-title>. <source><italic toggle="yes">Breast Cancer Res Treat</italic></source>. <year>2012</year>;<volume>134</volume>(<issue>2</issue>):<fpage>561</fpage>&#8211;<lpage>567</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10549-012-2092-7</pub-id><pub-id pub-id-type="pmid">22610646</pub-id></mixed-citation></ref><ref id="cit0125"><label>125.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Shao</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>H</given-names></string-name>. <article-title>Epidermal growth factor receptor gene amplification and protein overexpression in basal-like carcinoma of the breast</article-title>. <source><italic toggle="yes">Histopathology</italic></source>. <year>2011</year>;<volume>59</volume>(<issue>2</issue>):<fpage>264</fpage>&#8211;<lpage>273</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2559.2011.03921.x</pub-id><pub-id pub-id-type="pmid">21884205</pub-id></mixed-citation></ref><ref id="cit0126"><label>126.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Nakajima</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ishikawa</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Furuya</surname><given-names>M</given-names></string-name>, et al. <article-title>Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer</article-title>. <source><italic toggle="yes">Breast Cancer</italic></source>. <year>2014</year>;<volume>21</volume>(<issue>1</issue>):<fpage>66</fpage>&#8211;<lpage>74</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12282-012-0354-1</pub-id><pub-id pub-id-type="pmid">22481575</pub-id></mixed-citation></ref><ref id="cit0127"><label>127.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bernsdorf</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ingvar</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Jorgensen</surname><given-names>L</given-names></string-name>, et al. <article-title>Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial</article-title>. <source><italic toggle="yes">Breast Cancer Res Treat</italic></source>. <year>2011</year>;<volume>126</volume>(<issue>2</issue>):<fpage>463</fpage>&#8211;<lpage>470</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10549-011-1352-2</pub-id><pub-id pub-id-type="pmid">21234672</pub-id></mixed-citation></ref><ref id="cit0128"><label>128.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Matsuda</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>B</given-names></string-name>, et al. <article-title>Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer</article-title>. <source><italic toggle="yes">JAMA Oncol</italic></source>. <year>2018</year>;<volume>4</volume>(<issue>9</issue>):<fpage>1207</fpage>&#8211;<lpage>1213</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaoncol.2018.1436</pub-id><pub-id pub-id-type="pmid">29879283</pub-id><pub-id pub-id-type="pmcid">PMC6143003</pub-id></mixed-citation></ref><ref id="cit0129"><label>129.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Schuler</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Awada</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Harter</surname><given-names>P</given-names></string-name>, et al. <article-title>A phase II trial to assess efficacy and safety of Afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer</article-title>. <source><italic toggle="yes">Breast Cancer Res Treat</italic></source>. <year>2012</year>;<volume>134</volume>(<issue>3</issue>):<fpage>1149</fpage>&#8211;<lpage>1159</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10549-012-2126-1</pub-id><pub-id pub-id-type="pmid">22763464</pub-id><pub-id pub-id-type="pmcid">PMC3409367</pub-id></mixed-citation></ref><ref id="cit0130"><label>130.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yardley</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Ward</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Daniel</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Eakle</surname><given-names>JF</given-names></string-name>. <article-title>Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: a Sarah Cannon Research Institute Phase II Trial</article-title>. <source><italic toggle="yes">Clin Breast Cancer</italic></source>. <year>2016</year>;<volume>16</volume>(<issue>5</issue>):<fpage>349</fpage>&#8211;<lpage>355</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.clbc.2016.05.006</pub-id><pub-id pub-id-type="pmid">27340049</pub-id></mixed-citation></ref><ref id="cit0131"><label>131.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Greenberg</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rugo</surname><given-names>HS</given-names></string-name>. <article-title>Triple-negative breast cancer: role of antiangiogenic agents</article-title>. <source><italic toggle="yes">Cancer J</italic></source>. <year>2010</year>;<volume>16</volume>(<issue>1</issue>):<fpage>33</fpage>&#8211;<lpage>38</lpage>. doi:<pub-id pub-id-type="doi">10.1097/PPO.0b013e3181d38514</pub-id><pub-id pub-id-type="pmid">20164688</pub-id></mixed-citation></ref><ref id="cit0132"><label>132.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Papa</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Caruso</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Tomao</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rossi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zaccarelli</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Tomao</surname><given-names>F</given-names></string-name>. <article-title>Triple-negative breast cancer: investigating potential molecular therapeutic target</article-title>. <source><italic toggle="yes">Expert Opin Ther Targets</italic></source>. <year>2015</year>;<volume>19</volume>(<issue>1</issue>):<fpage>55</fpage>&#8211;<lpage>75</lpage>. doi:<pub-id pub-id-type="doi">10.1517/14728222.2014.970176</pub-id><pub-id pub-id-type="pmid">25307277</pub-id></mixed-citation></ref><ref id="cit0133"><label>133.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Da Silva</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Cardoso Nunes</surname><given-names>NC</given-names></string-name>, <string-name name-style="western"><surname>Izetti</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>De Mesquita</surname><given-names>GG</given-names></string-name>, <string-name name-style="western"><surname>De Melo</surname><given-names>AC</given-names></string-name>. <article-title>Triple negative breast cancer: a thorough review of biomarkers</article-title>. <source><italic toggle="yes">Crit Rev Oncol Hematol</italic></source>. <year>2020</year>;<volume>145</volume>:<fpage>102855</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.critrevonc.2019.102855</pub-id><pub-id pub-id-type="pmid">31927455</pub-id></mixed-citation></ref><ref id="cit0134"><label>134.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Linderholm</surname><given-names>BK</given-names></string-name>, <string-name name-style="western"><surname>Hellborg</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Johansson</surname><given-names>U</given-names></string-name>, et al. <article-title>Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer</article-title>. <source><italic toggle="yes">Ann Oncol</italic></source>. <year>2009</year>;<volume>20</volume>(<issue>10</issue>):<fpage>1639</fpage>&#8211;<lpage>1646</lpage>. doi:<pub-id pub-id-type="doi">10.1093/annonc/mdp062</pub-id><pub-id pub-id-type="pmid">19549711</pub-id></mixed-citation></ref><ref id="cit0135"><label>135.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Von Minckwitz</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Eidtmann</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Rezai</surname><given-names>M</given-names></string-name>, et al. <article-title>German Breast Group, Arbeitsgemeinschaft Gynakologische Onkologie-Breast Study Groups, Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2012</year>;<volume>366</volume>(<issue>4</issue>):<fpage>299</fpage>&#8211;<lpage>309</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1111065</pub-id><pub-id pub-id-type="pmid">22276820</pub-id></mixed-citation></ref><ref id="cit0136"><label>136.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Pal</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Mortimer</surname><given-names>J</given-names></string-name>. <article-title>Triple-negative breast cancer: novel therapies and new directions</article-title>. <source><italic toggle="yes">Maturitas</italic></source>. <year>2009</year>;<volume>63</volume>(<issue>4</issue>):<fpage>269</fpage>&#8211;<lpage>274</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.maturitas.2009.06.010</pub-id><pub-id pub-id-type="pmid">19632796</pub-id></mixed-citation></ref><ref id="cit0137"><label>137.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Giulianelli</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cerliani</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Lamb</surname><given-names>CA</given-names></string-name>, et al. <article-title>Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: a role for the FGF-2/FGFR-2 axis</article-title>. <source><italic toggle="yes">Int, J, Cancer</italic></source>. <year>2008</year>;<volume>123</volume>(<issue>11</issue>):<fpage>2518</fpage>&#8211;<lpage>2531</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ijc.23802</pub-id><pub-id pub-id-type="pmid">18767044</pub-id></mixed-citation></ref><ref id="cit0138"><label>138.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Katoh</surname><given-names>M</given-names></string-name>. <article-title>Cancer genomics and genetics of FGFR2 (Review</article-title>. <source><italic toggle="yes">Int J Oncol</italic></source>. <year>2008</year>;<volume>33</volume>(<issue>2</issue>):<fpage>233</fpage>&#8211;<lpage>237</lpage>.<pub-id pub-id-type="pmid">18636142</pub-id></mixed-citation></ref><ref id="cit0139"><label>139.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Eswarakumar</surname><given-names>VP</given-names></string-name>, <string-name name-style="western"><surname>Lax</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Schlessinger</surname><given-names>J</given-names></string-name>. <article-title>Cellular signaling by fibroblast growth factor receptors</article-title>. <source><italic toggle="yes">Cytokine Growth Factor Rev</italic></source>. <year>2005</year>;<volume>16</volume>(<issue>2</issue>):<fpage>139</fpage>&#8211;<lpage>149</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cytogfr.2005.01.001</pub-id><pub-id pub-id-type="pmid">15863030</pub-id></mixed-citation></ref><ref id="cit0140"><label>140.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Katoh</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nakagama</surname><given-names>H</given-names></string-name>. <article-title>FGF receptors: cancer biology and therapeutics</article-title>. <source><italic toggle="yes">Med Res Rev</italic></source>. <year>2014</year>;<volume>34</volume>(<issue>2</issue>):<fpage>280</fpage>&#8211;<lpage>300</lpage>. doi:<pub-id pub-id-type="doi">10.1002/med.21288</pub-id><pub-id pub-id-type="pmid">23696246</pub-id></mixed-citation></ref><ref id="cit0141"><label>141.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ornitz</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Itoh</surname><given-names>N</given-names></string-name>. <article-title>The Fibroblast Growth Factor signaling pathway</article-title>. <source><italic toggle="yes">Wiley Interdiscip Rev Dev Biol</italic></source>. <year>2015</year>;<volume>4</volume>(<issue>3</issue>):<fpage>215</fpage>&#8211;<lpage>266</lpage>. doi:<pub-id pub-id-type="doi">10.1002/wdev.176</pub-id><pub-id pub-id-type="pmid">25772309</pub-id><pub-id pub-id-type="pmcid">PMC4393358</pub-id></mixed-citation></ref><ref id="cit0142"><label>142.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Jafarian</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Kooshkiforooshani</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Farzad</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Mohamadian Roshan</surname><given-names>N</given-names></string-name>. <article-title>The Relationship Between Fibroblastic Growth Factor Receptor-1 (FGFR1) Gene Amplification in Triple Negative Breast Carcinomas and Clinicopathological Prognostic Factors</article-title>. <source><italic toggle="yes">Iran J Pathol</italic></source>. <year>2019</year>;<volume>14</volume>(<issue>4</issue>):<fpage>299</fpage>&#8211;<lpage>304</lpage>. doi:<pub-id pub-id-type="doi">10.30699/IJP.2019.96713.1952</pub-id><pub-id pub-id-type="pmid">31754359</pub-id><pub-id pub-id-type="pmcid">PMC6824770</pub-id></mixed-citation></ref><ref id="cit0143"><label>143.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Perez-Garcia</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Munoz-Couselo</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Soberino</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Racca</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Cortes</surname><given-names>J</given-names></string-name>. <article-title>Targeting FGFR pathway in breast cancer</article-title>. <source><italic toggle="yes">Breast</italic></source>. <year>2018</year>;<volume>37</volume>:<fpage>126</fpage>&#8211;<lpage>133</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.breast.2017.10.014</pub-id><pub-id pub-id-type="pmid">29156384</pub-id></mixed-citation></ref><ref id="cit0144"><label>144.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Soria</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Debraud</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bahleda</surname><given-names>R</given-names></string-name>, et al. <article-title>Corrections to &#8220;Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors&#8221;</article-title>. <source><italic toggle="yes">Ann Oncol</italic></source>. <year>2015</year>;<volume>26</volume>(<issue>2</issue>):<fpage>445</fpage>. doi:<pub-id pub-id-type="doi">10.1093/annonc/mdu547</pub-id><pub-id pub-id-type="pmid">32590894</pub-id></mixed-citation></ref><ref id="cit0145"><label>145.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Nogova</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sequist</surname><given-names>LV</given-names></string-name>, <string-name name-style="western"><surname>Perez Garcia</surname><given-names>JM</given-names></string-name>, et al. <article-title>Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: results of a Global Phase I, Dose-Escalation and Dose-Expansion Study</article-title>. <source><italic toggle="yes">J Clin Oncol</italic></source>. <year>2017</year>;<volume>35</volume>(<issue>2</issue>):<fpage>157</fpage>&#8211;<lpage>165</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2016.67.2048</pub-id><pub-id pub-id-type="pmid">27870574</pub-id><pub-id pub-id-type="pmcid">PMC6865065</pub-id></mixed-citation></ref><ref id="cit0146"><label>146.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bai</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Meetze</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Vo</surname><given-names>NY</given-names></string-name>, et al. <article-title>GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling</article-title>. <source><italic toggle="yes">Cancer Res</italic></source>. <year>2010</year>;<volume>70</volume>(<issue>19</issue>):<fpage>7630</fpage>&#8211;<lpage>7639</lpage>. doi:<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-1489</pub-id><pub-id pub-id-type="pmid">20709759</pub-id></mixed-citation></ref><ref id="cit0147"><label>147.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Tolcher</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Papadopoulos</surname><given-names>KP</given-names></string-name>, <string-name name-style="western"><surname>Patnaik</surname><given-names>A</given-names></string-name>, et al. <article-title>A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors</article-title>. <source><italic toggle="yes">Ann Oncol</italic></source>. <year>2016</year>;<volume>27</volume>(<issue>3</issue>):<fpage>526</fpage>&#8211;<lpage>532</lpage>. doi:<pub-id pub-id-type="doi">10.1093/annonc/mdv591</pub-id><pub-id pub-id-type="pmid">26646757</pub-id></mixed-citation></ref><ref id="cit0148"><label>148.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lyons</surname><given-names>TG</given-names></string-name>. <article-title>Targeted Therapies for Triple-Negative Breast Cancer</article-title>. <source><italic toggle="yes">Curr Treat Options Oncol</italic></source>. <year>2019</year>;<volume>20</volume>(<issue>11</issue>):<fpage>82</fpage>. doi:<pub-id pub-id-type="doi">10.1007/s11864-019-0682-x</pub-id><pub-id pub-id-type="pmid">31754897</pub-id></mixed-citation></ref><ref id="cit0149"><label>149.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Tarantino</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Hamilton</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Tolaney</surname><given-names>SM</given-names></string-name>, et al. <article-title>HER2-Low Breast Cancer: pathological and Clinical Landscape</article-title>. <source><italic toggle="yes">J Clin Oncol</italic></source>. <year>2020</year>;<volume>38</volume>(<issue>17</issue>):<fpage>1951</fpage>&#8211;<lpage>1962</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.19.02488</pub-id><pub-id pub-id-type="pmid">32330069</pub-id></mixed-citation></ref><ref id="cit0150"><label>150.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mittendorf</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Ardavanis</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Litton</surname><given-names>JK</given-names></string-name>, et al. <article-title>Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence</article-title>. <source><italic toggle="yes">Oncotarget</italic></source>. <year>2016</year>;<volume>7</volume>(<issue>40</issue>):<fpage>66192</fpage>&#8211;<lpage>66201</lpage>. doi:<pub-id pub-id-type="doi">10.18632/oncotarget.11751</pub-id><pub-id pub-id-type="pmid">27589688</pub-id><pub-id pub-id-type="pmcid">PMC5323226</pub-id></mixed-citation></ref><ref id="cit0151"><label>151.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Guler</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Himmetoglu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Jimenez</surname><given-names>RE</given-names></string-name>, et al. <article-title>Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features</article-title>. <source><italic toggle="yes">Breast Cancer Res Treat</italic></source>. <year>2011</year>;<volume>129</volume>(<issue>2</issue>):<fpage>421</fpage>&#8211;<lpage>432</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10549-010-1248-6</pub-id><pub-id pub-id-type="pmid">21069451</pub-id><pub-id pub-id-type="pmcid">PMC3677189</pub-id></mixed-citation></ref><ref id="cit0152"><label>152.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ribeiro</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ganzinelli</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Andreis</surname><given-names>D</given-names></string-name>, et al. <article-title>Triple negative breast cancers have a reduced expression of DNA repair genes</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2013</year>;<volume>8</volume>(<issue>6</issue>):<fpage>e66243</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0066243</pub-id><pub-id pub-id-type="pmid">23825533</pub-id><pub-id pub-id-type="pmcid">PMC3692506</pub-id></mixed-citation></ref><ref id="cit0153"><label>153.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Shah</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Roth</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Goya</surname><given-names>R</given-names></string-name>, et al. <article-title>The clonal and mutational evolution spectrum of primary triple-negative breast cancers</article-title>. <source><italic toggle="yes">Nature</italic></source>. <year>2012</year>;<volume>486</volume>(<issue>7403</issue>):<fpage>395</fpage>&#8211;<lpage>399</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature10933</pub-id><pub-id pub-id-type="pmid">22495314</pub-id><pub-id pub-id-type="pmcid">PMC3863681</pub-id></mixed-citation></ref><ref id="cit0154"><label>154.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Curtin</surname><given-names>NJ</given-names></string-name>. <article-title>DNA repair dysregulation from cancer driver to therapeutic target</article-title>. <source><italic toggle="yes">Nat Rev Cancer</italic></source>. <year>2012</year>;<volume>12</volume>(<issue>12</issue>):<fpage>801</fpage>&#8211;<lpage>817</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrc3399</pub-id><pub-id pub-id-type="pmid">23175119</pub-id></mixed-citation></ref><ref id="cit0155"><label>155.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Albiges</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Goubar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Scott</surname><given-names>V</given-names></string-name>, et al. <article-title>Chk1 as a new therapeutic target in triple-negative breast cancer</article-title>. <source><italic toggle="yes">Breast</italic></source>. <year>2014</year>;<volume>23</volume>(<issue>3</issue>):<fpage>250</fpage>&#8211;<lpage>258</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.breast.2014.02.004</pub-id><pub-id pub-id-type="pmid">24636978</pub-id></mixed-citation></ref><ref id="cit0156"><label>156.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Nanda</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chow</surname><given-names>LQ</given-names></string-name>, <string-name name-style="western"><surname>Dees</surname><given-names>EC</given-names></string-name>, et al. <article-title>Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: phase Ib KEYNOTE-012 Study</article-title>. <source><italic toggle="yes">J Clin Oncol</italic></source>. <year>2016</year>;<volume>34</volume>(<issue>21</issue>):<fpage>2460</fpage>&#8211;<lpage>2467</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2015.64.8931</pub-id><pub-id pub-id-type="pmid">27138582</pub-id><pub-id pub-id-type="pmcid">PMC6816000</pub-id></mixed-citation></ref><ref id="cit0157"><label>157.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Vesely</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Kershaw</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Schreiber</surname><given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Smyth</surname><given-names>MJ</given-names></string-name>. <article-title>Natural innate and adaptive immunity to cancer</article-title>. <source><italic toggle="yes">Annu Rev Immunol</italic></source>. <year>2011</year>;<volume>29</volume>(<issue>1</issue>):<fpage>235</fpage>&#8211;<lpage>271</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev-immunol-031210-101324</pub-id><pub-id pub-id-type="pmid">21219185</pub-id></mixed-citation></ref><ref id="cit0158"><label>158.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Riley</surname><given-names>JL</given-names></string-name>. <article-title>PD-1 signaling in primary T cells</article-title>. <source><italic toggle="yes">Immunol Rev</italic></source>. <year>2009</year>;<volume>229</volume>(<issue>1</issue>):<fpage>114</fpage>&#8211;<lpage>125</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1600-065X.2009.00767.x</pub-id><pub-id pub-id-type="pmid">19426218</pub-id><pub-id pub-id-type="pmcid">PMC3424066</pub-id></mixed-citation></ref><ref id="cit0159"><label>159.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Shi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>. <article-title>The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies</article-title>. <source><italic toggle="yes">J Hematol Oncol</italic></source>. <year>2013</year>;<volume>6</volume>(<issue>1</issue>):<fpage>74</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1756-8722-6-74</pub-id><pub-id pub-id-type="pmid">24283718</pub-id><pub-id pub-id-type="pmcid">PMC3851976</pub-id></mixed-citation></ref><ref id="cit0160"><label>160.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Shih</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Arkenau</surname><given-names>HT</given-names></string-name>, <string-name name-style="western"><surname>Infante</surname><given-names>JR</given-names></string-name>. <article-title>Clinical impact of checkpoint inhibitors as novel cancer therapies</article-title>. <source><italic toggle="yes">Drugs</italic></source>. <year>2014</year>;<volume>74</volume>(<issue>17</issue>):<fpage>1993</fpage>&#8211;<lpage>2013</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40265-014-0305-6</pub-id><pub-id pub-id-type="pmid">25344022</pub-id><pub-id pub-id-type="pmcid">PMC4224737</pub-id></mixed-citation></ref><ref id="cit0161"><label>161.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Garon</surname><given-names>EB</given-names></string-name>. <article-title>Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer</article-title>. <source><italic toggle="yes">Semin Oncol</italic></source>. <year>2015</year>;<volume>42 Suppl 2</volume>:<fpage>S11</fpage>&#8211;<lpage>8</lpage>. doi:<pub-id pub-id-type="doi">10.1053/j.seminoncol.2015.09.019</pub-id><pub-id pub-id-type="pmid">26477470</pub-id></mixed-citation></ref><ref id="cit0162"><label>162.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Rampurwala</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wisinski</surname><given-names>KB</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;regan</surname><given-names>R</given-names></string-name>. <article-title>Role of the androgen receptor in triple-negative breast cancer</article-title>. <source><italic toggle="yes">Clin Adv Hematol Oncol</italic></source>. <year>2016</year>;<volume>14</volume>(<issue>3</issue>):<fpage>186</fpage>&#8211;<lpage>193</lpage>.<pub-id pub-id-type="pmid">27058032</pub-id><pub-id pub-id-type="pmcid">PMC5221599</pub-id></mixed-citation></ref><ref id="cit0163"><label>163.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Barton</surname><given-names>VN</given-names></string-name>, <string-name name-style="western"><surname>D&#8217;amato</surname><given-names>NC</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>MA</given-names></string-name>, et al. <article-title>Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide In Vivo</article-title>. <source><italic toggle="yes">Mol Cancer Ther</italic></source>. <year>2015</year>;<volume>14</volume>(<issue>3</issue>):<fpage>769</fpage>&#8211;<lpage>778</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-14-0926</pub-id><pub-id pub-id-type="pmid">25713333</pub-id><pub-id pub-id-type="pmcid">PMC4534304</pub-id></mixed-citation></ref><ref id="cit0164"><label>164.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Barton</surname><given-names>VN</given-names></string-name>, <string-name name-style="western"><surname>D&#8217;amato</surname><given-names>NC</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>L</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Elias</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>K</surname><given-names>RJ</given-names></string-name>. <article-title>Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease</article-title>. <source><italic toggle="yes">Horm Cancer</italic></source>. <year>2015</year>;<volume>6</volume>(<issue>5&#8211;6</issue>):<fpage>206</fpage>&#8211;<lpage>213</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12672-015-0232-3</pub-id><pub-id pub-id-type="pmid">26201402</pub-id><pub-id pub-id-type="pmcid">PMC6897499</pub-id></mixed-citation></ref><ref id="cit0165"><label>165.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lebert</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Lester</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Powell</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Seal</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mccarthy</surname><given-names>J</given-names></string-name>. <article-title>Advances in the systemic treatment of triple-negative breast cancer</article-title>. <source><italic toggle="yes">Curr Oncol</italic></source>. <year>2018</year>;<volume>25</volume>:<fpage>S142</fpage>&#8211;<lpage>S150</lpage>. doi:<pub-id pub-id-type="doi">10.3747/co.25.3954</pub-id><pub-id pub-id-type="pmid">29910657</pub-id><pub-id pub-id-type="pmcid">PMC6001760</pub-id></mixed-citation></ref><ref id="cit0166"><label>166.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mcgrogan</surname><given-names>BT</given-names></string-name>, <string-name name-style="western"><surname>Gilmartin</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Carney</surname><given-names>DN</given-names></string-name>, <string-name name-style="western"><surname>Mccann</surname><given-names>A</given-names></string-name>. <article-title>Taxanes, microtubules and chemoresistant breast cancer</article-title>. <source><italic toggle="yes">Biochim Biophys Acta</italic></source>. <year>2008</year>;<volume>1785</volume>(<issue>2</issue>):<fpage>96</fpage>&#8211;<lpage>132</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbcan.2007.10.004</pub-id><pub-id pub-id-type="pmid">18068131</pub-id></mixed-citation></ref><ref id="cit0167"><label>167.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Carey</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Dees</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Sawyer</surname><given-names>L</given-names></string-name>, et al. <article-title>The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes</article-title>. <source><italic toggle="yes">Clin Cancer Res</italic></source>. <year>2007</year>;<volume>13</volume>(<issue>8</issue>):<fpage>2329</fpage>&#8211;<lpage>2334</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-1109</pub-id><pub-id pub-id-type="pmid">17438091</pub-id></mixed-citation></ref><ref id="cit0168"><label>168.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Koh</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Ross</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Isakoff</surname><given-names>SJ</given-names></string-name>, et al. <article-title>RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer</article-title>. <source><italic toggle="yes">Clin Cancer Res</italic></source>. <year>2021</year>;<volume>27</volume>(<issue>17</issue>):<fpage>4883</fpage>&#8211;<lpage>4897</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-21-0714</pub-id><pub-id pub-id-type="pmid">34168046</pub-id><pub-id pub-id-type="pmcid">PMC8416935</pub-id></mixed-citation></ref><ref id="cit0169"><label>169.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lemesle</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Geoffroy</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Alpy</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Tomasetto</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Kuntz</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Grillier-Vuissoz</surname><given-names>I</given-names></string-name>. <article-title>CLDN1 Sensitizes Triple-Negative Breast Cancer Cells to Chemotherapy</article-title>. <source><italic toggle="yes">Cancers</italic></source>. <year>2022</year>;<volume>15</volume>(<issue>1</issue>):<fpage>14</fpage>. doi:<pub-id pub-id-type="doi">10.3390/cancers15010014</pub-id><pub-id pub-id-type="pmid">36291810</pub-id><pub-id pub-id-type="pmcid">PMC9599637</pub-id></mixed-citation></ref><ref id="cit0170"><label>170.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Xiong</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>N</given-names></string-name>, et al. <article-title>DAB2IP attenuates chemoresistance of triple-negative breast cancer through sequestration of RAC1 to prevent beta-catenin nuclear accumulation</article-title>. <source><italic toggle="yes">Clin Transl Med</italic></source>. <year>2022</year>;<volume>12</volume>(<issue>12</issue>):<fpage>e1133</fpage>. doi:<pub-id pub-id-type="doi">10.1002/ctm2.1133</pub-id><pub-id pub-id-type="pmid">36536485</pub-id><pub-id pub-id-type="pmcid">PMC9763535</pub-id></mixed-citation></ref><ref id="cit0171"><label>171.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chen</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Deluca</surname><given-names>HF</given-names></string-name>. <article-title>Cloning of the human 1 alpha,25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements</article-title>. <source><italic toggle="yes">Biochim Biophys Acta</italic></source>. <year>1995</year>;<volume>1263</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>9</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0167-4781(95)00060-t</pub-id><pub-id pub-id-type="pmid">7632726</pub-id></mixed-citation></ref><ref id="cit0172"><label>172.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Nasoohi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ismael</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ishrat</surname><given-names>T</given-names></string-name>. <article-title>Thioredoxin-Interacting Protein (TXNIP) in Cerebrovascular and Neurodegenerative Diseases: regulation and Implication</article-title>. <source><italic toggle="yes">Mol Neurobiol</italic></source>. <year>2018</year>;<volume>55</volume>(<issue>10</issue>):<fpage>7900</fpage>&#8211;<lpage>7920</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12035-018-0917-z</pub-id><pub-id pub-id-type="pmid">29488135</pub-id><pub-id pub-id-type="pmcid">PMC6388721</pub-id></mixed-citation></ref><ref id="cit0173"><label>173.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>B</given-names></string-name>. <article-title>Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage</article-title>. <source><italic toggle="yes">Cell Death Dis</italic></source>. <year>2022</year>;<volume>13</volume>(<issue>4</issue>):<fpage>338</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41419-022-04783-z</pub-id><pub-id pub-id-type="pmid">35414060</pub-id><pub-id pub-id-type="pmcid">PMC9005717</pub-id></mixed-citation></ref><ref id="cit0174"><label>174.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gottesman</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Fojo</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Bates</surname><given-names>SE</given-names></string-name>. <article-title>Multidrug resistance in cancer: role of ATP-dependent transporters</article-title>. <source><italic toggle="yes">Nat Rev Cancer</italic></source>. <year>2002</year>;<volume>2</volume>(<issue>1</issue>):<fpage>48</fpage>&#8211;<lpage>58</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrc706</pub-id><pub-id pub-id-type="pmid">11902585</pub-id></mixed-citation></ref><ref id="cit0175"><label>175.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Salaroglio</surname><given-names>IC</given-names></string-name>, <string-name name-style="western"><surname>Gazzano</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Abdullrahman</surname><given-names>A</given-names></string-name>, et al. <article-title>Increasing intratumor C/EBP-beta LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer</article-title>. <source><italic toggle="yes">J Exp Clin Cancer Res</italic></source>. <year>2018</year>;<volume>37</volume>(<issue>1</issue>):<fpage>286</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13046-018-0967-0</pub-id><pub-id pub-id-type="pmid">30482226</pub-id><pub-id pub-id-type="pmcid">PMC6258159</pub-id></mixed-citation></ref><ref id="cit0176"><label>176.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Denard</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>J</given-names></string-name>. <article-title>CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy</article-title>. <source><italic toggle="yes">BMC Cancer</italic></source>. <year>2018</year>;<volume>18</volume>(<issue>1</issue>):<fpage>813</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12885-018-4724-8</pub-id><pub-id pub-id-type="pmid">30103710</pub-id><pub-id pub-id-type="pmcid">PMC6090630</pub-id></mixed-citation></ref><ref id="cit0177"><label>177.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Long</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>T</given-names></string-name>. <article-title>Atractylenolide-I Suppresses Tumorigenesis of Breast Cancer by Inhibiting Toll-Like Receptor 4-Mediated Nuclear Factor-kappaB Signaling Pathway</article-title>. <source><italic toggle="yes">Front Pharmacol</italic></source>. <year>2020</year>;<volume>11</volume>:<fpage>598939</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fphar.2020.598939</pub-id><pub-id pub-id-type="pmid">33363472</pub-id><pub-id pub-id-type="pmcid">PMC7753112</pub-id></mixed-citation></ref><ref id="cit0178"><label>178.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>XZ</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>MX</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>QY</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>YX</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>X</given-names></string-name>. <article-title>Atractylenolide-I Sensitizes Triple-Negative Breast Cancer Cells to Paclitaxel by Blocking CTGF Expression and Fibroblast Activation</article-title>. <source><italic toggle="yes">Front Oncol</italic></source>. <year>2021</year>;<volume>11</volume>:<fpage>738534</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fonc.2021.738534</pub-id><pub-id pub-id-type="pmid">34692516</pub-id><pub-id pub-id-type="pmcid">PMC8526898</pub-id></mixed-citation></ref><ref id="cit0179"><label>179.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Al-Marsoummi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Vomhof-Dekrey</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Basson</surname><given-names>MD</given-names></string-name>. <article-title>Schlafen12 Reduces the Aggressiveness of Triple Negative Breast Cancer through Post-Transcriptional Regulation of ZEB1 That Drives Stem Cell Differentiation</article-title>. <source><italic toggle="yes">Cell Physiol Biochem</italic></source>. <year>2019</year>;<volume>53</volume>:<fpage>999</fpage>&#8211;<lpage>1014</lpage>. doi:<pub-id pub-id-type="doi">10.33594/000000191</pub-id><pub-id pub-id-type="pmid">31838790</pub-id><pub-id pub-id-type="pmcid">PMC7007982</pub-id></mixed-citation></ref><ref id="cit0180"><label>180.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Raafat Elsayed</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Al-Marsoummi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Vomhof-Dekrey</surname><given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Basson</surname><given-names>MD</given-names></string-name>. <article-title>SLFN12 Over-expression Sensitizes Triple Negative Breast Cancer Cells to Chemotherapy Drugs and Radiotherapy</article-title>. <source><italic toggle="yes">Cancer Genomics Proteomics</italic></source>. <year>2022</year>;<volume>19</volume>(<issue>3</issue>):<fpage>328</fpage>&#8211;<lpage>338</lpage>. doi:<pub-id pub-id-type="doi">10.21873/cgp.20323</pub-id><pub-id pub-id-type="pmid">35430566</pub-id><pub-id pub-id-type="pmcid">PMC9016483</pub-id></mixed-citation></ref><ref id="cit0181"><label>181.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Guo</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Treude</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Kramer</surname><given-names>OH</given-names></string-name>, <string-name name-style="western"><surname>Luscher</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hartkamp</surname><given-names>J</given-names></string-name>. <article-title>PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1</article-title>. <source><italic toggle="yes">Sci Rep</italic></source>. <year>2019</year>;<volume>9</volume>(<issue>1</issue>):<fpage>8755</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-019-45209-9</pub-id><pub-id pub-id-type="pmid">31217499</pub-id><pub-id pub-id-type="pmcid">PMC6584570</pub-id></mixed-citation></ref><ref id="cit0182"><label>182.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>M</given-names></string-name>, et al. <article-title>ETS1 is associated with cisplatin resistance through IKKalpha/NF-kappaB pathway in cell line MDA-MB-231</article-title>. <source><italic toggle="yes">Cancer Cell Int</italic></source>. <year>2018</year>;<volume>18</volume>(<issue>1</issue>):<fpage>86</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12935-018-0581-4</pub-id><pub-id pub-id-type="pmid">29950928</pub-id><pub-id pub-id-type="pmcid">PMC6009945</pub-id></mixed-citation></ref><ref id="cit0183"><label>183.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Fan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>L</given-names></string-name>, et al. <article-title>Highly expressed SERCA2 triggers tumor cell autophagy and is a druggable vulnerability in triple-negative breast cancer</article-title>. <source><italic toggle="yes">Acta Pharm Sin B</italic></source>. <year>2022</year>;<volume>12</volume>(<issue>12</issue>):<fpage>4407</fpage>&#8211;<lpage>4423</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.apsb.2022.05.009</pub-id><pub-id pub-id-type="pmid">36561988</pub-id><pub-id pub-id-type="pmcid">PMC9764070</pub-id></mixed-citation></ref><ref id="cit0184"><label>184.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Qiao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Rao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yun</surname><given-names>Y</given-names></string-name>, et al. <article-title>Impeding DNA Break Repair Enables Oocyte Quality Control</article-title>. <source><italic toggle="yes">Mol Cell</italic></source>. <year>2018</year>;<volume>72</volume>:<fpage>211</fpage>&#8211;<lpage>221e3</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.molcel.2018.08.031</pub-id><pub-id pub-id-type="pmid">30270110</pub-id><pub-id pub-id-type="pmcid">PMC6426715</pub-id></mixed-citation></ref><ref id="cit0185"><label>185.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Adelaide</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Finetti</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bekhouche</surname><given-names>I</given-names></string-name>, et al. <article-title>Integrated profiling of basal and luminal breast cancers</article-title>. <source><italic toggle="yes">Cancer Res</italic></source>. <year>2007</year>;<volume>67</volume>(<issue>24</issue>):<fpage>11565</fpage>&#8211;<lpage>11575</lpage>. doi:<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-2536</pub-id><pub-id pub-id-type="pmid">18089785</pub-id></mixed-citation></ref><ref id="cit0186"><label>186.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chen</surname><given-names>YT</given-names></string-name>, <string-name name-style="western"><surname>Venditti</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Theiler</surname><given-names>G</given-names></string-name>, et al. <article-title>Identification of CT46/HORMAD1, an immunogenic cancer/testis antigen encoding a putative meiosis-related protein</article-title>. <source><italic toggle="yes">Cancer Immun</italic></source>. <year>2005</year>;<volume>5</volume>:<fpage>9</fpage>.<pub-id pub-id-type="pmid">15999985</pub-id></mixed-citation></ref><ref id="cit0187"><label>187.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zong</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lei</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>S</given-names></string-name>. <article-title>HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance</article-title>. <source><italic toggle="yes">Oncol Rep</italic></source>. <year>2021</year>;<volume>45</volume>(<issue>4</issue>):<fpage>46</fpage>. doi:<pub-id pub-id-type="doi">10.3892/or.2021.7997</pub-id><pub-id pub-id-type="pmid">34036395</pub-id><pub-id pub-id-type="pmcid">PMC8165579</pub-id></mixed-citation></ref><ref id="cit0188"><label>188.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lin</surname><given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Kuei</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>HH</given-names></string-name>, et al. <article-title>TNFSF13 upregulation confers chemotherapeutic resistance via triggering autophagy initiation in triple-negative breast cancer</article-title>. <source><italic toggle="yes">J Mol Med (Berl)</italic></source>. <year>2020</year>;<volume>98</volume>(<issue>9</issue>):<fpage>1255</fpage>&#8211;<lpage>1267</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00109-020-01952-5</pub-id><pub-id pub-id-type="pmid">32671412</pub-id></mixed-citation></ref><ref id="cit0189"><label>189.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Liao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>YL</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>L</given-names></string-name>, et al. <article-title>Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer</article-title>. <source><italic toggle="yes">Cancer Res</italic></source>. <year>2023</year>;<volume>83</volume>(<issue>3</issue>):<fpage>471</fpage>&#8211;<lpage>484</lpage>. doi:<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-22-2709</pub-id><pub-id pub-id-type="pmid">36484700</pub-id><pub-id pub-id-type="pmcid">PMC9896024</pub-id></mixed-citation></ref><ref id="cit0190"><label>190.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gobel</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Schroeder</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hube-Magg</surname><given-names>C</given-names></string-name>, et al. <article-title>Upregulation of centromere protein F is linked to aggressive prostate cancers</article-title>. <source><italic toggle="yes">Cancer Manag Res</italic></source>. <year>2018</year>;<volume>10</volume>:<fpage>5491</fpage>&#8211;<lpage>5504</lpage>. doi:<pub-id pub-id-type="doi">10.2147/CMAR.S165630</pub-id><pub-id pub-id-type="pmid">30519097</pub-id><pub-id pub-id-type="pmcid">PMC6234994</pub-id></mixed-citation></ref><ref id="cit0191"><label>191.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chong</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Sarac</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>CQ</given-names></string-name>, et al. <article-title>Deregulation of the spindle assembly checkpoint is associated with paclitaxel resistance in ovarian cancer</article-title>. <source><italic toggle="yes">J Ovarian Res</italic></source>. <year>2018</year>;<volume>11</volume>(<issue>1</issue>):<fpage>27</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13048-018-0399-7</pub-id><pub-id pub-id-type="pmid">29618387</pub-id><pub-id pub-id-type="pmcid">PMC5885411</pub-id></mixed-citation></ref><ref id="cit0192"><label>192.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>M</given-names></string-name>, et al. <article-title>CENPF knockdown inhibits Adriamycin chemoresistance in triple-negative breast cancer via the Rb-E2F1 axis</article-title>. <source><italic toggle="yes">Sci Rep</italic></source>. <year>2023</year>;<volume>13</volume>(<issue>1</issue>):<fpage>1803</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-023-28355-z</pub-id><pub-id pub-id-type="pmid">36720923</pub-id><pub-id pub-id-type="pmcid">PMC9889717</pub-id></mixed-citation></ref><ref id="cit0193"><label>193.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Xiao</surname><given-names>YS</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>YK</given-names></string-name>, et al. <article-title>Major vault protein is a direct target of Notch1 signaling and contributes to chemoresistance in triple-negative breast cancer cells</article-title>. <source><italic toggle="yes">Cancer Lett</italic></source>. <year>2019</year>;<volume>440-441</volume>:<fpage>156</fpage>&#8211;<lpage>167</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.canlet.2018.09.031</pub-id><pub-id pub-id-type="pmid">30336197</pub-id></mixed-citation></ref><ref id="cit0194"><label>194.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mao</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jia</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, et al. <article-title>HJURP regulates cell proliferation and chemo-resistance via YAP1/NDRG1 transcriptional axis in triple-negative breast cancer</article-title>. <source><italic toggle="yes">Cell Death Dis</italic></source>. <year>2022</year>;<volume>13</volume>(<issue>4</issue>):<fpage>396</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41419-022-04833-6</pub-id><pub-id pub-id-type="pmid">35459269</pub-id><pub-id pub-id-type="pmcid">PMC9033877</pub-id></mixed-citation></ref><ref id="cit0195"><label>195.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Deng</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>. <article-title>BAIAP2L1 accelerates breast cancer progression and chemoresistance by activating AKT signaling through binding with ribosomal protein L3</article-title>. <source><italic toggle="yes">Cancer Sci</italic></source>. <year>2023</year>;<volume>114</volume>(<issue>3</issue>):<fpage>764</fpage>&#8211;<lpage>780</lpage>. doi:<pub-id pub-id-type="doi">10.1111/cas.15632</pub-id><pub-id pub-id-type="pmid">36308067</pub-id><pub-id pub-id-type="pmcid">PMC9986062</pub-id></mixed-citation></ref><ref id="cit0196"><label>196.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Liu</surname><given-names>XY</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>D</given-names></string-name>, et al. <article-title>SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer</article-title>. <source><italic toggle="yes">Theranostics</italic></source>. <year>2020</year>;<volume>10</volume>(<issue>24</issue>):<fpage>10940</fpage>&#8211;<lpage>10956</lpage>. doi:<pub-id pub-id-type="doi">10.7150/thno.45207</pub-id><pub-id pub-id-type="pmid">33042263</pub-id><pub-id pub-id-type="pmcid">PMC7532662</pub-id></mixed-citation></ref><ref id="cit0197"><label>197.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Oudin</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Barbier</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Schafer</surname><given-names>C</given-names></string-name>, et al. <article-title>MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer</article-title>. <source><italic toggle="yes">Mol Cancer Ther</italic></source>. <year>2017</year>;<volume>16</volume>(<issue>1</issue>):<fpage>143</fpage>&#8211;<lpage>155</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-16-0413</pub-id><pub-id pub-id-type="pmid">27811011</pub-id><pub-id pub-id-type="pmcid">PMC5359014</pub-id></mixed-citation></ref><ref id="cit0198"><label>198.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, et al. <article-title>Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple-negative breast cancer</article-title>. <source><italic toggle="yes">J Cell Mol Med</italic></source>. <year>2019</year>;<volume>23</volume>(<issue>9</issue>):<fpage>6442</fpage>&#8211;<lpage>6453</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jcmm.14538</pub-id><pub-id pub-id-type="pmid">31359594</pub-id><pub-id pub-id-type="pmcid">PMC6714217</pub-id></mixed-citation></ref><ref id="cit0199"><label>199.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zhou</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>AS</given-names></string-name>. <article-title>Novel mechanism of anti-apoptotic function of 78-kDa glucose-regulated protein (GRP78): endocrine resistance factor in breast cancer, through release of B-cell lymphoma 2 (BCL-2) from BCL-2-interacting killer (BIK</article-title>. <source><italic toggle="yes">J Biol Chem</italic></source>. <year>2011</year>;<volume>286</volume>(<issue>29</issue>):<fpage>25687</fpage>&#8211;<lpage>25696</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M110.212944</pub-id><pub-id pub-id-type="pmid">21622563</pub-id><pub-id pub-id-type="pmcid">PMC3138298</pub-id></mixed-citation></ref><ref id="cit0200"><label>200.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Liu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>W</given-names></string-name>, et al. <article-title>Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway</article-title>. <source><italic toggle="yes">Biosci Rep</italic></source>. <year>2022</year>;<volume>42</volume>:<fpage>1</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BSR20210245</pub-id><pub-id pub-id-type="pmcid">PMC8738866</pub-id><pub-id pub-id-type="pmid">34935899</pub-id></mixed-citation></ref><ref id="cit0201"><label>201.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ha</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Debnath</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Neamati</surname><given-names>N</given-names></string-name>. <article-title>Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases</article-title>. <source><italic toggle="yes">Theranostics</italic></source>. <year>2017</year>;<volume>7</volume>(<issue>6</issue>):<fpage>1543</fpage>&#8211;<lpage>1588</lpage>. doi:<pub-id pub-id-type="doi">10.7150/thno.15625</pub-id><pub-id pub-id-type="pmid">28529637</pub-id><pub-id pub-id-type="pmcid">PMC5436513</pub-id></mixed-citation></ref><ref id="cit0202"><label>202.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gan</surname><given-names>L</given-names></string-name>. <article-title>CXCL8 Facilitates the Survival and Paclitaxel-Resistance of Triple-Negative Breast Cancers</article-title>. <source><italic toggle="yes">Clin Breast Cancer</italic></source>. <year>2022</year>;<volume>22</volume>(<issue>2</issue>):<fpage>e191</fpage>&#8211;<lpage>e198</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.clbc.2021.06.009</pub-id><pub-id pub-id-type="pmid">34284965</pub-id></mixed-citation></ref><ref id="cit0203"><label>203.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Biswas</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Slade</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Duffley</surname><given-names>L</given-names></string-name>, et al. <article-title>Inhibiting BCKDK in triple negative breast cancer suppresses protein translation, impairs mitochondrial function, and potentiates doxorubicin cytotoxicity</article-title>. <source><italic toggle="yes">Cell Death Discov</italic></source>. <year>2021</year>;<volume>7</volume>(<issue>1</issue>):<fpage>241</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41420-021-00602-0</pub-id><pub-id pub-id-type="pmid">34526485</pub-id><pub-id pub-id-type="pmcid">PMC8443725</pub-id></mixed-citation></ref><ref id="cit0204"><label>204.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Byerly</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Port</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Irie</surname><given-names>HY</given-names></string-name>. <article-title>PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim</article-title>. <source><italic toggle="yes">Breast Cancer Res</italic></source>. <year>2020</year>;<volume>22</volume>(<issue>1</issue>):<fpage>72</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13058-020-01302-w</pub-id><pub-id pub-id-type="pmid">32600444</pub-id><pub-id pub-id-type="pmcid">PMC7322866</pub-id></mixed-citation></ref><ref id="cit0205"><label>205.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wei</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>Q</given-names></string-name>, et al. <article-title>PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer</article-title>. <source><italic toggle="yes">Int J Biol Markers</italic></source>. <year>2018</year>;<volume>33</volume>(<issue>1</issue>):<fpage>102</fpage>&#8211;<lpage>108</lpage>. doi:<pub-id pub-id-type="doi">10.5301/ijbm.5000283</pub-id><pub-id pub-id-type="pmid">28623645</pub-id></mixed-citation></ref><ref id="cit0206"><label>206.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lai</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, et al. <article-title>LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP</article-title>. <source><italic toggle="yes">Sci China Life Sci</italic></source>. <year>2020</year>;<volume>63</volume>(<issue>3</issue>):<fpage>419</fpage>&#8211;<lpage>428</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11427-019-9581-8</pub-id><pub-id pub-id-type="pmid">31420851</pub-id></mixed-citation></ref><ref id="cit0207"><label>207.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sun</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>X</given-names></string-name>, et al. <article-title>Silencing of PGK1 Promotes Sensitivity to Paclitaxel Treatment by Upregulating XAF1-Mediated Apoptosis in Triple-Negative Breast Cancer</article-title>. <source><italic toggle="yes">Front Oncol</italic></source>. <year>2021</year>;<volume>11</volume>:<fpage>535230</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fonc.2021.535230</pub-id><pub-id pub-id-type="pmid">33747900</pub-id><pub-id pub-id-type="pmcid">PMC7969978</pub-id></mixed-citation></ref><ref id="cit0208"><label>208.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Lei</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Jing</surname><given-names>D</given-names></string-name>. <article-title>Knockdown of SERPINE1 reverses resistance of triple&#8209;negative breast cancer to paclitaxel via suppression of VEGFA</article-title>. <source><italic toggle="yes">Oncol Rep</italic></source>. <year>2020</year>;<volume>44</volume>(<issue>5</issue>):<fpage>1875</fpage>&#8211;<lpage>1884</lpage>. doi:<pub-id pub-id-type="doi">10.3892/or.2020.7770</pub-id><pub-id pub-id-type="pmid">33000256</pub-id><pub-id pub-id-type="pmcid">PMC7551184</pub-id></mixed-citation></ref><ref id="cit0209"><label>209.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Xie</surname><given-names>XQ</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Q</given-names></string-name>, et al. <article-title>Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria</article-title>. <source><italic toggle="yes">Cell Res</italic></source>. <year>2023</year>;<volume>33</volume>(<issue>3</issue>):<fpage>215</fpage>&#8211;<lpage>228</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41422-022-00766-z</pub-id><pub-id pub-id-type="pmid">36627348</pub-id><pub-id pub-id-type="pmcid">PMC9977947</pub-id></mixed-citation></ref><ref id="cit0210"><label>210.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Liu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>D</given-names></string-name>, et al. <article-title>TRA2A Promoted Paclitaxel Resistance and Tumor Progression in Triple-Negative Breast Cancers via Regulating Alternative Splicing</article-title>. <source><italic toggle="yes">Mol Cancer Ther</italic></source>. <year>2017</year>;<volume>16</volume>(<issue>7</issue>):<fpage>1377</fpage>&#8211;<lpage>1388</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-17-0026</pub-id><pub-id pub-id-type="pmid">28416606</pub-id></mixed-citation></ref><ref id="cit0211"><label>211.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Fusco</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fedele</surname><given-names>M</given-names></string-name>. <article-title>Roles of HMGA proteins in cancer</article-title>. <source><italic toggle="yes">Nat Rev Cancer</italic></source>. <year>2007</year>;<volume>7</volume>(<issue>12</issue>):<fpage>899</fpage>&#8211;<lpage>910</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrc2271</pub-id><pub-id pub-id-type="pmid">18004397</pub-id></mixed-citation></ref><ref id="cit0212"><label>212.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sgubin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pegoraro</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pellarin</surname><given-names>I</given-names></string-name>, et al. <article-title>HMGA1 positively regulates the microtubule-destabilizing protein stathmin promoting motility in TNBC cells and decreasing tumour sensitivity to paclitaxel</article-title>. <source><italic toggle="yes">Cell Death Dis</italic></source>. <year>2022</year>;<volume>13</volume>(<issue>5</issue>):<fpage>429</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41419-022-04843-4</pub-id><pub-id pub-id-type="pmid">35504904</pub-id><pub-id pub-id-type="pmcid">PMC9065117</pub-id></mixed-citation></ref><ref id="cit0213"><label>213.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Samanta</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pursell</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Mercurio</surname><given-names>AM</given-names></string-name>. <article-title>IMP3 protein promotes chemoresistance in breast cancer cells by regulating breast cancer resistance protein (ABCG2) expression</article-title>. <source><italic toggle="yes">J Biol Chem</italic></source>. <year>2013</year>;<volume>288</volume>(<issue>18</issue>):<fpage>12569</fpage>&#8211;<lpage>12573</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.C112.442319</pub-id><pub-id pub-id-type="pmid">23539627</pub-id><pub-id pub-id-type="pmcid">PMC3642304</pub-id></mixed-citation></ref><ref id="cit0214"><label>214.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Haynes</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Cunningham</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Shekhar</surname><given-names>MPV</given-names></string-name>. <article-title>RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage</article-title>. <source><italic toggle="yes">BMC Cancer</italic></source>. <year>2022</year>;<volume>22</volume>(<issue>1</issue>):<fpage>1073</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12885-022-10119-z</pub-id><pub-id pub-id-type="pmid">36258187</pub-id><pub-id pub-id-type="pmcid">PMC9578210</pub-id></mixed-citation></ref><ref id="cit0215"><label>215.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Luo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>R</given-names></string-name>, et al. <article-title>High Expression of G6PD Increases Doxorubicin Resistance in Triple Negative Breast Cancer Cells by Maintaining GSH Level</article-title>. <source><italic toggle="yes">Int J Biol Sci</italic></source>. <year>2022</year>;<volume>18</volume>(<issue>3</issue>):<fpage>1120</fpage>&#8211;<lpage>1133</lpage>. doi:<pub-id pub-id-type="doi">10.7150/ijbs.65555</pub-id><pub-id pub-id-type="pmid">35173543</pub-id><pub-id pub-id-type="pmcid">PMC8771852</pub-id></mixed-citation></ref><ref id="cit0216"><label>216.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lee</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gollahon</surname><given-names>L</given-names></string-name>. <article-title>Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple&#8209;negative breast cancer cells</article-title>. <source><italic toggle="yes">Int J Oncol</italic></source>. <year>2013</year>;<volume>42</volume>(<issue>3</issue>):<fpage>839</fpage>&#8211;<lpage>847</lpage>. doi:<pub-id pub-id-type="doi">10.3892/ijo.2013.1788</pub-id><pub-id pub-id-type="pmid">23340795</pub-id><pub-id pub-id-type="pmcid">PMC3597451</pub-id></mixed-citation></ref><ref id="cit0217"><label>217.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Shen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>C</given-names></string-name>. <article-title>Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing beta-catenin</article-title>. <source><italic toggle="yes">J Exp Clin Cancer Res</italic></source>. <year>2019</year>;<volume>38</volume>(<issue>1</issue>):<fpage>243</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13046-019-1231-y</pub-id><pub-id pub-id-type="pmid">31174562</pub-id><pub-id pub-id-type="pmcid">PMC6556028</pub-id></mixed-citation></ref><ref id="cit0218"><label>218.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zhu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, et al. <article-title>Ceramide kinase mediates intrinsic resistance and inferior response to chemotherapy in triple-negative breast cancer by upregulating Ras/ERK and PI3K/Akt pathways</article-title>. <source><italic toggle="yes">Cancer Cell Int</italic></source>. <year>2021</year>;<volume>21</volume>(<issue>1</issue>):<fpage>42</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12935-020-01735-5</pub-id><pub-id pub-id-type="pmid">33430896</pub-id><pub-id pub-id-type="pmcid">PMC7802356</pub-id></mixed-citation></ref><ref id="cit0219"><label>219.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Fernandez</surname><given-names>NB</given-names></string-name>, <string-name name-style="western"><surname>Sosa</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>JT</given-names></string-name>, et al. <article-title>RUNX1 Is Regulated by Androgen Receptor to Promote Cancer Stem Markers and Chemotherapy Resistance in Triple Negative Breast Cancer</article-title>. <source><italic toggle="yes">Cells</italic></source>. <year>2023</year>;<volume>13</volume>(<issue>1</issue>):<fpage>12</fpage>. doi:<pub-id pub-id-type="doi">10.3390/cells13010012</pub-id><pub-id pub-id-type="pmid">36766786</pub-id><pub-id pub-id-type="pmcid">PMC9913961</pub-id></mixed-citation></ref><ref id="cit0220"><label>220.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ogbu</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Rojas</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Weaver</surname><given-names>J</given-names></string-name>, et al. <article-title>DSTYK Enhances Chemoresistance in Triple-Negative Breast Cancer Cells</article-title>. <source><italic toggle="yes">Cells</italic></source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>11</fpage>. doi:<pub-id pub-id-type="doi">10.3390/cells11010011</pub-id><pub-id pub-id-type="pmid">35011659</pub-id><pub-id pub-id-type="pmcid">PMC8750327</pub-id></mixed-citation></ref><ref id="cit0221"><label>221.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hashimoto</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Koyama</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kamai</surname><given-names>Y</given-names></string-name>, et al. <article-title>A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization</article-title>. <source><italic toggle="yes">Clin Cancer Res</italic></source>. <year>2019</year>;<volume>25</volume>(<issue>23</issue>):<fpage>7151</fpage>&#8211;<lpage>7161</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-1745</pub-id><pub-id pub-id-type="pmid">31471314</pub-id></mixed-citation></ref><ref id="cit0222"><label>222.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Malumbres</surname><given-names>M</given-names></string-name>. <article-title>Cyclin-dependent kinases</article-title>. <source><italic toggle="yes">Genome Biol</italic></source>. <year>2014</year>;<volume>15</volume>(<issue>6</issue>):<fpage>122</fpage>. doi:<pub-id pub-id-type="doi">10.1186/gb4184</pub-id><pub-id pub-id-type="pmid">25180339</pub-id><pub-id pub-id-type="pmcid">PMC4097832</pub-id></mixed-citation></ref><ref id="cit0223"><label>223.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Malumbres</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Barbacid</surname><given-names>M</given-names></string-name>. <article-title>Cell cycle, CDKs and cancer: a changing paradigm</article-title>. <source><italic toggle="yes">Nat Rev Cancer</italic></source>. <year>2009</year>;<volume>9</volume>(<issue>3</issue>):<fpage>153</fpage>&#8211;<lpage>166</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrc2602</pub-id><pub-id pub-id-type="pmid">19238148</pub-id></mixed-citation></ref><ref id="cit0224"><label>224.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Carey</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Perou</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Livasy</surname><given-names>CA</given-names></string-name>, et al. <article-title>Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study</article-title>. <source><italic toggle="yes">JAMA</italic></source>. <year>2006</year>;<volume>295</volume>(<issue>21</issue>):<fpage>2492</fpage>&#8211;<lpage>2502</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.295.21.2492</pub-id><pub-id pub-id-type="pmid">16757721</pub-id></mixed-citation></ref><ref id="cit0225"><label>225.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Criscitiello</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Azim Jr</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>Schouten</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Linn</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Sotiriou</surname><given-names>C</given-names></string-name>. <article-title>Understanding the biology of triple-negative breast cancer</article-title>. <source><italic toggle="yes">Ann Oncol</italic></source>. <year>2012</year>;<volume>23</volume>(<issue>Suppl 6</issue>):<fpage>vi13</fpage>&#8211;<lpage>8</lpage>. doi:<pub-id pub-id-type="doi">10.1093/annonc/mds188</pub-id><pub-id pub-id-type="pmid">23012296</pub-id></mixed-citation></ref><ref id="cit0226"><label>226.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Pegram</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Lipton</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hayes</surname><given-names>DF</given-names></string-name>, et al. <article-title>Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment</article-title>. <source><italic toggle="yes">J Clin Oncol</italic></source>. <year>1998</year>;<volume>16</volume>(<issue>8</issue>):<fpage>2659</fpage>&#8211;<lpage>2671</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.1998.16.8.2659</pub-id><pub-id pub-id-type="pmid">9704716</pub-id></mixed-citation></ref><ref id="cit0227"><label>227.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wiggans</surname><given-names>RG</given-names></string-name>, <string-name name-style="western"><surname>Woolley</surname><given-names>PV</given-names></string-name>, <string-name name-style="western"><surname>Smythe</surname><given-names>T</given-names></string-name>, et al. <article-title>Phase-II trial of tamoxifen in advanced breast cancer</article-title>. <source><italic toggle="yes">Cancer Chemother Pharmacol</italic></source>. <year>1979</year>;<volume>3</volume>(<issue>1</issue>):<fpage>45</fpage>&#8211;<lpage>48</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF00254419</pub-id><pub-id pub-id-type="pmid">535127</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>